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ABSTRACT 
PATIENT CENTERED CARE APPROACH TO ADHERENCE WITH 
CARDIOVASCULAR MEDICATIONS: 
SELF-DETERMINATION THEORY INTEGRATION 
David S. Li 
Old Dominion University, 2010 
Director: Dr. Richardean Benjamin 
Problem statement. Behavioral intervention is used to improve adherence with 
medication in patients with cardiovascular diseases (CVD), but the effect was not 
sustainable. Patient-centered care (PCC) as a consumer movement has gained 
acceptance, but it lacks a theoretical framework. Self-determination theory (SDT) may 
provide an alternative to improve patients' adherence to chronic cardiovascular 
medication, as well as a theoretical framework for PCC. Both approaches to CVD 
management have not been evaluated. 
Methods. The study was a quasi-experimental pretest posttest comparison 
design with consecutive sampling of a hospitalized cardiac patient population. Sixty 
patients each for the usual care (UC) group and the PCC group were recruited. The 
patient sample consisted of 83% Caucasian, 39% female, 93% insured, an average age of 
68 years old, 43% had a NYHF classification of three and above, and an average of 9.7 
prescriptions at discharge. A medication teaching intervention was supported by an 
interactive system designed for PCC. The intervention addressed patients' socio-
economic needs, health literacy adequacy, illness level, timing and amount of teaching, 
and psychological needs for competence, relatedness, and autonomous motivation. 
Patients were surveyed once before discharged from the hospital and once three months 
post discharge. 
Results. The SDT motivation variables (perceived competence, perceived 
autonomous support and autonomous motivation) were significantly correlated with the 
adherence index. Stepwise multivariate regression analyses identified autonomous 
motivation as an independent predictor of adherence index, along with age, insurance 
coverage, adverse drug reaction, adequate health literacy, illness level and number of 
prescription doses taken per day. Patients in the PCC group had significantly higher 
scores on all three SDT motivation variables, adherence index and higher portion of 
adherence status than patients in the UC group. Sequential logistic regression analyses 
reported that PCC intervention, perceived competence and autonomous motivation were 
independent predictors of adherence status, as well as adverse drug reaction, illness level 
and number of doses taken per day. 
Conclusion. Self-determination theory helped to explicate patients' adherence 
behavior. A patient-centered care environment designed with SDT improved patients 
autonomous motivation, which improved cardiac patients' adherence to CVD 
medications. 
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CHAPTER I 
Introduction 
Purpose 
The purpose of this study is twofold: 1) to examine the extent to which self-
determination theory (SDT) can be used to model adherence to cardiovascular 
prescriptions; and 2) to describe the effect of a hospital patient-centered care (PCC) 
program on adherence to cardiovascular prescriptions for the secondary prevention of 
cardiovascular diseases. 
Significance 
Cardiovascular diseases (CVD) comprise conditions such as stroke, hypertension, 
congestive heart failure (CHF), and coronary heart disease (CHD) (also known as 
coronary artery disease or CAD) (Lloyd-Jones et al., 2009). CVD is caused by 
atherosclerosis from the deposition of lipoproteins (plasma proteins that carry cholesterol 
and triglycerides) to arterial blood vessels. The hardening of the arteries is due to the 
formation of multiple atherosclerotic plaques within the arteries. Acute coronary 
syndrome (ACS), an acute manifestation of CHD, occurs when one or more of the 
coronary arteries become severely or totally blocked by blood clots due to the disruption 
of unstable atherosclerotic plaque in the coronary artery. The blockage deprives the heart 
muscle of oxygen-rich blood, leading to subsequent cell death. ACS consists of a 
constellation of ischemic-induced syndromes such as myocardial infarction (MI; also 
known as heart attack) and Angina Pectoris (AP; also known as chest pain) (Topol, 
2002). The severity of a heart attack usually depends on how much of the heart muscle is 
injured or dies during the heart attack. If not stabilized by early intervention within the 
first one to two hours after the onset of symptoms (Sabatine et al., 2005; Antman et al., 
2004) from ventricular fibrillation (VF), the odds of survival decrease by 7% to 10% for 
each minute that a patient remains in VF (Antman et al., 2004; Cummins, Ornato, Thies 
&Pepe, 1991). 
After hospitalization for ACS, patients are at high risk of future heart failure, 
CHD, and stroke (Berthonneche et al., 2007; Cheng et al., 2007; Hochman et al., 2006; 
American Heart Association, 2005). Newer and more selective cardiovascular (CV) 
medication is important in the primary prevention of acute myocardial infarction (AMI) 
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medication is important in the primary prevention of acute myocardial infarction (AMI) 
and may have contributed to the decline of initial AMI. The age-adjusted incidence rates 
of initial AMI dropped from 272 per 100,000 in 1981, to 184 per 100,000 in 1995. 
Improved cardiac interventional technologies with effective CV medications may have 
further contributed to the decline of crude and multivariable-adjusted in-hospital case-
fatality rates (17.8% between 1975-1978, 17.0% between 1986-1988, and 11.7% between 
1993-1995), as well as morbidity associated with CVD (Spencer, 2003; Goldberg, 
Yarzebski, Lessard & Gore, 1999). However, patients saved from initial ACS later 
develop heart failure because of existing risk factors that continue (Hurst, 2002). One of 
the risk factors is non-adherence to important CV medication (Ho et al., 2006: WHO, 
2003). In general, non-adherence to medication, which occurs in 30% to 60% of cases, 
may lead to undesirable consequences both on an individual and a societal level 
(Osterberg & Blaschke, 2005; Gehi, Haas, Pipkin & Whooley, 2005; DiMatteo, 2004; 
Blue Cross & Blue Shield Association, 2003; WHO, 2003; Miller, Hill, Kottke & 
Ockene, 1997; Rogers & Bullman, 1995; National Pharmaceutical Council, 1992). 
Besides the simplification of medication regimens, approaches such as education or 
behavioral interventions alone have not always been effective in the improvement of 
adherence (Atreja, Bellam & Levy, 2005; DiMatteo, 2004; Blue Cross & Blue Shield 
Association, 2003; WHO, 2003; Peterson, Takiya & Finley, 2003; Rodgers, 2003; Wald 
& Law, 2003; Jackevicius, Mamdani & Tu, 2002; Wei et al., 2002; Frantz, Hammann, 
Pfautsch, Fleck & Herzzentrum, 2002). 
Psychologically, the concept of compliance is associated with blame, be it of 
providers or patients, and does not facilitate understanding of the underlying complex 
systemic issues (WHO, 2003). However, the concept of adherence captures the dynamic 
and complex changes required of patients and healthcare providers over long periods to 
maintain optimal health in people with chronic diseases (WHO, 2003). Because the 
concept of adherence reflects a more contemporary approach to medical treatments, and 
in the case of this study with secondary prevention of CVD in hospitalized cardiac 
patients, it is worthy of consideration and reexamination within the paradigm of patient-
centered care (PCC) (Kravitz & Melnikow, 2004). 
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The paradigm of PCC provides a framework of thought processes that allows 
convergence of psychological motivational factors, as addressed by self-determination 
theory (SDT) (Williams et al., 2006; Williams, McGregor, Freedman & Deci, 2004; 
Williams, Frankel, Campbell & Deci, 2000; Quill & Brody, 1996; Quill & Cassel, 1995; 
Deci & Ryan, 1985; Deci & Ryan, 1980). PCC also allows the examination of 
interventions that are patient-centered. The SDT theoretical framework provides a 
method of explaining the level of a patient's autonomous motivation within the arena of 
secondary prevention of C VD of hospitalized cardiac patients with recurrent acute 
coronary syndromesor chronic heart failure. With chronic CV illnesses, as well as other 
chronic illnesses, active engagement by a patient because of autonomous motivation may 
prove to be more important and beneficial than passive behavioral interventions, 
especially for long-term success with treatment (Williams, Freedman & Deci, 1998; 
Williams, Grow, Freedman, Ryan & Deci, 1996). Based on numerous precepts of 
motivational factors relevant to health-related behaviors (Deci & Ryan, 1985; Deci & 
Ryan, 1980), this study proposes to demonstrate that an autonomous supportive 
healthcare environment will encourage more self-perceived competence and autonomous 
motivation. With more autonomous motivation, it is hopeful that patients would be able 
to better regulate health-related behaviors such as adherence to regimens associated with 
chronic CVD (Williams et al., 2006; Williams et al , 2004; Williams et al., 2002; 
Williams, Rodin, Ryan, Grolnick & Deci, 1998; Williams, Freedman & Deci, 1998). 
Background 
Intervention to improve adherence with chronic CV medical regimens requires an 
understanding of the impact of CVD progression, CVD treatments, healthcare 
environments, as well as the social and psychological functioning of both patients and 
healthcare providers. 
Impact of cardiovascular diseases. 
CVD mortality. Since 1900, CVD, including heart diseases and cerebrovascular 
diseases, has been the number one killer in the United States every year (CDC, 2009) 
with the exception of 1918 due to the Spanish flu epidemics (Laver, Bischofberger & 
WTebster, 1999). CVD claims more lives each year than cancer, chronic lower respiratory 
diseases, accidents, and diabetes mellitus combined (CDC National Vital Statistics 
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Reports, 2007; Minino, Heron & Smith, 2006). CVD mortality was nearly 60 percent of 
the total mortality (CDC National Vital Statistics Reports, 2007). This means that of 
about 2.4 million deaths from all causes, CVD was listed as a primary or contributing 
cause on about 1.4 million death certificates (Minino et al., 2006). The 2006 overall 
death rate from CVD was 262.5 per 100,000 population (based on the year 2000 standard 
U.S. population), accounting for 1 out of every 2.9 deaths (34.3% of all deaths) in the 
United States. The death rate has declined 25% from 1994 to 2004 overall. The Centers 
for Disease Control (CDC) estimates that each year 400,000 to 460,000 people die of 
heart disease in an emergency department or before reaching a hospital, which accounts 
for more than 60 % of all cardiac deaths, and approximately 60% of unexpected cardiac 
deaths are treated by emergency medical services (EMS) (Chugh et al., 2004). About 2/3 
of unexpected cardiac deaths occur without prior recognition of cardiac disease. The 
National Center for Health Statistics estimates that life expectancy would rise by about 7 
years if all forms of major CVD were eliminated (National Center for Health Statistics, 
1999). 
CVD prevalence and incidence. Contributing to the total 79,400,000 cases of 
CVD in the United States were 15,800,000 cases of coronary heart disease (CHD), 
5,200,000 cases of heart failure (HF), 5,600,000 cases of stroke, 650,000 to 1,300,000 
cases of congenital cardiovascular defects, and 72,000,000 cases of high blood pressure 
(HBP) (Rosamond et al., 2007). CHD manifested as acute coronary syndrome (ACS) 
with 7,900,000 cases of myocardial infarction (MI), and 8,900,000 cases of angina 
pectoris (AP). Multiple kinds of CVD also affect people older than 65 years at a 
disproportionate rate. Of the American adults diagnosed with CVD, 47% were estimated 
to be age 65 or older (Rosamond et al., 2007). Since the progression of CVD is relatively 
silent, the devastating effects of CVD are not apparent until the manifestation of an acute 
coronary event such as angina or acute myocardial infarction (AMI). 
Admissions to hospital services and cost of cardiovascular disease. CVD as the 
first-listed diagnosis for short-stay hospitals increased 30% to 6,363,000 from 1979 to 
2004, with cardiovascular operations and procedures performed on 3.2 million males, 3.1 
million females (National Center for Health Statistics, 2006; Hurst, 2002), and ranked the 
highest among all disease categories in hospital discharges (DeFrances & Podgornik, 
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2006). In 2001, $29.3 billion in program payments, averaging $8,354 per discharge, 
were made to Medicare beneficiaries discharged from short-stay hospitals with a 
principal diagnosis of CVD (Centers for Medicare and Medicaid Services, 2003). In 
2007, the total direct and indirect cost was $431.8 billion (Rosamond et al., 2007). 
Despite the improved outcomes of cardiac interventions in patients who suffered from an 
initial acute coronary event, continuous vigilance of disease progression combined with 
risk reduction measures are needed to prevent future heart failure, to prevent recurrent 
coronary events, and to improve the quality of life of patients. 
Heart failure (HF). Prevalence of heart failure is on the rise due to people living 
longer with better health and better medical care. It is also due to the higher survival 
rates from ACS (Hurst, 2002), since ACS survivors tend to contribute to HF deaths later 
in life. Heart failure, also known as congestive heart failure (CHF), is a complex clinical 
syndrome manifested by shortness of breath, fatigue, and abnormal heart function (Topol, 
2002). As people age, progressive loss of cardiac function due to heart failure can cause 
another round of ACS, more heart failure, kidney failure, or stroke (Kannel & Belanger, 
1991). 
Currently, 5.7 million patients in this country suffer from HF (Lloyd-Jones et al , 
2009), and another 550,000 patients are being diagnosed with HF for the first time each 
year (Hunt et al., 2005). Hospital discharges for HF rose from about 0.88 million in 1996 
to 1.1 million in 2006 (Lloyd-Jones et al., 2009). Subsequently, the number of HF deaths 
has increased steadily despite better hospital treatment of CVD in general. In 2005, HF 
was mentioned on about 292,000 U.S. death certificates, and was selected as the 
"underlying cause" in about 59,000 of those deaths (Lloyd-Jones et al., 2009; National 
Center for Health Statistics, 2009). In 2006, $33 billion in hospital charges were incurred 
by about 1.1 million HF patients (Andrews, 2008). The total estimated direct and indirect 
costs for HF in 2009 were approximately $37.2 billion (Lloyd-Jones et al., 2009). In the 
United States, approximately $2.9 billion annually is spent on drugs for the treatment of 
HF (American Heart Association, 2005). HF is a major and growing public health 
problem in the United States that warrants a reevaluation of the current approach to the 
secondary prevention of CVD. 
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Secondary prevention of CVD with medication. 
Prevention strategies. Prevention studies and policies are based on the concept of 
dual strategies articulated by Rose as the "mass strategy" and "high-risk strategy" (Rose, 
1981). Mass strategy is also known as primary prevention, while high-risk strategy is 
known as secondary prevention. Each of these strategies may be seen as complementary, 
not as competing alternatives (Rose, 2001). 
Primary prevention. Primary prevention is a population-based approach to 
etiology that seeks to control the determinants of incidence in the population as a whole. 
Primary prevention of C V diseases involves the reduction of modifiable cardiovascular 
risks such as lack of physical activity to prevent the first episode of coronary disease, 
stroke, aortic aneurysm and peripheral arterial disease (Fiebach & Barker, 2006; Pearson 
et al., 2002). In cardiology, primary prevention is supportive of the traditional approach 
to health in the general population (i.e., healthy dietary pattern, weight control, 
appropriate exercise, avoidance of tobacco and secondhand smoke),as well as drug 
interventions to help patients achieve safe levels of blood pressure, blood sugar, blood 
cholesterol, and coagulation (Pearson et al., 2002).. 
Secondary CVD Prevention: 
Patients with ACS. HE stroke, etc. 
Primary CVD Prevention: 
1 Persons with major CVD risk 
factors but no acute episodes yet 
2 Entire population, including 
persons with no CVD risk 
factors. 
Figure 1-1. Primary and secondary prevention of CVD diseases 
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In Figure 1-1, primary CVD prevention to prevent the first episode of acute coronary 
syndrome (ACS) or stroke is represented in the lower portion of the pyramid, and the 
high-risk approach or secondary prevention of ACS is represented at the upper portion of 
the pyramid. 
Secondary prevention with CVD medications. Secondary prevention in non-
cardiac clinical practice means the early detection of disease before it becomes clinically 
apparent (Fiebach & Barker, 2006). Secondary prevention in cardiology refers to treating 
and rehabilitating patients after the occurrence of an ACS (such as myocardial infarction) 
to prevent future ACS and HF (Fiebach & Barker, 2006). It involves exercise, smoking 
cessation, management of dyslipidemia, hypertension, diabetes, weight, depression, social 
isolation, return to work, and other psychosocial factors (American Heart Association, 
2007). A major target of secondary CVD prevention is HF. Prevalence of HF has been 
increasing steadily because of better treatment and salvage of patients from ACS earlier 
in life (Hurst W, 2002). Since we cannot prevent eventual death in the high-risk CVD 
population, prevention strategies should not be viewed simply as ways to prevent heart 
diseases or death, but as a means to control CVD symptoms, slow down the progression 
of heart failure, and improve patients' quality of life. Most patients with HF do not 
typically show an uninterrupted worsening of symptoms. When CVD symptoms and 
risks are managed appropriately, secondary prevention can have marked favorable effects 
on patients' functional capacity and quality of life (Hunt et al., 2005). 
Medical management with medications is a major component in the secondary 
prevention of CVD (Braunwald et al., 2002; Antman et al., 2004; Eagle et al., 2004; Hunt 
et al., 2005). Depending on the signs and symptoms of CVD, physicians are 
recommended to customize a patient's medication regimen with one or more of the 
following: (a) control of hypertension (HBP), fluid, and electrolytes with diuretics, 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and 
beta-blockers; (b) prevention of ischemic events with antiplatelet and/or anticoagulation 
therapy, beta-blockers, and ACEI/ARB; (c) management of diabetes with antidiabetic 
medications, as well as using ACEI/ARB even with normal blood pressure; (d) 
management of atherosclerotic disease with antihyperlipidemics and ACEI/ARB; (e) 
recommendations to change behaviors that increase the risk of HF, such as smoking, 
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excessive alcohol intake, use of illicit drugs, excessive salt intake, unhealthy diet, 
sedentary life style, and over-weight; (f) management of depression with cognitive-
behavioral therapy and/or SSRI (selective serotonin reuptake inhibitor) medications; and 
(g) management of HF symptoms, arrhythmia, treatment of thyroid disorders and 
valvular disease, and immunization from respiratory infection as necessary. Successful 
secondary prevention of CVD requires continuous monitoring by the patient's healthcare 
team and adherence to CV medications by patients. 
Adherence to CV medications has the characteristic of being a "prevention 
paradox": "A preventive measure which brings much benefit to the population offers 
little to each participating individual" (Rose, 1985, p. 38). The benefit of preventing 
major CHD events due to "silent" causal factors such as atherosclerosis and high blood 
pressure is not obvious until it is too late (Labarthe, 1998; National Heart Lung and 
Blood Institute, 1995; WHO, 1994; Stamler, 1992; Silver, 1990; Keys, 1980; Brook et al., 
1979; WHO, 1952). This is significant because patients are not likely to adhere to CV 
medications unless the factors affecting the behavior of adherence are understood and 
addressed. The importance of behavioral factors in'health has been recognized and 
promoted in both primary and secondary prevention (U.S. Department of Health and 
Human Services, Nov. 2000). Healthy People 2010 estimates that individual behaviors 
and environmental factors were responsible for about 70% of all premature deaths in the 
United States by the end of the 20th century (U.S. Department of Health and Human 
Services, 2000), up from 50% during the 1980s (Centers for Disease Control and 
Prevention, 1986). Adherence to efficacious medical treatments as a health behavior is 
necessary for optimal outcomes in the secondary prevention of CVD (Hunt et al., 2005; 
Atreja et al., 2005; WHO, 2003; Bellg, Rivkin & Rosenson, 2002; Jackevicius et al., 
2002; Wei et al., 2002), and needs to be evaluated within the domain of CVD (Bellg, 
2003; Sheretal., 2002). 
Adherence to cardiovascular medications. 
Definition of adherence. Adherence is defined as "the extent to which a person's 
behavior - taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a healthcare provider" (WHO, 2003 p. 
3). Medical recommendations are multiple and range from taking a single pill to 
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following a complex drug regimen, seeking preventive care, returning for follow-up 
appointments, and modifying aspects of one's lifestyle (Roter et al., 1998). 
Motivational issues of adherence. Although "adherence" and "compliance" have 
been used interchangeably in healthcare, there are some fundamental differences between 
them. While adherence emphasizes the active participation of a patient in the patient's 
care, compliance implies the passive role a patient assumes in the patient and healthcare 
provider relationship. Compliance is defined as "the act of conforming, acquiescing, or 
yielding" (Random House Unabridged Dictionary, 2006, p. 419) and is operational in a 
paternalistic framework in which the physicians make all or most of the decisions, while 
the patients comply passively (Conrad, 1985). Superficially, complying with the use of 
prescription medication would seem to be a normal patient behavior. However, 
medication use involves an active and highly complex decision-making process with 
many trade-offs in the context of an individual's life choices (Conrad, 1985). Before 
adopting a medical recommendation from a physician, a patient may also consider drug 
information provided by other healthcare providers, on-line medical literature, news 
reports, second opinions, and experiences of family and friends who have taken similar 
prescriptions. A patient may also evaluate the expected therapeutic efficacy of drugs 
against the achievement of some specific outcomes in terms of expected time frames. A 
patient may also derive some idiosyncratic meaning from their decisions about 
medication use, such as using it as a means to assert control in the doctor-patient 
relationship (Hayes-Bartista, 1976) or to exert control over one's own life. A patient's 
decision in medication usage will also be influenced by restrictive managed care 
requirements and co-payments (Cunningham, 2005). Since a patient does make the 
ultimate healthcare decisions regarding prescriptions, the notion of adherence is a more 
appropriate term than compliance in trying to understand why patients decide to take or 
not take medication for their illnesses (Blue Cross & Blue Shield Association, 2003; 
WHO, 2003). Thinking in terms of non-compliance may lead to blaming the patient for 
being disobedient or ignorant. Thinking in terms of non-adherence may compel one to 
search for unresolved conflicts between an individual patient and recommendations from 
healthcare providers. 
Determinants of adherence. The key factors that contribute to poor patient 
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adherence to CVD medications are motivational reasons, along with the asymptomatic 
characteristic and lifelong nature of CVD (WHO, 2003). Other factors affecting 
medication adherence include depression, patient demographics, side effects of 
medication, convenience of drug dosing, cost and number of medications, patient's 
knowledge, beliefs and attitudes, involvement with care, and health system issues. The 
relationship between the determinants of adherence and the adherence rate of the cardiac 
patients at risk of HF discharged from Sentara Virginia Beach General Hospital is 
unknown. With the support of an interdisciplinary team of cardiac care providers, a 
patient-centered care model was developed to help address these factors. The model was 
further implemented and supported by an interactive information system. The proposed 
study was designed to explore the relationship between adherence to CV prescriptions 
and factors affecting adherence. 
Significance of non-adherence. Non-adherence is a hidden epidemic that has 
been shown to jeopardize patients' health and welUbeing, increase physician and patient 
frustration, and lead to incorrect diagnoses, unnecessary treatment, and wasted health 
resources (Osterberg & Blaschke, 2005; DiMatteo & DiNicola, 1982). Non-adherence is 
associated with the development of complications, disease progression, avoidable 
hospitalizations, premature disability, and death (Piadevall et al., 2004). In multivariate 
survival analysis, medication therapy discontinuation due to non-adherence was 
independently associated with higher mortality (hazards ratio, 3.81; 95% CI=1.88, 7.72) 
(Ho et al., 2006). The World Health Organization stated that, 
"...poor adherence increases with the duration and complexity of treatment 
regimens.. .duration and complex treatment are inherent to chronic illnesses. 
Across diseases, adherence is the single most important modifiable factor that 
compromises treatment outcome" (WHO, 2003, p. 135). 
The economic costs associated with poor medication adherence are estimated to approach 
$100 billion annually (Hughes, Bagust, Haycox & Walley, 2001; Berg, Dischler, 
Wagner, Raia & Palmer-Shevlin, 1993). Non-adherence to medication has been 
estimated to be responsible for as much as 22% of acute care admissions of primary care 
patients (Lynch & Grant, 2003), 2.5 million medical emergencies per year, 10% of 
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hospital admissions, 23% of nursing home admissions (National Pharmaceutical Council, 
1992), and nearly 125,000 deaths per year. 
Prevalence of non-adherence with CVD medications. In general, the rates of non-
adherence to medication vary from 30% to 60%. One'third of all prescriptions are never 
filled, and more than 50% of prescriptions that are filled are incorrectly administered 
(Blue Cross & Blue Shield Association, 2003; Peterson et al., 2003; Vermeire, 
Hearnshaw, Van Royen & Denekens, 2001; Rogers & Bullman, 1995). Almost one third 
of patients who receive prescriptions are using them in a manner that poses a serious 
threat to their health (Boyd, Covington, Stanaszek & Coussons, 1974). Yet, patients do 
not usually volunteer this information to their doctors, and doctors rarely ask (Roter et al., 
1998). 
Studies have been conducted on individual clinical risk factors of CVD such as 
hypertension and hyperlipidemia. For hypertension, of the 50% of patients who persisted 
with anti-hypertensive treatment, one-third did not take sufficient medication doses to 
achieve optimal blood pressure control. In terms of drug class, adherence has been 
shown to be higher with angiotensin-converting enzyme inhibitors (ACEI) or calcium 
channel blockers, when compared to diuretics or beta-blockers (Mallion, Baguet, Siche, 
Tremel & de Gaudemaris, 1998). For hyperlipidemia, fewer than 50% of elderly patients 
prescribed statin medications for hyperlipidemia were adherent 12 months after initiating 
therapy (Benner et al., 2002). Adherence for statins has been shown to be higher than 
adherence with other classes of lipid-lowering agents such as resins or niacin (Avorn et 
al., 1998). 
For secondary prevention of CVD with multiple prescriptions after hospitalization 
for ACS or MI, patients often stop taking medication therapy early. In one month after 
discharge, of the patients in a multicenter prospective study (n=1521) taking at least three 
of the most prescribed class of CVD drugs (aspirin, statin, and beta-blocker), only 66% of 
the patients continued taking all three medications, 12%) discontinued use of all three 
medications, 4%> discontinued use of two medications, and 18%) discontinued use of one 
medication (Ho et al., 2006). In a long-term study, only 3-9% of patients continued to 
take all three for secondary prevention of CVD from 1995 to 2002 (Newby et al., 2006). 
In secondary prevention of CVD, statins have demonstrated a reduction of the risk of 
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death by 30% after one to two years of treatment (Wei et al., 2005; GISSI-P Study 
Group, 2000; LIPID Study Group, 1998; Sacks et al., 1996; 4S Group, 1994), as well as 
protection of hypertensive patients with average or lower-than-average cholesterol 
concentration from CHD (Cannon et al., 2004; Sever et al., 2003; Ridker et al., 1999; 
Ridker et al., 1998; Sacks et al., 1996). However, the adherence rate for two years (based 
on refill records) of statin therapy in a cohort study of elderly patients was only 40% for 
secondary prevention of ACS and 36% for secondary prevention of CHD (Jackevicius et 
al., 2002). The adherence rates for CVD medications prescribed for the cardiac patients 
discharged from Sentara Virginia Beach General Hospital are not known. 
Intervention to improve adherence. Adherence to prescription medication is a 
health-related behavior that is susceptible to behavioral intervention. Interventions that 
seek to improve adherence include simplification of dosing, education, behavioral 
methods, and complex intervention using multiple modalities (Blue Cross & Blue Shield 
Association, 2003; WHO, 2003; Peterson et al., 2003; Roter et al., 1998). 
Simplification of dosing was the most commonly studied of all intervention types. 
Recent advances in pharmacokinetics and pharmaceutical science have resulted in the 
majority of CVD drugs being available in once-daily or twice-daily formulations instead 
of the previous three- or four-times-a-day dosing. There has been a significant 
improvement in adherence associated with less frequent dosing (Schroeder, Fahey & 
Ebrahim, 2004; Blue Cross & Blue Shield Association, 2003). 
Education methods were mainly pedagogic interventions, such as verbal or 
written information, with a knowledge-base emphasis to convey information. Specific 
strategies included one-to-one and group teaching, the use of written and audiovisual 
materials, mailed materials, and telephone instruction (Schroeder et al., 2004; Peterson et 
al.,2003). 
Behavioral methods were designed to change adherence by targeting, shaping, or 
reinforcing specific behavioral patterns. This included strategies such as skill-building 
and practice activities, self-monitoring, behavioral modeling and contracting, packaging, 
tailoring, rewards, and mail and phone reminders (Peterson et al., 2003; Blue Cross & 
Blue Shield Association, 2003; Roter et al., 1998). 
Complex interventions are programs that consist of more than one discrete 
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component, such as an education component combined with a behavioral or motivational 
component (Williams et al., 2006; Peterson et al., 2003; Blue Cross & Blue Shield 
Association, 2003; Center for the Advancement of Health, Health Care Financing 
Administration & National Institute on Aging, 1999; Martin et al., 1998; Rater et al., 
1998; Haynes, McKibbon & Kanani, 1996; Conrad, 1985). They are often 
interdisciplinary and non-homogeneous in nature. Major challenges of secondary 
prevention for CVD after acute hospitalization include the understanding of patients' 
needs, more in-depth patient education, managing the medication regimen effectively and 
safely, and providing customized services for an increasing number of older patients. 
Problem Statement 
Studies of interventions to improve medication use for chronic conditions were 
often inclusive of all diseases, multifaceted, appeared less effective overall, and made it 
difficult to synthesize conclusions (Haynes et al., 2005). Randomized controlled trials of 
interventions to improve medication use are few (Kripalani, Yao & Haynes, 2007). 
When the studies were more disease-oriented, they tended either to be too narrowly 
focused or to cover a broad spectrum of diseases. For the period from January 1967 to 
September 2004, examination of randomized controlled trials of interventions to improve 
adherence in chronic medical conditions found twelve articles focused on a single 
cardiovascular risk factor such as hypertension, two articles focused on the elderly 
population in all chronic illness, and only one study focused on the secondary prevention 
of CVD relying on lay support (Kripalani et al.. 2007). The study by Kripalani et al. 
represented a milestone in the attempt to understand the more holistic problems of 
adherence with CVD medication in the context of evidence-based medicine. More 
researchers have refocused their studies on three areas of concern related to improving 
medication adherence for secondary prevention of CVD. The areas are the disease 
domain, theoretical assumptions, and the healthcare environment. Murray et al. have 
recently investigated a behavioral intervention to improve adherence to multiple CV 
medications. No studies have focused on secondary prevention of CVD incorporating the 
SDT constructs within a healthcare environment. 
Disease domain. Supported by the systematic application of evidence-based 
medicine (Alexander et al., 1998; Sackett, Rosenberg, Gray, Haynes & Richardson, 
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1996) and better adherence by physicians to prescribing standardized multiple 
pharmacological therapies in the secondary prevention of CVD, more attention has been 
paid to understanding and improving adherence to CV medications by patients. Murray 
et al. and an interdisciplinary team of investigators^demonstrated improved adherence to 
CV medications, decreased health care use, and lower costs in an interventional study to 
improve medication adherence in the secondary prevention of CVD in HF patients 
(Murray et al., 2007). The overall adherence rate as well as adherence to various classes 
of pharmacological agents for CVD was also reported. The available data allows 
comparison of the efficacy of intervention to improve adherence to medication in 
secondary prevention of CVD with future studies. However, patient factors such as 
socio-economic status, resources, health-related factors, and prescription drug variables 
were not measured nor controlled for in the study. 
Theoretical assumption. Although Murray et al. demonstrated efficacy of the 
intervention to improve medication adherence in the secondary prevention of CVD after 
the cessation of a nine-month multi-level intervention, the effects dissipated in the three-
month post intervention follow-up period (Murray et al., 2007). The study confirmed that 
interventions with behavioral approaches can be effective in well-defined and limited 
circumstances, such as providing standardized medication counseling, simplified 
instructions for patients with low health literacy, easy-to-follow timelines to remind 
patients when to take their medications, monitoring patients' medication use, and 
intervening when patients appeared to be nonadherent. The study also confirmed that 
conventional medication education and behavioral approaches may not be effective in 
promoting prescription medication adherence in a sustained manner (Schroeder et al., 
2004; Blue Cross & Blue Shield Association, 2003; WHO, 2003; Peterson et al., 2003), 
without continuous reinforcement (Lee, Grace & Taylor, 2006; Miller et al., 1997; Bellg, 
2003; Deci & Ryan, 1985). This lack of sustainability resulted even after patients had 
experienced firsthand the dreadfulness of acute heart disease and were committed 
initially to taking steps toward healthy living (Charmaz, 2002; U.S. Department of Health 
and Human Services, 1996). An alternative understanding of behaviors beyond the 
behavioral approaches of reinforcement may be needed in a new patient-centered care 
paradigm (National Heart Lung and Blood Institute & Rothman, 2000; Sher et al., 2002). 
15 
Behavioral approaches are rooted in the empirical behavioral perspectives of the 
behavioral-centered theories. Behaviorists have argued that the concept of autonomy 
reflects an ignorance of the actual environmental factors that control behavior, and 
control over behaviors was defined as residing in reinforcements external to the organism 
(Skinner, 1971). Behavioral approaches with reinforcement do not acknowledge a 
functional self with autonomy (Skinner, 1971) and do not deal with the motivational 
questions of energization and direction of behavior (Ryan & Deci, 2006). Even in the 
modern cognitive approach to behavioral theories such as Social-Cognitive Theory, 
motivation is only implicitly inferred. In the cognitive behavioral approach, self-
motivation is defined as an expectation of meeting some internal belief or standards, 
while autonomy is defined as action that is independent of the environment (Bandura, 
1989). Several modern cognitive models, such as the Health Belief Model, Theory of 
Planned Behavior, Transtheoretical Model, and others have been employed in 
understanding, predicting, and improving adherence (DiMatteo & Martin, 2002; Bowen, 
Helmes & Lease, 2001). Their common components involve communication between 
health professionals and patients, patients' cognitive and social processes (e.g., beliefs, 
norms), and the role of external barriers in terms of patients' resources (e.g., financial, 
psychological, and social support). While the lifting of external barriers, improving 
competence, and believing in medical recommendations are important, they do not 
address the explicit or implicit reasons for patients' positively adopting desirable 
behaviors (Murray et al., 2007). Since the behavioral approaches have been dominant in 
healthcare, few empirical studies of adherence conducted during the last half-century 
were guided by alternative theories (Schroeder et al., 2004; Haynes, 2001; Williams, 
Rodin, et al., 1998; Botelho & Skinner, 1995), even though motivational factors have 
been acknowledged to be crucial in the success of cardiovascular risk factor modification 
(Blue Cross & Blue Shield Association, 2003; WHO, 2003), 
Self-determination theory (SDT) is a motivational theory that examines the 
regulation or motivation for behaviors (Deci & Ryan, 1985). SDT recognizes that while 
the role of external barriers and competence are important determinants for behaviors, by 
themselves they do not address the question of why patients want to adhere to a treatment 
or are willing to change their behaviors. SDT made explicit the energization and 
16 
direction of motivation, the locus of causality, the differentiation of degree of controlled 
versus autonomous motivation, and how new and desirable behaviors can be internalized 
and integrated. SDT further proposes that when one's psychological needs are met in a 
relationship-centered environment that is autonomous supportive, an individual will tend 
to be self or autonomously regulated to better integrate new skills. SDT has been used to 
guide research in chronic disease rehabilitation (Williams, Gagne, Ryan & Deci, 2002; 
Williams et al., 2002; Williams et al., 1996) and adherence to long-term prescriptions 
(Williams, Rodin, et al., 1998). It appears that with an explicit set of motivational 
Constructs and an explanation of how motivational factors are causal in the regulation of 
behavior, SDT may be useful in the exploration of adherence to CVD medication in the 
secondary prevention of CVD in the population at risk of developing HF. 
Empirically, motivation in SDT is represented as a qualitative range of how 
behaviors are motivated or regulated, with autonomous motivation on one end of the 
spectrum and controlled motivation on the opposite end of the spectrum. Autonomous 
motivation is considered to be well integrated, while controlled motivation is not well 
integrated. When the motivation is autonomous, the subsequent behavior is self-
determined and likely to be purposeful and with a sustainable outcome. When the 
motivation is controlled, the subsequent behavior is not of one's own choosing and is not 
as likely to be sustained. However, for psychological needs to be met and autonomous 
motivation to be acquired by patients, systemic factors beyond the management of 
disease and medication have to be addressed, such as what is found in a patient-centered 
environment. 
Healthcare environment. Patient-centered care (PCC) is a holistic approach to 
healthcare that is driven by consumer demand (Institute of Medicine [IOM], 2001). 
Though not a theory, patient-centered care is a relationship-centered approach (Tresolini, 
1994) rooted in the biopsychosocial model (Engel, 1997) that was defined in terms of 
general systems theory (von Bertalanffy, 1968). The historical development of PCC is 
likened to the healthcare system rediscovering its roots in putting the patient back as the 
center of attention. It involves healthcare providers trying to understand the patient's 
perspectives; being responsive to the needs of patients/families; sharing treatment-
relevant power; focusing on overarching goals in the context of the patient's values, 
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experience, and expectations; working together toward agreed-upon goals related to 
preventing or treating illness; or coping with untreatable illness and ensuing death 
(Frampton, Gilpin & Channel, 2003; Quill, 1983). The patient-centered perspective of 
adherence has recognized that patients are active agents in their treatment rather than 
passive and obedient recipients of medical instructions (Stimson, 1974). 
A PCC approach to the management of medication use also assumes the 
perspective that patients play an active role in adherence. Its perspective is consistent 
with the approach of SDT (Martin et al., 1998; Quill & Brody, 1996; Williams et al., 
2000). While SDT does not dictate the setting of a relationship-centered environment, 
PCC provides a structure for a relationship-centered environment within which SDT can 
be employed to guide the development and improvement of PCC. Within the context of 
integrating PCC with SDT, patient factors such as socio-economic status (age, marital 
status, gender, race/ethnicity), and resources (health literacy, insurance availability, social 
support) are just as important as the health-related factors (illness level, smoking status, 
depression risk), and prescription drug variables (prescription expenses, number of doses 
per day, adverse drug reactions) in the exploration of adherence to medication in the 
secondary prevention of CVD. 
Research questions. 
Descriptive questions. 
1. What is the rate of adherence to CVD medications three months post discharge? 
Inferential questions. 
1. Does SDT predict patient adherence? 
2. Do socio-economic status (SES), resources, health-related factors, or prescription 
drug variables predict patient adherence? 
3. Does SDT predict adherence when controlling for SES, resources, health-related 
factors, and prescription drug variables? 
4. Do the SDT constructs change over time (pre-test vs. post-test)? 
5. How does PCC affect the SDT constructs? The constructs are perceived autonomous 
support, perceived competence, and autonomous motivation. 
6. How does PCC affect adherence? 
7. How does PCC affect adherence after controlling for SDT and other factors? 
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Assumptions. The study was conducted with the assumption that participants 
will answer all questions honestly. Since family members or significant others may assist 
the patients after discharge from the hospital, it was also assumed that family members or 
significant others as well as the patients were interested in improving the health and well-
being of the patients and would answer all questions honestly if asked. 
Scope and limitations. This study examined medication adherence and sought to 
test a psychological theory in hospital patients who suffered from acute coronary 
syndrome (ACS), acute myocardial infarction (MI) or were at risk of future heart failure, 
ACS, MI, or stroke. 
The study sample was selected from the cardiac units from one hospital. 
Selecting the sample from only one hospital, as well as the small sample size, decreased 
the ability of the study to be generalized to other settings or larger populations. In 
addition, the short length (three months) of time between pre- and post-test 
administration may not have captured the full extent of non-adherence. 
The study respondents may have been tempted to appear to be more adherent than 
they actually were in studies of adherence. Socially desirable responses in research have 
typically been assumed to be a function of two factors: (1) "the demands of a particular 
situation," such as the demand to be adherent, and (2) a personality trait that is related to 
"the strength of need for approval felt by an individual" (Phillips & Clancy, 1972). In 
order to control for the influence of social desirability, the self-regulation of medication 
was explained to the participants as (1) a process of making personal choices among 
many priorities in the context of one's life, (2) a bigger issue beyond simply adherence 
versus non-adherence, (3) an important factor to consider in order to design a more 
patient-centered health care system, and (4) an activity that is legitimate and acceptable to 
the researchers of adherence. 
Because of the advanced age of this patient population, some participants dropped 
out of the study early because of their condition. Some participants in the comparison 
group might have dropped out early because they might feel that they were not receiving 
the same benefits as the experimental group or perceived themselves to be not as 
important as the experimental group. 
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CHAPTER II 
Literature Review 
Introduction 
Self-determination theory (SDT) is a general theory of motivation that details the 
motivationally-based regulatory dynamics and processes of behavior. SDT can be 
applied to the examination of motivational factors associated with behavior outcomes, 
such as adherence in a healthcare setting. The development and application of this theory 
will be explained in this chapter. The review of past research pertaining to the study will 
be discussed. Determinants of adherence and related literature will also be presented. 
The self-determination theory adherence model. Three main psychological 
factors, perceived autonomous support, perceived competence, and autonomous 
motivation have been identified and their dynamic relations described by SDT (Williams 
et al., 2006; Niemiec et al., 2006; Williams et al., 2006b; Sheldon, Williams & Joiner, 
2003; Ryan & Deci, 2000a; Deci & Ryan, 1985). These three SDT constructs were 
derived from the assumption that humans are innately oriented toward health and growth, 
and that humans have the innate psychological needs to feel: (1) related to other humans, 
(2) competent, and (3) self-determining (Deci & Ryan, 1985). These psychological 
factors, or motivational factors, are used to describe the energization of motivation in 
humans (Williams et al., 2006; Sheldon et al., 2003; Ryan & Deci, 2000a; Deci & Ryan, 
1985). Perceived autonomous support, perceived competence, and autonomous 
motivation can provide measures in the assessment of adherence behavior. 
The SDT adherence model (Figure 2-1) depicts an internal motivational dynamic 
of a person. It shows that when a healthcare environment provides autonomy-supportive 
services such as education that encourage participation and empower the patient, a patient 
will perceive the healthcare environment to be autonomy-supportive and will perceive 
self-competence to be enhanced. Consequently, the patient's autonomous motivation for 
desirable health-related behaviors will be enhanced (Williams et al., 2002; Ryan & Deci, 
2000a; Deci & Ryan, 1985). When behaviors are autonomously motivated by intrinsic or 
personal reasons instead of by controlled motivation (Williams, Cox, Hedberg, & Deci, 
2001; Deci, Ryan & Koestner, 1999), patients will be more likely to act to produce 
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change with a sense of volition and personal endorsement of the behavior (Ryan & Deci, 
2000a; Deci & Ryan, 1985). 
Perceived competence 
Perceived autonomy 
support 
Autonomous motivation 
Figure 2-1. The self-determination theory Adherence Model 
Health-related 
behaviors: Adherence 
In this study, the SDT model was used to predict perceived autonomy support of a 
healthcare environment, perceived competence, and autonomous motivation. Perceived 
competence and autonomous motivation regulate health-related behaviors such as 
adherence to medical regimens. Perceived competence and autonomous motivation also 
have a reciprocal relationship. The concepts related to these three motivational 
constructs and their operationalized variables are summarized in Table 2-1. 
Perceived autonomous support. Perceived autonomous support is represented by 
the Health-Care Climate Questionnaire (HCCQ) in SDT (Deci & Ryan, 2003a). As one 
of the three motivational factors, it arises out of the psychological need for relatedness 
that is distinct from a physiological need such as sex. The need for relatedness is 
considered the most fundamental psychological need (Baumeister & Leary, 1995) that 
provides energy for a person's strivings to relate to and care for others, feelings that 
others are related authentically to one's self, and feeling a satisfying and coherent 
involvement with the social world (Deci & Ryan, 1991; McClelland, 1985; Maslow, 
1943). The quality of others' presence, and the quality of the social context within which 
one interacts with others, can affect one's behaviors, and have an important effect on 
one's feelings about oneself and one's overall development (Niemiec et al., 2006; 
Williams et al., 2006). In the framework of SDT, since relatedness is important to the 
healthy functioning of autonomous motivation, supporting relatedness can be the starting 
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point for encouraging a shift towards more self-determined functioning (Williams et al., 
2006; Ryan & Deci, 2000a). 
Perceived competence. Perceived competence is represented by the Perceived 
Competence Scale (PCS) in SDT (Deci & Ryan, 2003b). As one of the three 
motivational factors, it arises out of a psychological need for competence. The need for 
competence provides the energy for the development of competence and subsequently 
effective behaviors. The inherent feeling of competence derived from effective behaviors 
in turn meets the experiential need for competence (Williams et al., 2006). Sometimes 
referred to as self-efficacy, perceived competence is the degree to which an individual 
perceives or feels competence for changing target behaviors or achieving a goal 
(Vallerand & Reid, 1984). 
Table 2-1. 
Psychological concepts and operational definition of SDT constructs 
Psychological 
needs concept Corresponding motivational constructs Measures 
Relatedness Perceived autonomous support or 
autonomy-supportive environment 
The Health-Care Climate 
Questionnaire (HCCQ) 
Feeling competent 
Self-determining 
Perceived competence, or 
supports for competence 
Autonomous motivation, or 
autonomous determination, or 
autonomous self regulation, or 
self-determination 
Perceived Competence 
Scale (PCS) 
Treatment Self-
Regulation Questionnaire 
(TSRQ) 
Autonomous motivation or self-determination. Autonomous motivation is 
represented by the Treatment Self-Regulation Questionnaire (TSRQ) (Deci & Ryan, 
2003c). As one of the three motivational factors, it arises out of a need for self-
determination. This need is a human's basic propensity to be the primary locus of 
causality for one's behavior (Deci & Ryan, 1985; DeCharms, 1968). When a person 
perceives oneself to be the locus of causality for one's own actions, the person will 
consider oneself to be self-determined or intrinsically motivated for a correspondent 
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behavior. Conversely, when a person perceives the locus of causality to be external, the 
person will consider oneself to be extrinsically motivated for a correspondent behavior 
(DeCharms, 1968). In addition, humans are intrinsically motivated to approach activities 
that are interesting, optimally challenging, and spontaneously satisfying (Ryan & Deci, 
2000b). Many non-intrinsically motivated behaviors may be competence-oriented, and 
some may even be characterized by interest. However, to be truly autonomously 
motivated, a person must feel free to choose and be free from contingencies such as 
rewards, threats, guilt, or shame (Ryan & Deci, 2000a). The need for self-determination 
is primarily the need to choose whether to be in control, or to be one's own causal agent, 
while the need to control for an outcome is only a secondary need (Schorr & Rodin, 
1984). The degree of autonomous motivation is influenced by how one perceives the 
relationship of one's environment and oneself. Autonomous motivation is also known as 
autonomous determination, or autonomous self-regulation, or self-determination in the 
literature. 
Adherence. Adherence is represented by the adherence status of whether a 
patient is adherent or non-adherent (Roter et al., 1998; DiMatteo, Giordani, Lepper & 
Groghan, 2002; Peterson, Takiya & Finley, 2003). Adherence is defined as 
"the extent to which a person's behavior - taking medication, following a diet, 
and/or executing lifestyle changes - corresponds with agreed recommendations 
from a health care provider" (WHO, 2003 p, 3). 
For this study, the behavior of interest is adherence to taking prescription medications 
(Roter et al., 1998). Persistence was sometimes used in studies to denote the duration of 
treatment and the length of time a patient fills his/her prescriptions in a longer-term study 
of adherence. Many studies still use the term "compliance" instead of adherence. The 
notion of compliance in healthcare is a medically centered orientation, based on a 
consensual model of doctor-patient relationships, where as noncompliance is considered 
to be a form of deviance (Parsons, 1951). Two prominent social science perspectives, the 
doctor-patient interaction perspective (Garrity, 1981) and the patient's health beliefs 
perspective (Becker et al., 1979; Becker, 1976; Becker & Maiman. 1975), were used to 
explain why patients were compliant or noncompliant. The doctor-patient interaction 
perspective assumed that the doctor is much more significant for compliance than the 
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patient (Davis, 1968; Becker & Maiman, 1975), while the health belief model assumed 
behavior is controlled by rational decisions based on health-related beliefs (Becker & 
Maiman, 1975). Most of the medication adherence intervention shared this assumption, 
unless explicitly stated otherwise. 
Non-adherence may be compounded in the populations with multiple morbidities 
which require multiple drug therapy. However, non-adherence may not be more 
prevalent in older patients and there is no consensus in the literature that age is a 
predictor of poor adherence (Hughes, 2004). In the absence of constant intervention, the 
quality of non-adherence for older patients may be more a matter of deliberately choosing 
not to adhere to medication (intentional non-adherence) rather than doing so for other 
reasons (Hughes, 2004). This observation points to the active role patients play in 
decision-making about medication as well as the relevance of a concept of concordance 
in adherence. This study will test the utility of self-determination theory in exploring 
medication adherence. 
Application of Self-Determination Theory 
Essential to cognitive and social development, SDT recognizes that there is a 
natural motivation toward spontaneous interest, exploration, assimilation, and mastery of 
unfamiliar but desirable tasks (Ryan, 1995; Csikszentmihalyi & Rathunde, 1993). The 
process of internalization is a SDT framework for transformation of desirable 
extrinsically motivated behaviors into personal values that is considered intrinsic and 
autonomous (Niemiec et al., 2006; Williams etal., 2006; Deci & Ryan, 1985). 
Internalization of external regulations. Internalization is the theoretical process 
developed to integrate the various styles of motivation involved in acquiring the skills for 
new functioning behaviors, in order to fulfill the human need to be related, competent, 
and self-determined. A self-determination continuum developed by Deci and Ryan 
(Figure 2-2), drawn by anchoring controlled motivation and autonomous motivation on 
the opposite ends of a spectrum, represents the degrees of internalization of the source of 
behavioral regulation (Deci & Ryan, 1985; Ryan & Connell, 1989). From left to right are 
the regulatory styles of motivation: (1) completely amotivated with non-regulated 
behavior, (2) extrinsic motivation with externally regulated or controlled behavior, (3) 
extrinsic motivation with introjected regulated behavior, (4) extrinsic motivation with 
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identified regulated behavior, (5) extrinsic motivation with integrated regulated behavior, 
and (6) intrinsic motivation with self-determined, or autonomous, or intrinsically 
regulated behavior. 
Behavior Nonself-Determined Self-Determined 
Motivation 
Regulatory 
Styles 
Perceived 
Locus of 
Causality 
Impersonal External Somewhat 
External 
Somewhat 
Internal 
Internal Internal 
Relevant Nonintentional, Compliance, 
Regulatory Nonvaluing, External 
Processes Incompetence, Rewards and 
Lack of Control Punishments 
Self-control, Personal Congruence, Interest, 
Ego-Involvement, Importance, Awareness, Enjoyment, 
Internal Rewards Conscious Synthesis Inherent 
and Punishments Valuing With Self Satisfaction 
Figure 2-2. The self-determination continuum showing types of motivation with their 
regulatory styles, loci of causality, and corresponding processes 
The degree of internalization and integration affects the structures and processes 
that give meaning to internal and external stimuli, thus facilitating or impeding behaviors 
toward the satisfaction of psychological needs (Deci & Ryan, 1985). The regulatory style 
determines the direction of associated motivation. The direction of motivation 
determines how much a behavior is perceived as autonomously regulated versus 
controlled regulated (Deci & Ryan, 1991). Subsequently, internalization determines the 
regulatory style of behaviors. Behaviors that are autonomously motivated, or stem from 
well-integrated personal values and regulatory processes, can be described as self-
determined, whereas behaviors that emanate from nonintegrated processes, such'as 
internal pressures and socially acquired introjections, are controlled motivated. 
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Controlled motivation includes external or extrinsic motivation prompted by 
external contingencies or intra-psychic forces. External contingencies include rewards, 
constraints, punishment, a desire to please others or meet societal expectations.. Intra-
psychic forces include acculturated guilt and shame (Ryan & Deci, 2000a; Ryan & 
Connell, 1989; Deci & Ryan, 1985; Deci, Nezlek & Sheinman, 1981). Initially external 
regulations or controlled motivation and their implicit values can be internalized to 
differing degrees through the processes of introjection, identification, and integration. 
Introjection involves complying with a contingency or regulation without accepting it as 
one's own so that the introjected regulation essentially controls the person. Identification 
involves identifying with the value of an activity so that the person, can regulate the 
behavior more willingly. Integration involves bringing the identified value into 
coherence with one's own value so the resulting regulation will be relatively autonomous, 
with a sense that it emanates from oneself and is perceived as having an internal locus of 
causality. 
Therefore styles of regulations reflect differing degrees to which the value and 
regulation of the requested behavior have been internalized and integrated. Compared to 
introjected controlled motivation, integrated autonomous motivation significantly affects 
and maintains change of the desired behaviors (Ryan & Deci, 2000a). Autonomy is 
sometimes confused with independence and individualism. From the SDT perspective, 
autonomy is concerned with the feeling that one is voluntarily engaging in a behavior, 
regardless of whether the behavior is dependant on others or not (Ryan, 1995; Ryan & 
Deci, 2000b). Cross-cultural studies have shown that there is a stronger relationship 
between autonomy and collectivist attitudes than between autonomy and individualistic 
attitudes (Kim, Butzel & Ryan, 1998). Classic developmental studies suggest that 
relatedness is essential for the growth of autonomous functioning. Infants who are more 
securely attached to their parents are more likely to engage autonomously in exploratory 
behavior (Bowlby, 1979), and relatedness to parents has been shown to be positively 
associated with autonomous functioning in adolescence (Ryan & Lynch, 1989; Ryan, 
Stiller & Lynn, 1994). 
Perceived locus of causality and direction of motivation. Medical regimens, 
such as learning to manage a healthy lifestyle and medication, usually require behaviors 
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that are not enjoyable and not intrinsically motivating. The initiation of these regimens 
may require the use of extrinsic or controlled motivators that are not autonomous or do 
not have an intrinsic locus of causality (Ryan, Deci & Grolnick, 1995), However, 
adherence studies have shown that compliant behaviors tend not to persist when extrinsic 
contingencies are not present (Murray et al., 2007; Lee, Grace & Taylor, 2006; WHO, 
2003; Deci & Ryan, 2000; Conrad, 1985). SDT recognizes that while controlled 
motivation is dependent on extrinsic contingencies, autonomous motivation depends on 
the perceived locus of causality in an individual's psyche. Perceived locus of causality 
reflects an individual's perception or representation of causal reality in an interpersonal 
context (Ryan & ConnelL 1989; DeCharms, 1968; Heider, 1958). The meaning of 
whether an event is controlled by others or autonomously motivated is influenced by the 
style of communication of the significant others and the perceived norm of a social 
environment. Accordingly, the impact of an external event on motivational dynamics is 
determined by its psychological meaning for the individual. A combination of the 
motivational dynamic and the supporting environment induces a change in the quality or 
direction of motivation for the behavior of interest. An autonomous supportive 
environment may induce a change in perceived locus of causality from external to 
internal and in the direction of behavioral control on the internalization spectrum. The 
change in the direction of behavioral control may further induce the integration of the 
previous external or introjected regulation into a more identified and integrated, 
motivation for the behavior (Deci & Ryan, 1985; Deci & Ryan, 1980). 
Relevant Studies 
Since adherence or compliance is often studied along with clinical research, it is 
often viewed as a natural phenomenon instead of a sociopsychological phenomenon. . 
Natural phenomena such as how medications interact with physiological receptors are 
usually value free. Adhering to a medication prescription by an individual is a 
sociopsychological phenomenon influenced by humans responding to one another in a 
healing and cultural context. In addition, institutionalizations of medical specialties also 
create their own social environment and language. The meaning of adherence may also 
change depending on different patient-physician-disease relationships. For example, 
adherence to a full course of antibiotics prescribed by an infectious disease specialist 
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means taking all the prescribed medication to avoid bacterial resistance, while adherence 
to taking a diuretic in self-management of CHF means to skip the medication when 
abnormal weight gain is noticeable under the supervision of a cardiologist. In addition to 
meta-analysis and adherence intervention studies, the following types of adherence 
studies were also surveyed: CVD domain, psychological approaches, and the patient-
centered care setting. 
Intervention for adherence in the domain of cardiovascular diseases. A major 
impediment in the interpretation of adherence studies is in finding comparable studies 
that are designed for the same disease domain, A systematic review of medication 
adherence studies for chronic conditions found 37 randomized controlled trials. Ten 
studies were for asthma, seven studies for hypertension, six studies for HIV, three studies 
for dyslipidemia, two studies for diabetes, two studies for rheumatoid arthritis, two 
studies for the elderly, one study for contraception, one study for thromboembolic 
diseases, one study for tuberculosis, one study for epilepsy, and one for CVD (Kripalani 
et al., 2007). Though 16 of these 37 trials reported an improvement in adherence, the 
study populations were too heterogeneous to warrant pooling for a formal meta-analysis 
(Kripalani, Yao & Haynes, 2007). The CVD study investigated rehabilitating cardiac 
patients' adherence to lifestyle modifications but not cardiac medication (Coull, Taylor, 
Elton, Murdoch & Hargreaves, 2004). A recent randomized controlled trial using 
behavioral intervention to improve adherence to multiple CV medications found the 
intervention group to be more adherent than the usual care group (78.8% vs. 67.9% [95% 
CI, 5.0-16.7]) during a nine-month period (Murray et al., 2007). This study is important 
because it addresses the behavioral approach to medication adherence in the domain of 
secondary prevention of coronary heart disease. 
Beyond behavioral intervention. Though the cardiac medication adherence 
study by Murray et al. showed that adherence was enhanced during the nine-month 
behavioral intervention period, the positive effects observed in the intervention group 
dissipated from 78.8% adherence to 70.6%) adherence in the three-month post-
intervention period (Murray et al., 2007). The dissipation of salutary effects has also 
been observed in other behavioral interventions involving self-management of diseases 
(Kramer, Jeffery, Jeffery & Snell, 1989; Stunkard & Albaum, 1981). This result is 
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consistent with meta-analytical findings that interventions to improve medication 
adherence for chronic diseases appear to be less effective than interventions to improve 
adherence to short-term regimens (Haynes et al., 2005). 
Given the sociopsychological influences on a patient, motivational theorists have 
suggested that meeting patients' intrinsic psychological needs is the key to understanding 
the persistence of behavioral changes (Ryan & Deci, 2000a; Williams, Grow, Freedman, 
Ryan & Deci, 1996; Deci & Ryan, 1985). SDT has been applied in self-management of 
glycemic control in diabetes (Williams, McGregor, Freedman & Deci, 2004), a chronic 
disease management challenge that is similar in nature and complexity to chronic CVD. 
Though an information-behavioral approach was important, the glycemic control study 
showed that when patients were engaged by autonomous choice, glycemic self-
management behaviors were better integrated and more sustained. Perceived autonomy 
support at three months was found to relate to changes in both autonomous motivation (r 
= 0.27, pO.Ol) and perceived competence (r = 0.29, p<0.01). Both change in 
autonomous motivation and change in perceived competence were found to predict 
improvement in glycemic control over a 12 month period at the beginning, six months 
and 12 months. However, the intervention did not affect perceptions of autonomous 
support at three months. The investigators speculated that there was an indirect effect of 
perceived autonomy support on achieving glycemic control in this model. 
Smoking cessation is important in the prevention of CVD and other chronic 
diseases. The Public Health Service's tobacco-dependence guidelines (Department of 
Health and Human Services, 2000) suggested that support for autonomy and self-efficacy 
may be important factors that predict abstinence from smoking. One of the fifteen 
studies of behavior change funded by the Behavior Change Consortium of NIH tested a 
SDT guided intervention for motivating tobacco cessation (Williams et al., 2006). Over a 
six-month period, participants in the intervention group of the randomized controlled trial 
received autonomous supportive counseling four times in addition to the same 
recommendations and materials given to those in the usual care. The counseling was 
designed to support the participants in making a clear and autonomous decision about 
whether or not to make a quit attempt. The participants were encouraged to explore their 
smoking history, attitudes, past quit attempts, perceived health risks from smoking, 10-
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year risk for developing CV disease from smoking, and their life strivings and how 
smoking might help or hinder their attainment. The outcomes included the use of 
medication to quit, abstinence for six months, as well as prolonged abstinence for six 
months after the reported quit date. In one month, patients in the intervention group 
perceived greater autonomy support, perceived greater competence, and internalized 
more autonomous motivation for taking smoking cessation medication than those in the 
usual care group. In six months, patients in the intervention group reported greater 
perceived competence, autonomous motivation, greater abstinence, greater prolonged 
abstinence, and more days not smoking (25.1 vs. 9,4 days) than the usual care patients. 
Mediational effect (Baron & Kenny, 1986) of the block of change in SDT motivation 
variables on the relation between the intervention and the smoking cessation outcomes 
were examined with multivariate regression techniques. The intervention condition 
significantly predicted both six-month smoking cessation and six-month prolonged 
abstinence, controlling for baseline motivation variables. This study is significant 
because it addresses the mediational role of motivational factors in an adherence 
intervention. However, it was tested in a relatively poor, young, and undereducated 
population. The result may not be generalizable to medication adherence in older, 
suburban CVD populations. 
SDT has been tested in a medication adherence study with a general non-cardiac 
adult population (Williams, Rodin, et al. 1998). Medication adherence was 
operationalized by three self-reported indicators of adherence, a composite adherence 
measure, and a dichotomous adherence status. Of the three self-reported indicators, the 
first one was derived from patient's recall of the pills taken over the last two days, the 
second one was from patient's estimation of the percentage of dosages taken as 
prescribed, and the third was derived from dividing the pills taken by the number of pills 
prescribed. The composite adherence measure was derived from the average of the above 
three self-reported adherence measures. The adherence composite was dichotomized so 
that 80% or more were considered to be adherent and the remainder were considered to 
be nonadherent. The cross sectional study found that perceived autonomy support was 
positively correlated with autonomous regulation and with the composite adherence 
outcome. Autonomous regulation was positively correlated with composite adherence. 
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In regression analysis, the dichotomized adherence status was regressed onto 
demographic variables (age, gender, and education level) and health status (current health 
and severity of illness) first, then the three SDT motivation variables were added in the 
second step, resulting in a significant improvement in the model. Only autonomous 
regulation explained significant variance in composite adherence. No demographic or 
health status variables were significantly related to composite adherence. 
Of additional interest is that this study also compared the motivational approach 
to a cognitive behavioral model, the Health Belief Model (HBM). The HBM survey 
assembled 46 examples of barriers to medication adherence from previous studies 
(Glasgow, McCaul & Schafer, 1986; Schafer, Glasgow, McCaul & Dreher, 1983). As 
expected, perceived barriers from the HBM were found to be negatively correlated with 
composite adherence. However, the perceived barriers measure was not significant in the 
logistic regression model with autonomous regulation, suggesting that autonomy 
mediates the relation between perceived barriers and adherence. In addition, the 
perceived barriers measure was negatively correlated with autonomous regulation, 
suggesting that individuals who were more autonomously motivated tend to perceive 
fewer barriers. The perceived barriers measure was also negatively correlated with 
autonomous support, suggesting that patients who felt autonomy support from their care 
providers perceive fewer barriers. Even though the study is not generalizable to a 
population in which patients are older, sicker, and are prescribed more complicated 
medical treatment, it showed that it is feasible to employ a motivational approach to 
medication adherence. 
A patient-centered care platform for SDT. SDT is a psychological theory that 
does not specify how it should be implemented in a social setting such as in a hospital. 
On the other hand, patient-centered care (PCC) provides a platform for improving care. 
Since PCC grew out of a consumer movement, its emphasis is on patient satisfaction, it is 
not theory grounded, and it does not address patient behaviors. A PCC platform may 
therefore be an ideal setting for the implementation of SDT because PCC recognizes the 
importance of patients' physical, social, and psychological needs. The Planetree patient-
centered care trial was the first PCC study designed to test the effect of a PCC unit on 
patient satisfaction, health education, patient involvement in care, health behaviors, 
31 
perceived health status, and use of services (Martiri et al., 1998). Compared to patients in 
the control group, patients in the PCC group were significantly more satisfied in terms of 
hospital stay, care environment, nursing care, involvement in their care, satisfaction with 
education received, with better mental health status and role functioning after discharge. 
However, the impact of PCC on health-related behaviors (nutrition, weight control, 
exercise, alcohol use, cigarette use, and stress control) and health status was not 
significant. This study showed that PCC can have a positive impact on patient 
involvement in their care and health education. Both of these elements are compatible 
with SDT. According to SDT, patient involvement is related to autonomous motivation, 
while improved health education is related to both autonomous support and perceived 
competence. The study was conducted in a regular medical-surgical patient population 
and may not be generalizable to a chronically ill population that requires more self-
management. 
The feasibility of applying SDT in a PCC environment has been demonstrated in 
chronic diabetes management (Williams, McGregor, King, Nelson & Glasgow, 2005). 
Diabetes management shares many similar complexities and challenges with secondary 
prevention of CVD. There is considerable variation in care provided to patients related to 
symptom control, preventive services, and degree of patient-centered support. This 
cross-sectional study aimed to extend previous SDT-guided diabetes management studies 
in a PCC environment by including a larger number of patients in a more diverse setting 
measuring several outcomes such as patient satisfaction, quality of life, and level of 
HbAlc. Autonomy support was positively associated with perceived competence, 
autonomy support was negatively associated with the glycemic outcome, and perceived 
competence was negatively related with glycemic outcome. As a key feature of PCC, 
patient satisfaction was found to be related to autonomous support, .perceived 
competence, and negatively related to depression. However, patient satisfaction was not 
related to the glycemic outcome HbAlc. This finding is consistent with the idea that 
patient satisfaction regarding outcomes is not as important as supporting patients' need 
for self-determination, relatedness, and competence as proposed by SDT. The study 
suggested that training clinicians on how to support patients' autonomy may be an 
important avenue to improve health-related outcomes. This study is supportive of 
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grounding PCC with SDT as a paradigm to explore the motivational dimension of self-
management in chronic care. However, medication adherence and patient factors were 
not assessed in this study. 
Patient factors related to medication adherence. Patient factors related to 
adherence were also explored in this study. These variables are categorized as socio-
economic factors, resources, health-related factors, and prescription drug variables. 
Socio-economic factors. 
Age. Age has not been consistently shown to be related to non-adherence 
(Hughes, 2004; Conrad, 1985). In the domain of CVD, older patients have been reported 
to have higher adherence to antihypertensive medications than younger patients 
(Marentetta, Gerth, Billings & Zarnke, 2002; Caro, Salas, Speckman, Raggio & Jackson, 
1999; Monane et al., 1996; Shea, Misra, Ehrlich, Field & Francis, 1992). However, a 
more recent study of elderly patients with coronary artery disease shows that patients 
who discontinued CV medications one year post discharge were more likely to be older, 
female, unmarried, and less educated (Kulkarni, Alexander, Lytle, Heiss & Peterson, 
2006). Age is also sometimes associated with how patients perceive health and health-
related behaviors (Sirey et al., 2001). Inadequacy of health literacy is also common 
among the elderly (Gazmararian et al., 1999), partly due to less schooling (US 
Department of Education, 1993a), failing eyesight, diminished hearing, and declining 
mental alertness (Wilson, 2003; Williams et al., 1995). Age may indirectly impact 
perceived competence via an inadequate level of health literacy, Advanced age is well 
known for its association with CVD, with CVD disproportionately affecting people age 
65 and older. After age 65, the incidence of HF approaches 10 per 1000 population 
(Rosamond et al., 2007), and approximately 80% of patients hospitalized with HF are 
more than 65 years old (Masoudi, Havranek & Krumholz, 2002). Prevalence of HF is on 
the rise because it is primarily a condition of older people (Rosamond et al., 2007; 
Kannel & Belanger, 1991), people are living longer with better health, and more people 
are surviving initial Mis due to better medical care (Hurst, 2002). Meanwhile, the 
coming wave of aging baby boomers reaching age 65 will contribute significantly to the 
incidence and prevalence of CVD (U.S. Bureau of the Census, 1996). 
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Marital status. Although marital status has not been found to be consistently 
associated with non-adherence (Friedman, Applegate & Grant, 2007; DiMatteo, 2004; 
Conrad, 1985), single patients were found to have lower adherence rates overall when 
compared to married patients (Dunbar-Jacob & Mortimer-Stephens, 2001), while a recent 
study on adherence to a CVD drug regimen showed that marital status predicts higher 
adherence in multivariate analysis (Kulkarni et al., 2006). 
Gender. Gender has not been found to be consistently associated with adherence 
(Conrad, 1985). Women with newly diagnosed hypertension were found to be more 
adherent to therapy than males in some studies (Marentetta et al., 2002; Caro et al., 
1999), yet women were also found to be more likely than men to discontinue medication 
in a CVD drug adherence study (Kulkarni et al., 2006). The inconsistency may be 
attributable to the fact that risk factors for development of CVD differ by sex. Though 
CVD affects men and women similarly, with a corresponding prevalence of 34.4% versus 
33.9%, women have a higher mortality rate than men from CVD, 53.2% versus 46.8%. 
The first major cardiovascular or coronary event experienced by men ranges from 
7/1,000 per year at ages 35-44 to 68/1,000 at ages 85-94. The first major cardiovascular 
event experienced by women is comparable with men but occurs 10 years later in life, 
with a narrowing gap. Men less than 75 years of age suffer more coronary heart disease 
(CHD or CAD) than women, while women younger than 75 years of age suffer more 
heart failure (HF) than men (Hurst, 2002). Menopausal women are two to three times 
more likely to be affected by CVD than women the same age who have not experienced 
menopause (Misra, 2001). While coronary heart disease plays a greater role in men than 
in women, hypertension and diabetes mellitus play a greater role in women than in men 
(Wenger, 2002). Women also have a greater risk of developing symptomatic heart 
failure after myocardial infarction (Ho, Anderson, Kannel & Levy, 1993). 
Race/Ethnicity.. Lower adherence was reported among black clinical trial 
participants in a hypertension trial in older patients (Furberg, Black & SHEP Research 
Group, 1988), while white race was a significant predictor of higher adherence to 
antihypertensive medications in a population-based study (Monane etal., 1996), though a 
long-term secondary prevention CVD drug adherence study did not find race/ethnicity to 
be a predictor of adherence or non-adherence (Kulkarni et al., 2006). The inconsistency 
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may be attributed to the fact that race and ethnicity are associated with varying degrees of 
literacy. Low literacy is generally higher among racial and ethnic minorities because of 
cultural and language variations, as well as differing educational opportunities (Wilson, 
2003; Baker et al., 2002). Patients with inadequate health literacy are at risk of a higher 
rate of medication nonadherence (Kalichman, Ramachandran & Catz, 1999). Race and 
ethnicity may indirectly impact adherence via an inadequate level of health literacy. 
Resources. 
Health Literacy. Health literacy may be an important confounder for the 
adherence model because medication knowledge (e.g., knowing the name of drugs, 
dosages, and how to take them) is highly correlated with medication adherence (Okuno et 
al., 1999; Lipton & Bird, 1994), and patients with inadequate health literacy are at risk of 
a higher rate of medication nonadherence (Kalichman et al., 1999). 
As a socio-economic resource, Healthy People 2010 defines health literacy as "the 
degree to which individuals have the capacity to obtain, process and understand basic 
health information and sendees needed to make appropriate health decisions" 
(Department of Health and Human Services, 2000). In addition to the ability to perform 
basic reading and numerical tasks for functioning in the healthcare environment and 
acting on healthcare information (American Medical Association, 1999), health literacy 
may also include other skills such as a working knowledge of disease processes, self-
efficacy, and motivation for political action regarding health issues (Nutbeam, 2000). 
Nearly half of all American adults, about 90 million people, have difficulty understanding 
and using health information (Institute of Medicine [IOM], 2004), while one third of the 
English-speaking patients admitted to hospitals have been classified as having inadequate 
functional health literacy (Williams et al., 1995), and 34% of the Medicare managed care 
enrollees aged 65 and older had inadequate or marginal functional health literacy 
(Gazmararian, Baker, Williams & et al., 1999). 
Studies that investigated health literacy have reported that it is the single best 
predictor of health status, correlating more closely with health status than age, income, 
employment status, education, and race or ethnicity (Weiss, Hart, McGee & D'Estelle, 
1992; Baker, Parker, Williams, Clark & Nurss, 1997; Williams, Baker, Honig, Lee & 
Nowlan, 1998; Williams, Baker, Parker & Nurss, 1998) and hospital admission (Baker et 
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al., 2002). Limited health literacy has also been shown to be associated with worse 
health outcomes (Kalichman & Rompa, 2000; Williams, Baker, Honig, et al., 1998; 
Williams, Baker, Parker, et al., 1998), lower use of preventive services (Scott, 
Gazmararian, Williams & Baker, 2002), a higher rate of hospitalization (Baker, Parker, 
Williams & Clark, 1998; Baker et al., 2002), and poorer self-reported health (Baker et al., 
1997). 
The causal factors of poor health literacy remain to be explored. Even though 
44% of adults aged 65 and older were classified as functionally illiterate (US Department 
of Education, 1993), the lower reading ability is not explained by their having less 
education, a higher prevalence of chronic diseases, worse physical or mental health, or 
dementia (Baker, Gazmararian, Sudano & Patterson, 2000), The lower reading ability 
among older adults is likely the result of age-related declines in information processing 
(Baker et al., 2002). Regardless of their educational background, patients are often 
unprepared given the fast-changing and complicated healthcare environment, because 
educational attainment is not an accurate prediction of health literacy (Baker, Johnson, 
Velli & Wiley, 1996; Meade & Byrd, 1989; Public Health Agency of Canada, 1999). 
Patients may also be ashamed of their low health literacy and attempt to conceal their 
inadequacy from others (Baker et al., 1996; Parikh, Parker, Nurss, Baker & Williams, 
1996). 
Insurance availability. For inner-city urban populations and elderly patients, the 
lack of prescription coverage is a major impediment to medication adherence 
(Balkrishnan, 1998). While the federal government requires states that participate in 
Medicaid to provide a core set of benefits (such as physician services, hospitalization, 
and nursing home and home health care), it also permits states the flexibility to provide 
"optional" services at the state's discretion. Prescription drug coverage is considered to 
be one of the optional services in Medicaid (other optional services are prosthetic-
devices, dental care, and hospice care). Medicaid is the nation's major health insurer of 
low-income families, the elderly, and the disabled, covering more than 47 million people. 
Since most Medicaid beneficiaries have limited access to alternative sources of insurance, 
beneficiaries in states that are reducing eligibility are likely to become uninsured (Center 
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for Studying Health System Change. 2006; The Henry J. Kaiser Family Foundation, 
2002). 
Social support. Informal caregivers including family members or friends fulfill an 
important role not only for the people they assist but for society as a whole, accounting 
for an estimated economic value of $257 billion annually (Arno, 2002), approximately 
20% of the total national health expenditure (Levit, Smith, Cowan, Lazenby & Martin, 
2002). Most caregivers reported the person they care for takes prescription medicine, 
with 92% of the care recipients age 50 or older taking prescription medicine (National 
Alliance for Caregiving & AARP, 2004). The greater the level of burden in care, the 
more likely the caregiver is to say that the care recipient needs help with their 
prescription medications such as taking the right amount at the right time. Of caregivers 
whose recipient takes prescription medicine, 45% say the person they care for needs 
someone to oversee or manage taking medicine, while 55% say the person they care for 
manages on their own (National Alliance for Caregiving & AARP, 2004). Social support 
may be an important factor in the health-related behaviors of patients. 
Health related factors. 
Illness level. Illness level has not been applied in adherence studies with CVD. 
However, a patient's level of illness may influence health behavior and outcomes (Sirey 
et al., 2001) and may be a potential confounder in the study. A motivated patient with a 
high illness level may choose to be adherent to prescription medications, while an 
unmotivated patient with a lower illness level may not be adherent. In this study, illness 
level is represented by the summation of a patient's New York Heart Association 
(NYHA) heart failure classification and coexisting chronic comorbidities. 
Smoking status. Smoking status also has not been studied as. a confounder for 
medication adherence. Although it has been estimated that tobacco use is the largest 
avoidable cause of illness and death and is responsible for about one in five of all 
American deaths annually (McGinnis & foege, 1993), there are no published studies of 
the effects of smoke cessation in patients with heart failure (The National Collaborating 
Center for Chronic Conditions, 2003). It has been shown that patients who continue to 
smoke after successful cardiac interventions (percutaneous coronary revascularization) 
are at greater risk for MI and death than nonsmokers (Hasdai, Garratt, Grill, Lerman & 
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Holmes, 1997). The relative risks of death corresponding to smoking status are (1) 1.0 
for nonsmokers, (2) 1,34 for former smokers (who quit at least six months before 
hospitalization), (3) 1.21 for recent quitters (who quit immediately following 
hospitalization), and (4) 1.75 for persistent smokers (Hasdai et al., 1997). Smoking status 
is included in the study because adherence to smoking cessation is an important 
intervention for CVD diseases (U.S. Department of Health and Human Services, 1990), 
and counseling has been used to support patients who want to quit smoking (Fiore et al., 
1996). Patients who are motivated to quit smoking may also be motivated to adhere to 
prescription medications. 
Depression risk. Depression risk is included as a confounder to be controlled in 
this study because of the following five reasons. First, depression has been shown to be a 
risk factor for noncompliance with medication (DiMatteo, Lepper & Croghan, 2000) and 
is associated with medication non-adherence in outpatients with CHD (Gehi, Haas, 
Pipkin & Whooley, 2005; Gottlieb et al., 2004; Kim, Han, Hill, Rose & Roary, 2003). 
Second, depression is often found to be associated with CVD. Third, depression has been 
established as a risk factor for morbidity and mortality in patients with CHD. Fourth, 
major depression has been established as one of nine modifiable risk factors that account 
for more than 90% of the risk of myocardial infarction (MI) worldwide. Finally, 
pharmacologic or non-pharmacologic treatment of depression might improve the quality 
of life of HF patients. 
Prescription drug variables. 
Prescription drug expenses. While the insured population is likely to be covered 
for prescription drugs, the amount of co-pay may still affect their adherence (Blue Cross 
& Blue Shield Association, 2003). In the United States, national spending on 
prescription drugs exceeded $160 billion in the year 2002. Some employers and insurers 
have moved from insurance systems with flat co-payments (where policyholders pay a 
specific dollar amount per prescription) to systems of coinsurance (where policy holders 
pay a fixed percentage of the total prescription price). Proponents of the coinsurance 
system have argued that this trend does not undermine overall health, since patients 
facing rising costs will reduce consumption of nonessential medications more than 
consumption of vital chronic care drugs. However, underutilization may be an 
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unintended problem because patients do not always understand the long-term benefits of 
medication use in chronic illnesses, and many chronically ill adults frequently cut back 
on medications owing to cost (Piette, Heisler & Wagner, 2004), with too much cost-
sharing leading to a loss of welfare (Dor & Encinosa, 2004). In the up-front co-payment 
system, a co-payment increase from $6 to $10 results in a 6.2 percent increase in 
nonadherence and a 9 percent reduction in the share of fully adherent persons. In the 
coinsurance sample, a proportional increase in the coinsurance rate from 20 percent to 75 
percent results in a 9.9 percent increase in nonadherence and a 24.6 percent reduction in 
fully adherent individuals. In another test, holding the out-of-pocket share constant at $15 
in both samples leads to a 45.3 percent nonadherence rate in the coinsurance sample, and 
a 35 percent nonadaherence rate in the co-payment sample (Dor & Encinosa, 2004). 
Compared to uninsured adults, studies have found that 8.7 percent of people with 
employer coverage did not purchase at least one prescription drug because of the co-
payment, while 26 percent of uninsured adults did not purchase at least one prescription 
drug because of cost (Cunningham, 2005). The current prescription co-payment and 
coinsurance schemes were found to have an adverse effect on medication adherence (Dor 
& Encinosa, 2004; Mojtabai & Olfson, 2003) and subsequently poorer health outcomes. 
Number of prescriptions and number of doses/day. Lowering the total number of 
pills patients have to take in a day has been shown in meta-analysis to be the most 
effective manner to improve adherence (Roter et al., 1998; Blue Cross & Blue Shield 
Association, 2003). However, the number of daily doses or medicines did not appear to 
affect the adherence rate in patients with diabetes (Bezie et al., 2006; Grant, Devita, 
Singer & Meigs, 2003). The number of prescriptions and number of doses taken per day 
by a patient is uncertain in CVD and may be a confounding factor that may affect the 
adherence outcome. 
Adverse drug reactions (ADR). Adverse drug reactions, also known as drug side 
effects, were commonly reported with medication use (Grant et al., 2003). Elderly 
cardiac patients are more likely to be taking multiple medicines, metabolize them less 
effectively, be more sensitive to their effects, and be more susceptible to adverse drug 
reactions (ADR). "Adverse drug reactions" is a term used to describe the unwanted, 
negative consequences sometimes associated with the use of different medications. The 
39 
term is preferred over the colloquial use of "side effect," as the term "side effect" may 
imply the potential for either beneficial or adverse consequences and the effects are not 
explained by the pharmacological actions of the drug (The Merck Manuals Online 
Medical Library, 2006-2008). The relationship between ADR and adherence is rarely 
quantified and reported in the study of adherence. This is probably because determining 
the precise number of adverse drug reactions that are experienced is virtually impossible 
given the difficulties in assessing causality and the low proportion of reported adverse 
drug reactions (British Medical Association, 2006). The level of risk for individual side 
effects is often imprecise because clinical trials are rarely large enough to calculate 
incidence rates with any certainty. At least 30,000 people need to use a medication in 
order to identify, with 95 percent power, an adverse reaction with an incidence of one in 
10,000 (Pirmohamed, Breckenridge, Kitteringham & Park, 1998). ADR also vary in their 
severity, by the type of medication causing them, and in the setting they are experienced, 
making identification complex. Adverse drug reactions are also under-reported (British 
Medical Association, 2006). Standardized methods to assess patients' attitudes or 
perceptions of ADR are not available. Though a main concern to patients, ADR by 
themselves are insufficient to explain the level of nonadherence (Conrad, 1985). It 
appears that it is the combination of ADR and a lack of confidence in immediate or future 
benefits that predicts suboptimal adherence (Grant et al., 2003). ADR may negatively 
impact patients' motivation to adhere with CV medications. Because of the lack of 
measurement standard, patients were asked whether they had any negative experiences 
with their CV medications during the post intervention interview. 
Integration of Self-Determination Theory in Patient-Centered Care 
The SDT patient-centered care adherence model shows how the conceptualization 
of patient-centered care and self-determination theory were integrated (Figure 2T3). There 
are parallel elements between PCC and SDT that lend to the adaptation of SDT to PCC. 
Autonomy support is closely related to the idea of patient-centeredness (Laine & 
Davidoff, 1996). PCC provides a physical framework, while the self-determination 
theory model provides a theoretical framework. Grounded by SDT in the study, PCC 
was explored for its potential to promote autonomous motivation and desirable health-
related behaviors in CVD. In addition to satisfying patients' immediate medical needs, 
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an autonomous supportive environment was designed to meet the patients' need for 
relatedness by considering the patients' perspective, encouraging and answering their 
questions, supporting their initiatives, and offering choices about treatment options yet 
minimizing control (Deci & Ryan, 2003; Williams, Frankel, Campbell & Deci, 2000). 
Customized medical education was designed to educate patients in managing CVD 
medications, help with perceived competence, and enhance their autonomous motivation 
to adhere to CVD medications. 
Figure 2-3. SDT guided patient-centered care adherence model 
Hypotheses 
1. SDT will predict adherence. 
2. Socio-economic status (SES), resources, health-related factors, and prescription drug 
variables will predict adherence. 
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3. SDT will predict adherence when controlling for SES, resources, health-related 
factors, and prescription drug variables. 
4. Levels of SDT variables will increase over time. 
5. PCC will predict a higher level of SDT constructs. 
6. PCC will predict adherence. 
7. Patients who receive PCC teaching will be more likely to be adherent at post-test than 
patients who received Usual Care (UC) teaching after controlling for the SDT 
constructs, SES, resources, health-related factors, and prescription drug variables. 
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CHAPTER III 
Method 
This study examined the extent to which the self-determination theory model 
could describe adherence with CV medication in two groups of hospitalized cardiac 
patients: a group that was taught about their medications in an autonomously supportive 
way and a group that received the usual instruction. Variables related to the model were 
measured once before discharge and once in a three-month follow-up. These variables 
included adherence measures, autonomous motivation, perceived autonomous support, 
perceived competence, age, gender, race/ethnicity, illness level, smoking status, 
depression risk, adequacy of health literacy, insurance availability, prescription drug cost, 
number of doses per day, and social support. 
Study Design 
Quasi-experimental design. A patient-centered care teaching method using 
interactive technology was developed to support medication teaching in a hospital CVD 
care environment. The patient-centered care adherence model was designed to examine 
the effects of the intervention on the SDT motivational variables and medication 
adherence, as well as the relationship between the motivational variables and medication 
adherence. The investigator used a pretest post-test comparison group design. 
X2 01 02 Patient-Centered Care (PCC) 
XI 01 02 Usual Care (UC) 
During the first part of data collection, 60 patients received the usual medical 
teaching (XI). After program implementation, another 60 patients received the patient-
centered care teaching (X2). For both groups of patients, a pre-discharge questionnaire 
(pretest) was administered on-site before the patient was discharged from the hospital 
(time 01). Approximately 3 months later (time 02), a post-hospitalization questionnaire 
was administered by the investigator. 
Development of Survey Instruments. A pre-discharge questionnaire (Appendix 
G) referred to as Survey 1 and a post-hospitalization questionnaire (Appendix H) referred 
to as Survey 2 were developed for this study. For the assessment of medication 
adherence, Survey 1 contains only subjective questions, while Survey 2 contains both 
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adherence, Survey 1 contains only subjective questions, while Survey 2 contains both 
subjective and objective questions as well as an open-ended comment section. Both 
surveys contain the three SDT motivational instruments that were adopted from previous 
SDT-guided studies (Ryan & Connell, 1989; Ryan, Plant & O'Malley, 1995). 
The three SDT survey instruments, Health Care Climate Questionnaire (HCCQ), 
Perceived Competence Scale (PCS), and Treatment Self-Regulation Questionnaire 
(TSRQ) were operationalized for their correspondent motivational constructs, the needs 
for relatedness, perceived competence, and self-determination (Deci & Ryan, 2003a; 
Deci & Ryan 2003b; Deci & Ryan 2003c). Both surveys contain assessment items for 
patient factors such as depression risk, adequacy of health literacy, smoking status, 
alcohol drinking status, activity, dietary habits, education level, social support, 
prescription expenses, access to prescription drugs, health status, and feedback on the 
utility of the "GetWellNetwork" patient interactive education system. In addition, 
Survey 2 contains an accounting section for pill counts for each category of cardiac 
medication, a quick assessment of major physical signs and symptoms related to heart 
failure, and admission diagnoses to health services. A Medical Record Abstraction Form 
(Appendix E) was used for clinical data collection. 
Study Variables and Measurements 
Data dictionaries. Five categories of variables were measured in the study. 
These were the adherence variables, the three self-determination theory constructs of 
motivation variables, the patient-centered care (PCC) intervention group variable, the 
socioeconomic status/resources variables, the health-related variables and prescription 
drug variables. Data dictionary 1 summarizes the sources of these variables and their 
relationship with the model (Table 3-1), data dictionary 2 summarizes their correspondent 
variable field names and values to be implemented with computerized: databases and 
statistical software (Appendix I). 
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Table 3-1. 
Data Dictionary 1: Sources' of variables 
I, Adherence: 
subjective measure, objective measure, composite adherence index, and adherence status. 
Variable How Measured Survey Time Relationship 
Subjective measure of individual prescription adherence by self-report 
self reported % medications 
taken as prescribed 
The question is measured with a 
visual analog scale (VAS) with a 
0%-100% range. High % indicates 
high level of adherence. (Pretest, 
question 25; post-test, question 19.) 
Pre-test Dependent 
and variable: self 
post- reported 
test adherence 
Objective adherence measure (obtained from the medication log at time 02) consists of: 
(1) Adherence rate of individual prescription 
(2) An overall adherence rate (average adherence rate of individual prescription) 
adhere to antithrombotic 
Aspirin 
adhere to antithrombotic 2: 
Plavix 
3. adhere to antithrombotic 3: 
Warfarin 
4. adhere to ACEI/ARB, e.g., 
Zestril, Avapro 
5. adhere to angina 
management, e.g., Imdur, 
nitrates 
6. adhere to beta-blocker, e.g.. 
Toprol 
adhere to alpha/beta-
blocker, e.g,, Coreg 
adhere to 
antihyperlipidemic agents, 
e.g., Zocor, Zetia, Niaspan 
adhere to cigarette 
cessation with Zyban or 
Chantix 
% adherence = # aspirin taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # Plavix taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # Warfarin taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # ACEI/ARB taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # nitrate taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # beta-blocker taken 
divided by # pills prescribed for the 
period x 100 
% adherence = # alpha/beta-blocker 
taken divided by # pills prescribed 
for the period x 100 
% adherence = # antihyperlipidemics 
taken divided by # pills prescribed 
for the period x 100 
% adherence = # Zyban or Chantix 
divided by # pills prescribed for the 
period x 100 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Post-
test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent, 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
Dependent 
variable: pill 
count at post-test 
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Variable How Measured Survey Time Relationship 
10. adhere to Ca chan nel 
blocker, e.g., Norvasc 
% adherence = # Calcium channel 
blockers taken divided by # pills 
prescribed for the period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
11. adhere to digitalis , e.g.. 
Digoxin 
% adherence = # Digoxin taken 
divided by # pills prescribed for the 
period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
12. adhere to diuretic , e.g., 
Lasix, Bumex 
% adherence = # diuretic taken 
divided by # pills prescribed for the 
period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
13. adhere to antialdosterone , 
e.g., Spironolactone, 
Eplerenone 
% adherence = # antialdosterone 
taken divided by # pills prescribed 
for the period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
14. adhere to dysr hythmias 
management 1, e.g., 
Cordarone, Betapace 
% adherence = # dysrhythmic taken 
divided by # pills prescribed for the 
period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
15. adhere to diabetic % adherence = # antidiabetic taken 
medication management, divided by # pills prescribed for the 
e.g., Glyburide, Metformin period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
16. adhere to electrolyte a nd 
fluid management, e.g., 
KCL 
% adherence = # electrolyte pills 
taken divided by # pills prescribed 
for the period x 100 
Post-
test 
Dependent 
variable: pill 
count at post-test 
• Objective measure of . , „ , ,, „ J
 „ . . . . Average of % adherence for 
overall (average) prescription . ,. .J , v
 ° '
r r
 individual prescription 
adherence at post-test 
Post-
test 
Dependent 
variable: 
calculated 
• Composite adherence index 
(Cadh) at post-test 
Composite adherence (Cadh)% = 
average of the subjective adherence 
and objective adherence = 
[adh_subj4_2% + adh_avg%] 
divided bv 2 
Post-
test 
Dependent 
variable: 
calculated 
Adherence status at post-test 
Dichotomized from Cadh 
l=adherentrate>80% 
2=non-adherent rate = or < 80% 
Post-
test 
Dependent 
variable: 
dichotomized 
Cadh 
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Table 3-1. Continued 
II. Self-determination theory constructs of three motivation variables 
1. Autonomous motivation subscale (Treatment Self-Regulation Questionnaire, TSRQ-AM) 
2. Perceived autonomy support (Healthcare Climate Questionnaire, HCCQ) 
3. Perceived competence (Perceived Competence Scale, PCS) 
Variable How Measured _,. Relationship 
Time 
1. Treatment Self-
Regulation 
Questionnaire 
(TSRQ-AM), 
(autonomous 
motivation) 
• TSRQAM1 at pretest 
• TSRQAM2 at post-
test 
2. Healthcare Climate 
Questionnaire 
(HCCQ) (perceived 
autonomy support) 
• HCCQ 1 at pretest 
• HCCQ2 at post-test 
3. Perceived 
Competence Scale 
(PCS) (perceived 
competence) 
• PCS1 at pretest 
• PCS2 at post-test 
5 items from the 13 items questionnaire on a 
Likert scale (1 to 7). 
TSRQAM1: Average of the responses on pretest 
questions 5d, 5f, 5g, 5i, 51. 
TSRQAM2: Average of the responses on post-test 
questions 5d, 5f, 5g, 5i, 51 
High score indicates the person's motivation tends 
to be autonomously regulated. 
Six items questionnaire on a Likert scale (1 to 7). 
HCCQ1: Average of the responses on pretest 
questions 3a, 3b, 3c, 3d, 3e, 3f. 
HCCQ2: Average of the responses on post-test 
questions 2a. 2b, 2c, 2d, 2e, 2f. 
High score indicates the healthcare environment is 
perceived to have a high degree of support for the 
patient's autonomous motivation. 
Four items on a Likert scale (1 to 7). 
PCS1; Average of the responses on pretest 
questions 4a, 4b, 4c, 4d. 
PCS2: Average of the responses on post-test 
questions 4a, 4b, 4c, 4d. 
High score indicates a high degree of self 
perceived competence. 
0 1 , 02 
01, 02 
0 1 , 02 
Independent 
variables in 
the SDT 
model: 
model 
constructs 
Independent 
variables in 
the SDT 
model: 
model 
constructs 
Independent 
variables in 
the SDT 
model: 
model 
constructs 
III. Intervention group variable 
Variable How Measured „. ' Relationship Time 
Group assignment Group 1 = comparison group (or the usual teaching 
group) 
Group 2 = experimental group (or the PCC 
teaching group) 
Independent 
Ol, 02 variable 
Table 3-1. Continued 
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IV. Socioeconomic status and resources 
Variable How Measured Survey Time Relationship 
1. Age at pretest 
2. Age 65 
3. Gender 
4. Race/ethnicity 
Age in year from birthday to admit day 
Dummy variable dichotomized from "age" 
1: age = or >65, 0: age<65 
1 = Male, 2 = female 
1. White/Caucasian (reference group), 2. African-
American, 3. Latino/Hispanic, 4. Asian/Pacific 
Islander, 5. Other. 
Ol 
01 
01 
Ol 
Independent 
• variables/SES 
Independent 
variables/SES 
Independent 
variables/SES 
Independent 
variables/SES 
5. Caucasian 
(dummy 
variable) 
6. Marital status 
7. Married 
(dummy 
variable) 
8. Adequacy of 
health literacy 
dichotomized from "race" 
1: Caucasian, 0: Black/African American, 
Latino/Hispanic, Asian/Pacific Islander, Others 
1 = married, 2 = divorced, 3 = widowed, 4 = 
separated, 5 = never married, 6 = a member of 
unmarried couple 
dichotomized from "marital" 
1 = married, 0 = divorced, widowed, separated, never 
married, and unmarried couple. 
Brief Health Literacy Screening Questions (BHLSQ) 
Average of 3 questions, 5 point Likert scale (0 to 4). 
In rank order of 1 = inadequate, 2 = marginal, 3 = 
adequate. High score indicates adequate health-
related literacy. 
Ol 
Ol 
Ol 
01 
Independent 
variables/SES 
Independent 
variables/SES 
Independent 
variables/SES 
Independent 
variables/ 
resource 
9. Adequate 
health literacy 
(dummy 
variable) 
10.Insurance 
availability 
11. Social support 
a. discharge-
help 
b. support-
relation 
c. live-alone 
dichotomized from "Illiteracy" 
1 = adequate health literacy, 0 = 
inadequate health literacy 
marginal & 
One question of yes/no answer. 1 = yes (has 
coverage), 2 = no (no coverage) 
3 questions 
a. any help with discharge from the hospital, yes/no. 
b. who will help with discharge: 0 = no one, 1 = 
spouse, 2 = child or children, 3 = family member 
besides spouse & children, 4 = companion, 5 = 
paid healthcare provider, 6 = other 
c. do you live alone, yes/no 
Ol 
Ol 
01 
Independent 
variables/ 
resource 
Independent 
variables/ 
resource 
Independent 
variables/ 
resource 
12. Support 
(dummy 
variable) 
Coded 0 (no) if questions 1 la = no, or l ib = 0, or 
11c = yes, otherwise coded 1 (yes). Ol 
Independent 
variables/ 
resource 
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V. Health related variables 
Variable How Measured Survey Time Relationship 
Illness level Illness level = 
NYHA/ACC/AHA heart failure class 
-•- comorbidities score (fluid & electrolyte disorder, 
COPD, dysrhythmia, anemia, tumor and cancer, Ol 
hypothyroidism, PAD, renal failure, obesity). 
High score indicates a high level of illness severity. 
2. Smoking status 
3. Depression 
4. Depressed 
(dummy 
variable) 
1 question with 2 choices: 1 = nonsmokers, 2 = 
smoker (persistent smokers or former smokers) Ol 
3 questions with yes/no answers: 
1. depressed = or > 2 weeks; 2. depressed = or > 2 o i 
years; 3. taking antidepressant. 
If there is a yes for any one of the depression risk 
questions (from item 3. Depression), the patient will Ql 
be considered to be at risk of depression. 
Independent 
variables/ 
health- related 
Independent 
variables/ 
health- related 
Independent 
variables/ 
health- related 
Independent 
variables/ 
health- related 
VI. Prescription drug variables 
Variable How Measured 
1. Prescription expenses 
(monthly co-payment) 
2. Number of 
prescriptions/day 
3. Number of medication 
doses/day 
4. Adverse drug reactions 
(ADR) 
One question for monthly total out-of-pocket 
dollars spent on prescriptions 
Number of cardiac prescriptions taken daily 
Number of doses to be taken daily 
One question with yes/no answer: Any 
adverse drug reactions that are troublesome 
enough to cause missing doses, 1 = yes, 0 = 
no. 
Survey 
Time Relationship 
02 
02 
02 
02 
Independent 
variables/Presc 
riptions 
Independent 
variables/Presc 
riptions 
Independent 
variables/Presc 
riptions 
Independent 
variables/Presc 
riptions 
Adherence Measures. There is no gold standard for measuring adherence, and 
rigorous study of adherence measurement techniques is uncommon because measurement 
of adherence to long-term medical therapy is complex and requires longitudinal 
assessment (Liu et al., 2001). Meta-analysis has shown that among the seven standard 
methods of measuring adherence (pill count, self-report, physiological test, medical 
record, collateral report, electronic monitor, composite measure), the most frequently 
used methods were pill count, self-report, and medical records (DiMatteo, 2004). This 
study used self-report, pill count, and composite measure. Physiological tests, such as 
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measurement of drug levels in the blood or urine, is the most direct, the most objective, 
the most expensive, and the least convenient method. Physiological tests may be affected 
by other physiological factors and be influenced by patient behavior if they know when 
the levels will be taken. Medical or pharmacy records are convenient and represent a 
direct and objective measure of medication refills, but it may not necessarily reflect the 
actual amount of medication taken. Collateral reports from other sources are indirect and 
also recorded the lowest level of adherence. An electronic monitor that records each 
opening of prescription bottle provides an objective measure (Liu H et al., 2001). 
However, this advanced method of measuring adherence can be as vulnerable to the 
"Hawthorne effect" as any other less technological method (Wetzels, Nelemans, 
Schouten, van Wijk & Prins, 2006; Liu et al., 2001). 
Subjective self-report of adherence. The subjective approach with self reporting 
is direct, simple, and inexpensive. Though limited by accurate recall, self-reported 
medication adherence has been validated as a reliable predicator of health outcomes, 
including blood pressure control (Morisky, Green & Levine, 1986), hospitalization for 
heart failure (Ghali, Kadakia, Cooper & Ferlinz, 1988), in the Coronary Artery Risk 
Development in Young Adult (CARDIA) study (Cutter et al., 1991), serum drug 
concentrations (Blumberg et al., 2005), response to antiretroviral therapy (Godin, Gagne 
& Naccache, 2003), medication adherence (Gehi et al., 2005), and in self-reported 
research in the field of personality measurement (Herbert et al., 2001). A visual analogue 
scale (Figure 3-1) was used to access the proportion of prescription doses taken. 
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 
1 1 
0% didn't 
take any 
1 1 
25% 
sometimes 
1 1 1 
50% 
half of 
the time 
! 
75% 
most of 
the time 
1 1 
90% 100% 
nearly all 
all of of 
the the 
time time 
Figure 3-1 Visual analog scale for adherence to prescription 
During the interview, the investigator asked the questions in the following 
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manner: "What is the percentage of all the medication you think you have taken during 
the last three months as originally prescribed? Please point to or put a cross at the point 
on the following scale of 0 to 100% showing your best guess about how much medication 
you have taken. We would be surprised if this was 100% for most people, e.g. ,0% means 
you have taken no medication; 50% means you have taken half your medication; 100%) 
means you have taken every single dose of medication." 
Objective measures of adherence. 
Pill count. Adherence based on pill counts was used. Total number of pills 
remaining in the prescription container subtracted from the total number of pills 
prescribed was used to determine the total number of pills taken over a period of time for 
a prescription or a prescription refill (Kogos, 2004). The interviewer also reviewed the 
medication log for reasons of nonadherence with the patient during the visit at time 02. 
Pill count has been one of the standard measures for medication compliance or adherence 
studies; the highest level of adherence observed amongst varying means of adherence 
measurement was observed with pill count (DiMatteo, 2004; Liu et al., 2001). The 
objective approach with pill counts, with or without electronic assisted monitoring, can 
be useful as long as patients do not dispose of the pills that have not been taken from the 
bottle before the visits to appear to be more compliant than they actually are. This is 
especially true when the patient anticipates negative consequences resulting from non-
adherence and knows the methods being used to measure adherence. 
The potential Hawthorne effect might have been softened by the investigator 
explaining to the participants ahead of time that adherence is essentially ambivalent and 
that one of the goals in teaching medication management is so patients would know when 
to adhere and when to deviate from a prescription in order to reap the maximum benefit 
from medication therapies. During the second interview, the investigator clarified with 
the participant that, "It is common that people find it difficult to always take their 
medicine exactly as prescribed because of different reasons like side effects, a need for 
dosage adjustment, and other life situations. There is no need to feel guilt or shame that 
you might not have adhered to the prescription. Learning the reasons why and when 
prescription medications should be interrupted is just as important as why medications 
should be taken for treatment." 
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Accounting for non-adherence. Reasons for non-adherence were accessed and 
recorded. Incidences of non-adherence were categorized into (1) medically acceptable 
with consultation, (2) medically acceptable without consultation but sanctioned, (3) non-
medical reason and without potential harm (4) non-medical reason and with potential 
harm, (5) life situation and without potential harm, (6) life situation and with potential 
harm, (7) forgot. Categories (1) and (2) are acceptable non-adherence. Number of pills 
belonging to categories (1) or (2) were deducted from the number of pills prescribed. 
Acceptable deviation from prescription included the following: adjusting dosage changes 
up or down as instructed by a physician before a new prescription is issued with the 
change, temporarily holding the dosage due to adverse drug reactions or acute illnesses, 
discontinuation of drug before completion of a prescription, and other agreed-upon 
arrangements negotiated between the physician and the individual. Adverse drug effects 
were also assessed to see if they had any negative effect on patient adherence (see 
"Adverse drug reactions" under the section "Prescription drug variables"). 
Calculating adherence rate. Adherence rate of a prescription or prescription refill 
was calculated by dividing the total number of pills taken by the total number of pills 
prescribed. The total number of pills prescribed was adjusted for sanctioned non-
adherence. For example, with a once-a-day blood pressure medication regimen, when a 
patient skipped two days of blood pressure medication because of a lower-than-desirable 
level of blood pressure, the number of pills prescribed for a 31-day period would be 
reduced to 29 (31 - 2 sanctioned non-adherent doses). 
(1) total # of pills prescribed and filled for 31 days = 31 pills 
(2) # of pills remaining = 3 
(3) # of pills skipped with a valid reason (i.e., blood pressure too low, 
dizziness, etc.) — 2 
(4) # of pills prescribed adjusted for non-adherence = 31 - 2 = 29 
(5) # of pills taken = 31 - 3 (# pills left over) = 28 
(6) Adherence % of the prescription = # of pills taken divided by # of pills 
prescribed adjusted for non-adherence, e.g. adherence % = 28/29 = 0.965 
or .96.5% 
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Adherence rate of individual cardiovascular medications. The CV drugs that are 
most likely to be prescribed and to be assessed for their adherence rates are listed below 
(Table 3-2). The drug names are listed in the format as "generic name (brand name)". 
Drugs that are available only in generic form were listed without their corresponding 
brand names. 
Table 3-2. 
Cardiovascular medications most likely to be prescribed for patients with cardiovascular 
diseases 
Drug Class: 
Generic name (Brand name) 
Medication Adherence rate 
Antithrombotics: 
Aspirin*, Clopidogrel (Plavix), Warfarin (Coumadin) 
% adherence = 
# of Antithrombotic taken/month 
divided by 
# of Antithrombotic/month 
prescribed 
Angiotensin converting enzyme inhibitors (ACEI): 
Benazepril (Lotensin), Captopril (Capoten), Enalapril 
(Vasotec), Fosinopril (Monopril), Lisinopril (Prinivil), 
Moexipril (Univasc), Perindopril (Aceon), Quinapril 
(Accupril), Ramipril (Altace), Trandolapril (Mavik) 
% adherence = 
# of ACE taken/month divided by 
# of ACEI prescribed/month 
3. Angiotensin II receptor blocker (ARB): 
Candesartan (Atacand), Eprosartan (Teveten), Irbesartan 
(Avapro), Losartan (Cozaar), Olmesartan (Benicar), 
Telmisartan (Micardis), Valsartan (Diovan) 
% adherence = 
# of ARB taken/month divided by 
# of ARB prescribed'month 
4. Nitrate: 
Isosorbide dinitrate, Isosorbid mononitrate, Nitroglycerin 
% adherence = 
# of Nitrate taken/month divided by 
# of Nitrate prescribed/month 
Beta-blocker: 
Acebutolol, Atenolol, Betaxolol, Bisoprolol. Esmolol 
(Brevibloc), Metoprolol (Lopressor, Toprol-XL), Nadolol 
(Corgard), Penbutolol (Levatol), Pindolol, Propranolol, 
Sotalol, Timolol (Blocadrin) 
% adherence = 
# of Beta-blocker taken/month 
divided by 
# of Beta-blocker prescribed'month 
4. Alpha/Beta-blocker; 
Carvedilol (Coreg) 
% adherence = 
# of Alpha/Beta-adrenergic blocker 
taken/month divided by 
# of Alpha/Beta-adrenergic blocker 
prescribed/month 
5. Antihyperlipidemics: 
Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin 
(Mevacor), Pravastatin (Pravachol). Rosuvastatin 
(Crestor), Simvastatin (Zocor), Niacin SR. (Niaspan), Zetia 
% adherence = 
# of Antihyperlipidemics 
taken/month divided by 
# of Antihyperlipidemics 
prescribed/month 
6. Calcium Channel Blocker: 
Amlodipine (Norvasc), Diltiazem (Cardizem), Felodipine 
(Plendil), Isradipine (DynaCirc), Nicardipine (Cardene), 
Nifedipine (Procardia), Nimodipine (Nimotop), 
Nisoldipine (Sular), Verapamil (Calan, Isoptin, Verelan, 
Covera^ 
% adherence = 
# of Calcium Channel Blocker 
taken/month divided by 
# of Calcium Channel Blocker 
prescribed/month 
7. Digitalis: 
Digoxin 
% adherence = 
# of Digoxin taken/month divided by 
# of Digoxin prescribed/month 
Table 3-2. Continued 
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8. 
9. 
10 
11 
12 
Diuretics: 
Furosemide (Lasix), Bumetanide (Bumex), Torsemide 
(Demadex), Indapamide (Lozol), Hydrochlorothiazide 
Antialdosterone: 
Spironolactone (Aldactone), Eplerenone (Inspra) 
. A ntiarrhythmics: 
Amiodarone (Cordarone), Sotalol (Betapace), 
Dofetilide (Tikosyn) 
. A ntidiabetics: Metformin (Glucophage) Glimepiride 
(Amaryl), Glyburide (Diabeta, Glynase, Micronase), 
Glipizide (Glucotrol), Metformin (Glucophage), 
Rosiglitazone (Avandia), Pioglitazone (Actos) 
. Electroly tes: Potassium chloride, Magnesium oxide, 
Calcium Citrate. 
% adherence = 
# of Diuretic taken/month divided by # 
of Diuretic prescribed/month 
% adherence •= 
# of Antialdosterone taken/month 
divided by # of Antialdosterone 
prescribed/month 
% adherence = 
# of antiarrhythmics taken/month 
divided by # of antiarrhythmics 
prescribed/month 
% adherence -
# of antidiabetics taken/month divided 
by 
# of antidiabetics prescribed/month 
% adherence = 
# electrolytes taken/month divided by 
# of electrolytes prescribed/month 
13. A ntidepressant: % adherence = 
Amitriptyline (Elavil), Bupropion (Wellbutrin or Zyban), # of Antidepressant taken/month 
Buspirone (Buspar), Citalopram (Celexa), Duloxetine divided by 
(Cymbalta), Escitalopram (Lexapro), Fluoxetine 
(Prozac), Nefazodone (Serzone), Paroxetine (Paxil), 
Sertraline (Zoloft), Sibutramine (Meridia), Trazodone 
(Desyrel), Venlafaxine (Effexor) 
# of Antidepressant prescribed/month 
Mean objective adherence rates of all cardiovascular medications taken. A 
mean objective adherence rate was calculated for each patient, which is the average 
medication adherence rate (adh_avg %). Adh_avg% = (sum of percentage of all 
prescriptions)/ # of prescriptions. 
Composite adherence index (Cadh). Composite index is derived by averaging 
the adherence rates from a subjective and an objective measure and can be used to check 
for variance in the correlations between different methods of measuring adherence (Liu et 
al., 2001; Williams, Rodin, et al., 1998). In a study that evaluated various adherence 
measures (an electronic monitoring system, self-report, pill counts, and composite 
measure) used in HIV studies, composite measures were shown to be the strongest 
predictor of undetectable viral load over time (Liu et al., 2001). A composite adherence 
index was validated in a long-term medication adherence study with a Cronbach's a of 
0.79 (Williams, Rodin, et al., 1998). The composite adherence index (cadh) was 
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calculated by averaging the sum of the subjective and objective adherence measures: 
Adherence index (cadh) = (adh_subj4% + adh_avg %)/2. 
Adherence status. Adherence index was dichotomized into adherence status at 
80% threshold with two categories, "adherent" or "non-adherent." Adherence index 
(Cadh) greater than 80% was considered to be adherent, while an adherence rate equal to 
or less than 80% was considered nonadherent. Adherence status was reported as the 
percentage of patients that were adherent or non-adherent. Though this threshold is 
somewhat arbitrary and has not been validated empirically as a clinically significant 
cutoff point for defining adherence, it is an accepted standard and has been used in most 
of the adherence studies (Peterson et al, 2003; DiMatteo et al., 2002; Roter et al., 1998). 
Perceived Autonomous Support. 
Operationalization. Perceived Autonomous Support was operationalized by the 
Health Care Climate Questionnaire (HCCQ) (Deci & Ryan, 2003a). The questionnaire 
was used to assess patients' perceptions of the degree to which they experienced their 
healthcare providers to be autonomy supportive in providing services or with respect to a 
specific healthcare issue. The wordings were adjusted slightly to reflect the particular 
studied environment. The participants were asked to rate each of the six items with a 7 
point Likert scale from 1 being not at all true, to 4 being somewhat true, to 7 being very 
true at time 01 (Appendix G, question 3) and at time 02 (Appendix H, question 2). The 
interviewer introduced the HCCQ with the following preface: "Healthcare givers 
(doctors, nurses, pharmacists, therapists, counselors, etc.) have different styles in talking 
with patients. We want to know if you feel that they understand your condition, talk to 
you in ways you understand, and provide you information that you can use after you 
leave the hospital. Most likely you would have met with several practitioners over time, 
so please answer in terms of your overall experience of all these practitioners together. 
There is no right way or wrong way in responding to this question. Your responses will 
be kept confidential, so none of your practitioners will know about your responses. 
Please tell us how true the statements below are for you with the 7-point scale, from 1 
being not at all, to 7 being very true." An individual's score on the Health Care Climate 
Questionnaire was the average of his or her responses on the six HCCQ items. 
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Validity and reliability. The original Health Care Climate Questionnaire is a 15-
item measure. Alpha reliability for the 15-item scale had consistently been above .090. 
It had been validated in a study of obese patients participating in a weight-loss program 
(Williams et al., 1996), teenage smoking cessation (Williams, Cox, Kouides & Deci, 
1999), and participating in a methadone treatment (Zeldman, Ryan & Fiscella, 2004). 
Shorter versions of the Health Care Climate Questionnaire have also been used. A 6-item 
version was used in a study of autonomous motivation promotion in diabetes control 
(Williams, Freedman, et al., 1998). A 4-item version had been used in a medication 
adherence study (Williams, Rodin, et al., 1998). Both shorter versions demonstrated 
alpha reliability of 0.82. To reduce item redundancy and economize the content of the 
survey, the investigator felt that the 6-item scale with an alpha reliability of 0.82 was 
adequate for the study. 
Perceived Competence. 
Operationalization. Patients' perceived competence is operationalized by the 
Perceived Competence Scale (PCS) (Deci & Ryan, 2003b). This is a 4-item 
questionnaire that assesses the degree to which participants feel confident about being 
able to manage their condition with CVD medications along with their healthcare 
providers, participate in a health-care program, or carry out a treatment regimen. It has 
been adopted to capture adherence behavior (Williams et al., 1996; Williams, Rodin, et 
al., 1998). The participants were asked to rate each of the four items with a 7 point Likert 
scale from 1 being not at all true, to 4 being somewhat true, and to 7 being very true at 
time 01 (Appendix G, question 4) and at time 02 (Appendix H, question 4). The 
interviewer introduced the PCS with the following preface: "Dealing with heart problems 
and treatment needs much effort and patience. Please tell us how you feel about dealing 
with your heart treatments and conditions. There are no right or wrong answers to these 
questions because everybody's condition is different. Please tell us how true the 
statements below are for you using the 7-point scale, from 1 being not at all, to 7 being 
very true." An individual's perceived competence score was the average of his or her 
responses on the four PCS items. 
Validity and reliability. The PCS scale is one of the most face valid of the 
instruments designed to assess constructs from SDT. The alpha measure of internal 
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consistency for the perceived competence items in previous studies was above 0.80 
(Williams et al., 1996; Williams, Rodin, et al., 1998). Though cognitive behavioral 
theories try to explain motivation as manifested by perceived competence, it is 
theoretically important to differentiate perceived autonomy (assessed with the TSRQ, as 
explained later) from perceived competence (assessed with the PCS). The constructs do 
have discriminative validity in this regard (Williams et al., 1996; Williams, Rodin, et al., 
1998). 
Autonomous Motivation. 
Operationalization. The degree of autonomous motivation is operationalized 
with the autonomous motivation portion of the Treatment Self-Regulation Questionnaire 
(TSRQ) (Deci & Ryan, 2003c). The TSRQ assesses the degree to which a person's 
motivation or regulation for a particular behavior (or set of behaviors) is relatively 
autonomous (also known as self-determined motivation). TSRQ also reflects the 
composite nature of motivation as explicated by SDT, such as controlled regulation and 
autonomous motivation as explicated by Organismic Integration Theory. The SDT 
literature used the terms "motivation" and "regulation" interchangeably in describing 
behaviors, e.g., the regulation of behavior versus the motivation of behavior. For the 
purpose of clarity in this thesis, motivation was used in association with autonomous 
motivation, while regulation is used in association with controlled regulation. The 
development and adaptation of the Self-Regulation Questionnaire have been applied in 
the fields of education, organizations, health care, sport & exercise, parenting, and mental 
health. The spectrum of behavioral regulation is a result of various degrees of 
internalization of external regulations. External control, introjection, identification, and 
integration are the types of behavioral regulatory styles most likely to be encountered in 
health care (Ryan et al., 1995). On the spectrum, external control represents the least 
internalization, while integration represents the most internalization. Less internalization 
corresponds to more controlled regulated behaviors, while more internalization 
corresponds to more autonomously motivated behaviors. In this study, TSRQ was 
patterned after the self-regulation questionnaires introduced by Ryan and Connell (1989) 
and adapted from a treatment motivation questionnaire in an alcohol treatment program 
(Ryan et al., 1995). There are thirteen items grouped into two stems. The two stems are 
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(1) "The reason I would learn to manage the medications prescribed for me" with eight 
items, and (2) "The reason I would adhere to the medication regimens is" with 5 items. 
The items following each of the two stems are different reasons that represent various 
tendencies of behavioral regulation. Items h and j represent external control; items a, b, 
c, e, k, and m represent introjection; items d, i, and 1 represent identification; items f and 
g represent integration. An example of an introjection, which is one of the controlled 
reasons, is: "I want others to see that I am really trying to adhere to my prescription." An 
example of integration, which is one of the autonomous reasons, is: "It is my 
responsibility to learn to manage my medication usage." For hypothesis testing to see 
whether a patient is more autonomously motivated versus more controlled regulated, 
identification and integration are grouped as autonomous motivated reasons, while 
introjection and external control are grouped as controlled regulated reasons. Questions 
d, f, g, I, and 1 (or the corresponding numbering of 4, 6, 7, 9, and 12) were for the 
autonomous motivation subscale (TSRQAM), while the controlled regulation subscale 
(TSRQCM) included the following questions: a, b, c, e, h, j , k, and m (or the 
corresponding numbering of 1, 2, 3, 5, 8, 10, 11, and 13). There are more controlled 
regulation items than autonomous motivation items in TSRQ because there are more 
kinds of controlled reasons for the regulation of behaviors. The survey of this study 
included both autonomous motivation subscale and the controlled regulation subscale, so 
patients could describe their style of behavioral regulation on the spectrum of self-
determination continuum. However, only the autonomous motivation subscale was used 
for hypotheses testing in this study. Controlled regulation had not been shown to be 
associated with sustained changes in desirable health behaviors in earlier SDT studies 
(Williams, Rodin, Ryan, Grolnick, & Deci, 1998; Williams, Freedman, & Deci, 1998; 
Williams, Grow, Freedman, Ryan, & Deci, 1996), only autonomous motivation was used 
in later SDT studies (Williams et al., 2009; Williams et al., 2006; Williams, Gagne', 
Ryan, & Deci, 2002). Autonomous motivation, represented by the autonomous 
motivation subscale of TSRQ (TSRQAM), is the behavioral regulation of interest that 
promotes autonomously driven health behaviors. The participants were asked to rate 
each of the 13 items from two stems with a 7-point Likert scale from 1 being not at all 
true, to 4 being somewhat true, and to 7 being very true. This was assessed at time 01 
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(Appendix G, question 5) and at time 02 (Appendix H, question 5). The interviewer 
introduced the TSRQ with the following preface "This question contains items that are 
related to your feelings about why you want to participate in managing your heart 
medicine. Different people have different reasons for doing that, so there is no right or 
wrong reason for the question. All 13 responses are related to this one question. Please 
tell us how true the statements below are for you using the 7-point scale, from 1 being not 
at all, to 7 being very true." Scoring was done by averaging the responses to each of the 
items that make up that subscale. Only autonomous motivation was used for hypothesis 
testing. 
Validity and reliability. Factor analysis of the TSRQ in a study of motivation for 
weight loss (Williams, Freedman & Deci, 1996) revealed two clear factors labeled 
Autonomous Reasons and Controlled Reasons. The TSRQ scale used in promoting 
motivation for patients with diabetes to self-regulate their HbAlc (Williams, Freedman & 
Deci, 1996) had an alpha value of 0.81 for the autonomous motivation subscale and 0.84 
for the controlled regulation subscale. The questionnaire has been validated in two 
studies in diabetes management (Williams, Freedman, et al., 1998; Williams et al., 2004). 
Group assignment. There are two groups in this study, the usual medication 
teaching group versus the patient-centered care (PCC) medication teaching group. 
Participants in the usual teaching group were taught the traditional way, such as verbal 
explanation of medication supplemented with medication pamphlets. The medication 
teaching provided in the PCC medication teaching group, or the experimental group, was 
supported by the GetWellNetwork interactive system. 
Socioeconomic factors and resources. Variables were used to measure 
socioeconomic and resource factors which included age, marital status, gender, ethnicity, 
health literacy, insurance availability, and social support. 
Health literacy. The ability to identify patients with potential literacy problems is 
important if healthcare providers attempt to overcome the adverse effects of low health 
literacy, provide an appropriate level of health education in a patient-centered care 
environment, and be able to empower patients in an autonomous supportive manner. The 
Brief Health Literacy Screening Questions (BHLSQ) was used to assess a participant's 
level of health literacy. BHLSQ consists of three questions about "how often a person 
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may need help" or "how confident a person is" in understanding health-related 
instructions or literature. A final BHLSQ score was used to rank participants' health 
literacy as being one of the following three levels, 1 = "inadequate," 2 = "marginal," or 3 
= "adequate." The scale of the response for each question was set on a 5-point Likert 
scale from zero to four. The developers of BHLSQ also suspected that patients were 
likely to under-report reading difficulties and applied several methods to their questions 
that have been successfully used to screen for other stigmatized behavior (Bradley, 
Kivlahan, Bush, McDonell & Fihn, 2001). The questions were phrased to ask patients 
"how often" they had a problem or "how confident" they were in each of the six themes 
rather than asking " i f they had a problem. At time 01 , each participant was asked to 
answer each of the following three questions with the five point scale: 
Never Occasionally Sometimes Often Always 
0 1 2 3 4 
1. "How often do you have someone help you read prescription bottles or hospital 
materials?" 
2. "How confident are you filling out medical forms by yourself?" 
3. "How often do you have problems learning about your medical condition because of 
difficulty understanding written information?" 
Since the rank direction of "how confident" in question 2 is opposite to that of questions 
1 and 3, this score was reversely coded during data entry before the health literacy score 
was calculated. Then the answers of 3 (Often) or 4 (Always) were recoded to the value 
of 1. The answers of 1 (Occasionally) or 2 (Sometimes) were recoded to a value of 2. 
The answer of 0 (Never) was recoded to a value of 3. The score from each of the three 
questions, "Help read," "Confident with forms," and "Problem learning" was averaged 
and rounded as follows: 1-1.5 = 1; 1.6-2.5 = 2; 2.6-3 = 3. The score of 1 corresponded to 
inadequate health literacy, 2 corresponded to marginal health literacy, and 3 
corresponded to adequate health literacy as follows: 1 = inadequate, 2 = marginal, and 3 
= adequate. A current accepted gold standard for the measurement of health literacy is 
not available. Other instruments considered were either too long or too potentially 
embarrassing to patients to be integrated into routine clinical settings (Brez & Taylor, 
1997). BHLSQ was developed for busy clinical settings to detect inadequate or marginal 
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health literacy among the adult patient population in a quick and unobtrusive manner 
(Chew, Bradley & Boyko, 2004). The development of BHLSQ was based on five 
domains identified in a qualitative study of patients with limited health literacy: 
navigating the health care system, completing medical forms, following medication 
instructions, interacting with providers, and reading appointment slips (Baker et al., 
1996). For the purpose of identifying inadequate health literacy, three out of sixteen 
questions were found to have significantly higher areas under the Receiver Operating 
Characteristic (AUROC) curve (Footnote 3-2). They are 1. "Help Read" (How often do 
you have someone help you read hospital materials) had an AUROC of 0.87 (95% CI = 
0.78-0.96); 2. "Confident With Forms" (How confident are you filling out medical forms 
by yourself) had an AUROC of 0.8 (95% CI = 0.67-0.93); and 3. "Problems Learning" 
(How often do you have problems learning about your medical condition because of 
difficulty understanding written information?) had an AUROC of 0.76 (95% CI = 0.62-
0.90). The questions were also found to be effective in identifying 80%) of patients with 
inadequate health literacy and somewhat weaker in identifying patients with marginal 
health literacy (Chew, Bradley & Boyko, 2004). 
Insurance availability. Each patient's insurance coverage (i.e., private insurance, 
Medicare, Medicaid, and Tricare) was accessed during the hospital stay and obtained 
from the medical record. It is a dichotomous variable with a yes or no answer. For 
patients who did not have prescription insurance coverage, assistance in exploring 
alternative coverage or prescription assistance programs was provided for the needy 
patients by the healthcare team. Patients with temporary assistance programs were not 
considered to have insurance coverage. 
Social Support. The availability of social support for each participant during 
cardiac rehabilitation was determined by assessing three related factors. Discharge-help, 
support-relation, and live-alone were used to assess the variable social support. For 
discharge-help, each patient was asked if there was anyone to help with discharge from 
the hospital. It is a question with a yes or no answer. For support-relation, the patient 
was asked about the relationship of the social support. The choices include: no one, 
spouse, child or children, family member besides spouse or child or children, companion, 
paid healthcare provider, and other. For live-alone, patient was asked if he or she lived 
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alone. It is a question with a yes or no answer. The three questions were summarized to 
obtain a social support status as follows. If the patient answered no to all three questions, 
the patient had no social support. If the patient answered yes to the question about 
discharge-help or answered other than "no one" to the question about support-relation or 
no to the question about living alone, the patient had social support. 
Health-related variables. These variables are illness level, smoking status, and 
depression risk. 
Illness level. In this study, illness level was calculated by the summation of a 
patient's NYHA/ACC/AHA (New York Heart Association / American College of 
Cardiology / American Heart Association) heart failure classification and coexisting 
chronic comorbidities. The clinical information was obtained from a patient's medication 
record and recorded in the Medical Record Abstraction Form (Appendix E). The risk 
levels for heart failure of a patient can be assessed with the New York Heart Association 
(NYHA) New York Heart Association, 2002) and American College of Cardiology 
(ACC) classification by using Table 3-3. The degree of potential for heart failure can be 
captured by the New York Heart Association (NYHA) classification. The NYHA 
Functional Classification provides a simple way of classifying the extent of heart failure 
by symptoms. Patients' symptoms and the degree of limitation imposed on physical 
activity are grouped into one of the four categories in this scheme. Class I represents the 
least degree of heart failure, while Class IV represents the most severe form of heart 
failure (Table 3-3). The NYHA classification has been updated by the American College 
of Cardiology (ACC) and American Heart Association (AHA) with disease states and 
risk factors (Hunt et al., 2005). For example, the NYHA class II with mild symptoms and 
some limitation during activity is expanded to the NYHA/ACC/AHA class B that 
includes the diagnostic workup of left ventricular hypertrophy (LVH) with or without 
impaired left ventricular (LV) function. This helps to clarify the relationship between 
symptoms and underlying cardiac functions in the classification of the risk of heart 
failure. 
In addition to the NYHA/ACA/AHA heart failure classification, the most 
common comorbidity categories reported by the Healthcare Cost and Utilization Project 
62 
(Agency for Healthcare Research and Quality, 2005) were included to arrive at the level 
of illness. 
Table 3-3. 
New York Heart Association (NYHA) functional classification of heart failure and 
American College of Cardiology (ACC)/American Heart Association (AHA) update for 
Chronic Heart Failure in Adults 
NYHA 
class Symptom 
NYHA/ACC/ 
AHA class Disease stage and Risk factors 
No symptoms and no 
limitation in ordinary 
physical activity. 
Patients with coronary artery disease, 
hypertension, or diabetes mellitus who do not yet 
Class A demonstrate impaired left ventricular (LV) 
function, hypertrophy, or geometric chamber 
distortion. 
Mild symptoms and 
slight limitation during 
ordinary activity. 
Comfortable at rest. 
Patients who are asymptomatic, meet class A 
Class B description but demonstrate LV hypertrophy 
(LVH) and/or impaired LV function. 
Ill 
Marked limitation in 
activity due to 
symptoms, even during 
less-than-ordinary 
activity. Comfortable 
only at rest. 
Patients with current or past symptoms of HF 
Class C associated with underlying structural heart disease. 
This includes the bulk of patients with HF. 
Severe limitations. 
IV Experiences symptoms 
even while at rest. 
Patients with truly refractory HF who might be 
eligible for specialized, advanced treatment 
strategies (e.g., mechanical circulatory support, 
Class D procedures to facilitate fluid removal, continuous 
inotropic infusions), or cardiac transplantation or 
other innovative or experimental surgical 
procedures, or for end-of-life care. 
Comorbidities are coexisting medical conditions that originated prior to the 
current hospital stay. These may be recorded as secondary diagnoses besides the 
principle CVD diagnosis. Comorbidity has been found to be associated with higher 
mortality in patients with heart failure (Goldberg, Ciampa, Lessard, Meyer & Spencer, 
2006). The progressive nature of comorbidity may contribute to the decline in survival 
among patients with heart failure. For patients with age 45 to 79 years old, the most 
common comorbidities reported are: (1) fluid and electrolyte disorders and kidney 
diseases, (2) chronic obstructive pulmonary diseases (emphysema or chronic bronchitis), 
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(3) irregular heartbeat (cardiac arrhythmia), (4) iron deficiency and other anemia, (5) 
solid tumor without metastasis and carcinomas, (6) hypothyroidism, (7) peripheral 
vascular disease, and (8) renal failure. The number of comorbidities was obtained by 
counting each category that matches the patients' pre-existing symptoms. The illness 
level was calculated by the addition of the NYHA/ACC/AHA categories and number of 
comorbidities during data analysis. For example, if a patient had an MI (NYHA category 
B), and a history of COPD and anemia, the illness level score would be 2+2 or = 4. 
Smoking status. A patient's history of smoking was dichotomized into either a 
smoker or a nonsmoker. A smoker was one who might have been a persistent smoker, a 
recent quitter, or a former smoker. A non-smoker was one who has never developed a 
habit of smoking. 
Depression risk. An excess of deaths from CVD has also been reported in 
patients with bipolar depression (Vestergaard & Aagaard, 1991; Sharma & Markar, 
1994). Though the diagnosis of depression is not part of the survey, participants were 
screened for potential risk for depression. Symptoms of depression may include 
persistent sad mood, feelings of hopelessness, guilt, loss of interest in activities that were 
once enjoyed, suicidal ideation, and others. Three yes or no questions were asked to 
assess a participant's risk for depression. Two questions from the Diagnostic Interview 
Schedule (DIS) were thought to be sensitive and selective enough for routine screening as 
a case-finding instrument and were less time-consuming (Wassertheil-Smoller et al., 
2004). They were (1) "In the past year, have you had two weeks or more during which 
you felt sad, blue, or depressed or lost pleasure in things that you usually cared about or 
enjoyed?" and (2) "Have you had two years or more in your life when you felt depressed 
or sad most days, even if you felt okay sometimes?" The first question was the stem 
question for major depression, while the second question was the stem question for 
dysthymia in the DIS (Robins et al., 1981). A third item, "Is the patient taking any 
antidepressants?" was extracted from the patient's home medication record in the Patient 
Data Collection Sheet (Appendix E). For the purpose of this study, a person who 
responded with "yes" to any of the three items was classified as at risk for depression. In 
addition, a participant was considered to be treated for depression if any antidepressant 
was prescribed. The third item was important because it helped to capture patients with 
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bipolar depression. These patients might not consider themselves to be depressed, but 
were likely to be prescribed with one of the antidepressants for their worsening 
depressive episodes. 
Validity and reliability. The two-question instrument from the DIS appears to be 
useful in classifying patients as having a history of depression and is more specific than a 
similar two-question approach using Primary Care Evaluation of Mental Disorders 
(PRIME-MD) (Wassertheil-Smoller et al , 2004). The two-question instrument was 
found to be less time-consuming than the other standardized diagnostic instruments for 
depression such as the Center for Epidemiological Studies Depression Scale (CES-D) 
(Radloff, 1977), Beck Depression Inventory (BDI) (Beck, Ward & Mendelson, 1961), 
depressive symptom severity with the Patient Health Questionnaire (PHQ-9) (Kroenke & 
Spitzer, 2002), Primary Care Evaluation of Mental Disorders (PRIMEMD) (Spitzer, 
Williams, Kroenke & et al, 1994), Symptom Driven Diagnostic System-Primary Care 
(SDDS-PC) (Broadhead, Leon, Weissman & et al., 1995), Hamilton depression rating 
scale (HAM-D) (Hamilton, 1960), Zung Self-Rating Depression Scale (SDS) (Zung, 
1965), and Diagnostic Interview Schedule (DIS) (Robins, Helzer, Croughan & Ratcliff, 
1981; Robins et al., 2000) when a depression diagnosis is not needed (Whooley et al., 
1997). If a patient was found to be at risk of depression (answering "yes" to the first 
and/or second depression items) but has not been diagnosed or treated, the interviewer 
would ask, "Would you like for our hospital chaplain to visit you?" If the patient 
consented to it, the interviewer made an arrangement with the chaplain for a visit. The 
interviewer also related the finding to the patient's nurse. The nurse documented the 
finding on the emotional assessment portion of the nursing information system, 
"Careminder," and communicated with the attending physician via a reminder on the 
progress note. The physician would then decide whether a full depression workup and 
treatment were necessary. 
Prescription Drug Variables. Prescription drug variables include prescription 
drug expenses, number of prescriptions, number of doses taken per day, and adverse drug 
reactions. 
Prescription drug expenses. Participants were asked to save their receipts for the 
prescriptions obtained during the study period. The cost of purchasing prescription 
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medication, including co-payments, was assessed at the end of the study period. An 
average monthly expense of prescription medication was tallied and included in the 
adherence model. 
The total number of prescriptions, as well as doses of all cardiac related 
medication taken within a day from both pretest and post-test, were included for analysis. 
Adverse drug reactions (ADR). Adverse drug reactions (ADR) of medications 
are unpredictable, not always recognized, and underreported. Qualitative descriptions are 
used to convey medication side-effects information, but with little or imprecise 
information about risk levels. ADR also increases with irrational drug use, overdoses, 
polypharmacy and interactions, increasing use of traditional and herbal medicines, illegal 
sale of drugs over the Internet, self-medication practices, substandard medicines, 
medication errors, and lack of efficacy. Adverse drug reactions information in the 
context of medication use, coping with disease condition, or adherence are limited. Since 
patients' perception of the safety of medication may affect their adherence to medical 
regimens, patients were asked if they had experienced any adverse drug reactions that 
might have caused them to skip doses or stop taking prescribed medications. Special 
attention was also paid to the following CV drugs that had caused most preventable 
admissions to hospitals: antiplatelets, diuretics, nonsteroidal anti-inflammatory drugs, or 
anticoagulants (Howard et al., 2007). 
Research Questions and Hypotheses 
The research questions and their correspondent hypotheses are summarized in 
Table 3-4. For the testing of hypotheses, adherence is operationalized by a Composite 
adherence index (Cadh). In addition, a patient's adherent status is dichotomized by 
considering Cadh = or >80% to be adherent, and Cadh <80% to be non-adherent. 
Table 3-4. 
Research questions, hypotheses, and statistics 
Descriptive questions 
Question: What is the rate of adherence to CVD medications three months post discharge? 
Inferential questions 
Question 1: Does SDT predict patient adherence at post-test? 
• SDT constructs consist of: 
1. Perceived autonomous support (operationalized by HCCQ - Health Care Climate 
Questionnaire) 
2. Perceived competence (operationalized by PCS - Perceived Competence Scale) 
3. Autonomous motivation (operationalized by the autonomous motivation portion of TSRQ • 
Treatment Self-Regulation Questionnaire) 
• Adherence is operationalized by: 
1. Composite adherence index (Cadh) 
2. Adherence status: Cadh >80% is adherent; Cadh <= 80% is non-adherent 
Hypothesis Statistics 
H1 SDT will predict adherence. 
n •• * *u u- u u/-/-^ /-u- u J t-test or Mann-Whitney U-Test 
Patients with a higher HCCQ score (higher perceived
 f „ ,, , u p p o -Hla autonomous support) will be more likely than patients with a ._,.
 r ,, i „ r ^ ; , . . . ,, . , Chi-square for adherence status lower HCCQ score to have a higher adherence index , „•„„ 
r> ..• * iu u- u nnc su- u - J t-test or Mann-Whitney U-Test 
Patients with a higher PCS score (higher perceived
 f „ „ , p p „
 J 
Hlb competence) will be more likely than patients with a lower „ , . , ' 
„ „ / / , . . . ,.J . , Chi-square for adherence status PCS score to have a higher adherence index , _"i,0 b
 and PCS 
Patients with a higher autonomous motivation score on TSRQ t-test or Mann-Whitney U-Test 
j , . (higher autonomous motivation) will be more likely than for Cadh and TSRQ; 
patients with a lower autonomous motivation score on TSRQ Chi-square for adherence status 
to have a higher adherence index and TSRQ 
When considered together in one model, all of the SDT 
motivation variables (HCCQ score, PCS score, autonomous Multiple linear regression for 
Him motivation score on TSRQ) at post-test will be significant Cadh; Logistical regression for 
predictors of adherence (both adherence index and adherence adherence status 
status) at post-test. 
Question 2: Do patient factors (socioeconomic measures, resources, health-related factors, and 
prescription drug variables) predict patient adherence? 
Socio-economic status, resources, health related factors, and prescription drug variables will predict 
adherence. 
• Socio-economic status: age, marital status, gender, race/ethnicity 
• Resources: adequacy of health literacy, insurance coverage, social support 
• Health-related factors: illness level, smoking status, depression 
• Prescription drug variables: Prescription drug expense, number of prescriptions (pretest and post-
test), number of doses/day (pretest and post-test), side effects 
• Adherence as operationalized by: 
1. Composite adherence index (Cadh) 
2. Adherence status: Cadh >80% is adherent; Cadh <=80% is non-adherent 
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Hypothesis Statistics 
H2 Patient factors will predict adherence. 
H2a 
H2b 
H2c 
H2d 
H2e 
H2f 
H2g 
H2h 
H2i 
H2j 
H2k 
H21 
H2m 
H2n 
Older patients (age = or > 65) will be less likely to be 
adherent than younger patients at post-test. 
Married patients will be more likely to be adherent 
than patients who are not married at post-test. 
Marital code: 1 = married, 2 = divorced, 3 = widowed, 
4 = separated, 5 = never married, 6 = a member of 
unmarried couple 
Female patients will be more likely to be adherent 
than male patients at post-test. 
Caucasian patients will be more likely to be adherent 
than non-Caucasian patients at post-test. 
Patients with an adequate level of health literacy will 
be more likely to be adherent than patients with a less 
adequate level of health literacy at pos-ttest. 
Patients with insurance coverage for prescription 
drugs will be more likely to be adherent than patients 
without insurance coverage at post-test. 
Patients with social support will be more likely to be 
adherent than patients without social support at post-
test. 
Patients with a higher illness level (illness-
comorbidity index) will be more likely to be adherent 
than patients with a lower illness level at post-test. 
Patients who smoked will be less likely to be adherent 
than patients who did not smoke at post-test. 
Patients at risk of depression will be less likely to be 
adherent than patients who are not at risk of 
depression at post-test. 
Patients who spend more for prescription drugs will 
be less likely to be adherent than patients who spend 
less for prescription drugs at post-test. 
Patients who take fewer prescriptions will be more 
likely to be adherent than patients who take more 
doses of prescriptions at post-test. 
Patients who take fewer doses of medication per day 
will be more likely to be adherent than patients who 
take more doses of medication at post-test. 
Patients who perceive drug side-effects to be tolerable 
will be more likely to be adherent than patients who 
perceive drug side-effects to be intolerable at post-
test. 
t-test for Cadh and age; Chi-square for 
adherence status and age 
t-test for Cadh and marital status; Chi-
square (crosstab) for adherence status 
and marital status 
t-test for Cadh and gender; Chi-square 
for adherence status and gender 
t-test for Cadh and race; Chi-square 
for adherence status and race 
t-test for Cadh and adequacy of 
literacy; Chi-square for adherence 
status and adequacy of literacy 
t-test for Cadh and insurance 
coverage; Chi-square for adherence 
status and insurance coverage 
t-test for Cadh and social support; 
Chi-square for adherence status and 
social support 
t-test for Cadh and illness level; 
Mann-Whitey U-test for adherence 
status and illness level 
t-test for Cadh and smoking status; 
Chi-square for adherence status and 
smoking status 
t-test for Cadh and depression status; 
Chi-square for adherence status and 
depression status 
t-test for Cadh and money spent on 
prescriptions; Chi-square for 
adherence status and money spent on 
prescriptions 
t-test for Cadh and number of 
prescriptions; Chi-square for 
adherence status and number of 
prescriptions 
t-test for Cadh and number of doses; 
Chi-square for adherence status and 
number of doses 
t-test for Cadh and drug side-effect; 
Chi-square for adherence status and 
drug side effect 
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Question 3: Does SDT predict adherence when controlling for socio-economic status (SES), resources, 
health-related factors, and prescription drug variables? 
• SDT consists of 
1. HCCQ score (perceived autonomous support) 
2. PCS score (perceived competence) 
3. TSRQ-AM (treatment self-regulation questionnaire for autonomous motivation) 
• Adherence as operationalized by: 
1. Composite adherence index (Cadh) 
Adherence status: Cadh >80% is adherent; Cadh <=80% is non-adherent 
Hypothesis Statistics 
H3 Hypothesis: SDT will predict adherence when controlling for SES, 
resources, health-related factors, and prescription drug variables. 
Patients with a higher HCCQ score, a higher PCS score, and/or a , . .^ , ,, 
, . , „ „ „
 A A , . . t ' . „ , ... . ' , Multiple regression for 
higher TSRQ-AM score at post-test will be more likely to be r Hh H th th snT 
adherent at post-test than patients with a lower HCCQ score, a lower * * , * ! _ 
r.oc AI i L D n , u . 11 . . constructs + other 
PCS score and/or a lower TSRQ-AM score at post-test, when „ . 
controlling for age, gender, race/ethnicity, health literacy, insurance '. ^ ,, 
° . , ° ... . . . . _ . regression for adherence 
coverage, social support, illness level, smoking status, depression, ° , „,
 iL „ „ „ 
. ' . . c • +• u f status and the three SDT prescriptions drug expense, number of prescriptions, number ot ,
 f 
. ,. . . . ~~ constructs + otner iactors doses/day, and side-effects. 
Question 4: Do the SDT constructs change over time (pre-test vs. post-test)? 
Hypothesis Statistics 
H4 Hypothesis: Levels of SDT factors will increase over time. 
H . Patients will be more likely to have a higher HCCQ score (perceived autonomous 
support) at post-test than at pretest. 
„ , , Patients will be more likely to have a higher PCS score (perceived competence) at 
post-test than at pretest. 
„ . Patients will be more likely to have a higher autonomous motivation score on 
TSRQ (higher autonomous motivation) at post-test than at pretest. 
Question 5: How does patient-centered care (PCC) affect the SDT constructs? 
Groups: PCC teaching group versus comparison or usual care (UC) group. 
Hypothesis Statistics 
H5 Hypothesis: PCC will predict a higher level of SDT constructs. 
Patients who received PCC teaching will be more likely to have a higher HCCQ 
score (perceived autonomous support) at post-test than patients who received UC, 
„„ controlling for HCCQ score at pretest, as well as age, gender, race/ethnicity, health . 
literacy, insurance coverage, social support, illness level, smoking status, 
depression, prescription drug expense, number of prescriptions, number of 
doses/day, and side-effects. 
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Hypothesis Statistics 
H5b 
Patients who received PCC teaching will be more likely to have a higher PCS score 
(perceived competence) at post-test than patients who received UC, controlling for 
PCS score at pretest, as well as age, gender, race/ethnicity, health literacy, 
insurance coverage, social support, illness level, smoking status, depression, 
prescription drug expense, number of prescriptions, number of doses/day, and side-
effects. 
Ancova 
H5c 
Patients who received PCC teaching will be more likely to be have a higher 
autonomous motivation score on TSRQ-AM (more autonomously motivated) at 
post-test than patients who received UC teaching, controlling for TSRQ-AM score 
at pretest, as well as age, gender, race/ethnicity, health literacy, insurance coverage, 
social support, illness level, smoking status, depression, prescription drug expense, 
number of prescriptions, number of doses/day, and side-effects. 
Ancova 
Question 6: How does PCC affect adherence? 
• PCC is the group membership (PCC group or comparison group) 
• Adherence as operationalized by: 
1. Composite adherence index (Cadh) 
2. Adherence status: Cadh >80% is adherent; Cadh <= 80% is non-adherent 
Hypothesis Statistics 
H6 Hypothesis: PCC will predict adherence (Cadh and adherence 
status). 
H6a Patients who received PCC teaching will be more likely to be 
adherent at post-test than patients who received UC teaching. 
t-test for Cadh and group 
assignment; Chi-square for 
adherence status and group 
assignment 
Question 7: How does PCC affect adherence after controlling for SDT factors, socio-economic status 
(SES), social economic status, resources, health-related factors, and prescription drug variables? 
Hypothesis Statistics 
Hypothesis: PCC will predict adherence (Cadh and 
H7 adherence status) controlling for SDT and other patient 
factors 
H7a 
Patients who received PCC teaching will be more likely to 
be adherent at post-test than patients who received UC 
teaching after controlling for perceived autonomous support 
(HCCQ), perceived competence (PCS), autonomous 
motivation (autonomous motivation portion of TSRQ), and 
other patient factors. 
Multiple regression &/or 
Hierarchical regression) for 
Cadh; Logistical regression for 
adherence status 
Population and Sample 
Population and sample characteristics. The study site was a community 
hospital serving the city of Virginia Beach. Virginia Beach is an independent city located 
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in the South Hampton Roads area of Virginia. Virginia Beach is the most populous city 
in Virginia and the 42nd largest city in the US. Table 3-5 shows the population 
characteristics (U.S. Census Bureau, 2008). The patient sample consisted of about 83% 
Caucasian, 39% female, 93% insured, with an average age of 68 years, 43% > NYHF 
class III, and took an average of 9.7 prescriptions at discharge. 
Table 3-5. 
Population of Virginia Beach, Virginia (2008)* 
N % 
TOTAL POPULATION 433,746 
POPULATION IN HOUSEHOLDS 422,298 
Total households 162,366 
Average household size 2.6 
Average family size 3.09 
HOUSEHOLD TYPE 
Family households (families) 70.10% 
• Married-couple family 53.30% 
• Male householder, no wife present, family 3.70% 
• Female householder, no husband present, family 13.10% 
Nonfamily households 29.90% 
e Householder living alone 23.90% 
• 65 years and over 7.60% 
Households with one or more people 65 years and over 19.60% 
GENDER AND MARITAL STATUS 
Males 15 years and over 167,031 
• Never married 31.10% 
• Now married, except separated 56.10% 
• Separated, widowed or divorced 12.70% 
Females 15 years and over 177,472 
• Never married 24.70% 
• Now married, except separated 51.10% 
• Separated, widowed or divorced 24.30% 
EDUCATIONAL ATTAINMENT 
Population 25 years and over 282,279 
• no diploma 7.50% 
• High school graduate (includes equivalency) 24.90% 
• Some college, no degree 26.90% 
• College, with degrees 40.70% 
VETERAN STATUS 
Civilian population 18 years and over 293,912 
• Civilian veterans 20.80% 
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N % 
DISABILITY STATUS OF THE CIVILIAN NONINSTITUTIONALIZED POPULATION 
Total Civilian Non-institutionalized Population 399,570 
• With a disability 9.20% 
Under 18 years 109,143 
• With a disability 4.30% 
18 to 64 years 246,451 
• With a disability 7.80% 
65 years and over 43,976 
• With a disability 29.80% 
PLACE OF BIRTH 
Native 
• Born in United States 
o State of residence 
o Different state 
• Born in Puerto Rico, U.S. Island areas, or born abroad to 
American parent(s) 
Foreign born 
• Naturalized U.S. citizen 
• Not a U.S. citizen 
LANGUAGE SPOKEN AT HOME 
Population 5 years and over 403,582 
English only 
Language other than English 
• Spanish 
• Other Indo-European languages 
• Asian and Pacific Islander languages 
• Other languages 
ANCESTRY 
American 
Dutch 
English 
French (except Basque) 
German 
Irish 
Italian 
Polish 
Scotch-Irish 
Scottish 
Subsaharan African 
Welsh 
West Indian (excluding Hispanic origin groups) 
Others (Arab, Czech, Danish, French Canadian, Greek, Hungarian, Lithuanian, 
Norwegian, Portuguese, Russian, Slovak, Swedish, Swiss, Ukrainian) 
Unknown 
91.90% 
89.40% 
37.70% 
51.70% 
2.60% 
8.10% 
63.40% 
36.60% 
89.40% 
10.60% 
3.70% 
2.70% 
3.80% 
0.40% 
10.50% 
1.80% 
11.80% 
2.90% 
14.50% 
12.90% 
6.40% 
2.80% 
1.30% 
2.70% 
5.80% 
1.30% 
1.00% 
7.00% 
17.30% 
*Source: U.S. Census Bureau, 2008 American Community Survey. 
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Sampling criteria, group assignment and sample size. 
Sampling. The method of consecutive sampling was used. This nonprobability 
technique made possible the sampling of a good representation of the overall population 
in a reasonable period of time. The consecutive sample would include every available 
and eligible patient admitted to the hospital with any of the following diagnoses or their 
correspondent DRG: acute coronary syndrome, acute myocardial infarction, heart failure, 
atrial fibrillation, or valvular heart disease. A participant also had to be at least 18 years 
of age, be willing to provide informed consent, and be willing and able to be followed for 
at least three months. A patient would not be eligible for study entry if he/she met any of 
the following criteria: DNR (Do Not Resuscitate) status, going to a skilled care facility 
after discharge, totally dependent on others for their care, from out of town, or with a 
diagnosis of psychosis, dementia, or mental retardation. 
Group assignment Two groups of patients were recruited in two blocks of time 
periods prospectively. The first group, or the comparison group, was recruited during the 
first block of time. The second group, or the patient-centered care (PCC) teaching group, 
was recruited during the second block of time. Data was collected over these two 
periods. There were two reasons for this method instead of assigning participants 
alternatively to the comparison group and experimental group. One reason was to avoid 
potential contamination between patient groups. The other reason was to ensure a 
consistent way of providing teaching methods. 
Sample size. Since the study was a pilot study in nature, the initial goal was to 
have enough data to test SDT in a PCC environment for the secondary prevention of 
CVD. A rigorous power analysis with effect size as recommended by Cohen (Cohen, 
1988) is not being used at the moment. Instead, a sample size of 30 was chosen for 
regression analysis based on the Central Limit Theorem (Casella & Berger, 2002; 
Virtanen, Kairisto & Uusipaikka, 1998). The plan was to recruit 60 patients per group, 
allowed for a 50% drop out rate, giving at least 30 patients per group left in the final 
analysis. Approximately 20 to 30 patients were enrolled into the study each month. 
Setting Characteristics 
The study was conducted at Sentara Virginia Beach General Hospital (Sentara 
Virginia Beach General Hospital, 2008) which is a community hospital in Virginia 
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Beach, Virginia. It is a 274-bed acute care facility that specializes in cardiology and 
cardiac surgery, cancer care, high-risk pregnancy, women's health, oncology, 
orthopedics, and neurosciences. The hospital has a dedicated nursing wing for stroke 
treatment, total joint replacements and trauma surgery, a neonatal intensive care unit, and 
the region's only Level III Trauma Center. The hospital offers 24-hour, seven-day-a-
week coverage by intensivists for its intensive care unit patients. It is also home to the 
local diabetes education center, an accredited sleep disorders center, and hospitalist 
program. Cardiac care is provided within a new healing environment that includes a new 
Heart Center and a dedicated cardiac care floor with 46 private rooms in the new West 
Wing (Sentara Virginia Beach General Hospital Heart Services, 2008), specially trained 
cardiac nurses, technologists, and support staff. Performance measures of both cardiac 
surgery and intervention are above national standards. For heart surgery, the mortality 
rates are better than national standards as reported by the Society of Thoracic Surgeons. 
For interventional procedures such as angioplasty and stents, the cardiologists had a 97% 
success rate compared with a national standard of 90% as reported by the American 
College of Cardiology (Sentara Virginia Beach General Hospital Heart Services, 2008). 
The hospital treats almost a thousand heart patients a year. The Heart Center also works 
closely with volunteers of Mended Hearts, Inc., an international support group for cardiac 
patients, their families, and caregivers (Mended Hearts, 2008). The hospital adopted the 
Planetree Model (Frampton et al., 2003) of patient-centered care with the following 
characteristics: human interaction, informing and empowering diverse populations, 
healing partnerships, nutrition, spirituality, human touch, healing arts, integrating 
complementary and alternative practices into conventional care, and healing 
environments. 
Protection of Human Participants 
A research proposal was approved by the Institutional Review Boards (IRB) of 
Sentara Virginia Beach General Hospital and of Old Dominion University. There were 
minimal risks from the survey study. The cardiac patients meeting the inclusion criteria 
were invited to participate. Patients were informed that participation in the study was 
voluntary, that they had a right to withdraw from the study at any time, and that their 
confidentiality and anonymity were assured. A patient package was left for the 
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participant to review. The package included the letter of invitation (Appendix C), the 
consent form (Appendix D), medication log (Appendix F), pre-discharge survey 
(Appendix G), and post-hospitalization survey (Appendix H). A copy of the IRB 
approval is included in Appendix J. When a patient agreed to participate, a signed 
consent form was obtained. 
Protocol 
Usual medication teaching protocol. The usual medication teaching protocol 
included the following: (1) explain to patients the purpose of the medication during 
medication administration, (2) answer any questions the patient may have about the 
medication, (3) instruct the patient how to take the prescribed medications before 
discharge, (4) give patients medication information leaflets with the prescriptions for 
reference. 
Patient-centered care medication-teaching protocol. The patient-centered care 
medication teaching protocol included the usual medication teaching protocol as well as a 
PCC interactive education platform, Congestive Heart Failure (CHF) interactive care 
pathway. The CHF interactive care pathway was designed for cardiac patients who are at 
risk of developing heart failure. 
Implementation of patient-centered care. The goals of designing and 
implementing a PCC setting included the following: providing appropriate information at 
an appropriate education level with sufficient time for comprehension; health/treatment 
recommendations that consider both clinical facts and personal experience; minimizing 
the use of pressure to change; providing choices and information; promoting competence 
and the feeling of competence; honoring patient choices and preferences; positive 
feedback; exploration of any disagreements to determine areas of agreement and areas of 
differences. The PCC setting is expected to provide an autonomy-supportive 
environment that creates opportunities for creative problem solving, with final choices 
belonging to a fully informed patient (Quill & Brody, 1996). 
CHF interactive care pathway. Guided by self-determination theory, the CHF 
interactive care pathway was developed and implemented in an automated interactive 
environment for patient teaching (Figure 3-2). The interactive pathway was developed 
by a hospital multidisciplinary team and implemented by GetWellNetwork® (Footnote 3-
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1). The goal of the interactive patient care system is to support the healthcare provider in 
teaching patients about their disease condition and medication management within the 
Planetree Model of patient-centered care. 
CHF Interactive Care Pathway: Patient Alert/Engagement Schedule 
Day 1 Day 2 Day 3 Day 4 
Literacy 
Assessment 
(1 hour after 
Admission) 
CHF Education 
(Diet/Weight/ 
Signs & 
Symptoms) 
Review Signs & 
Symptoms 
I Wait S minutes 
f 
CHF Introductory 
Education and 
Comprehension 
f~" rat ™~ 
/ Results / 
/ populated hi / 
/ Record? J 
i Medications ', 
I Profiie / ' 
/ (Manual / 
/ Trigger) / 
Wait 2 hours 
Test Results 
Review and 
Education 
Medications 
Reactions 
Teaching 
Medication 
History and 
Education 
/ Medications 7 
/ Populated / 
/ In record? / 
Wait 2 hours 
Support 
System 
Assessment 
Medication 
Teaching and 
Comprehension 
/ .Home • ' • / 
Health 
Referral? / 
Patient 
Responsibility 
Teaching and 
Acceptance 
/ 
Motivation 
Assessment 
Patient 
Registers for 
Home Health 
Patient builds 
Self Care Tools 
Reassess 
Motivation 
Patient 
Completes 
Health 
Assessment 
(SF-12?) 
Patient 
Completes 
Satisfaction 
Survey 
Figure 3-2. A 4-day schedule of the CHF interactive care pathway 
The interactive system pathway allowed the clinicians to ask and assess their patients' 
literacy level, special needs, support system, and motivation level; to teach and advise 
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patients how to care for themselves and take their medication after being discharged from 
the hospital; to assist patients in learning how to manage their medication; to arrange for 
various support based on individuals' needs; to survey patients and to document defined 
clinical events. The pathway was organized around a four-day conceptual care plan. The 
actual day might fall on part of the conceptual day or encompass the last part of one 
conceptual day with the beginning of the next conceptual day. The progression of the 
pathway was dependent on factors such as admission time, procedure schedules, triggers 
that are activated by outputs from the hospital information systems, inputs and 
assessment threshold levels from patients' feedback, inputs from the clinicians, and built-
in timers for certain events. The flow diagram of the pathway on conceptual day 1 
(Figure 3-3 and Figure 3-4) shows the progression and the relation of the five interrelated 
modules, health literacy assessment, CHF condition overview, medication history and 
education, support system assessment, and motivation assessment. 
CHF Interactive Care Pathway: Day 1 (Continued) 
£ 
3 c 
o ? 
II 
tf) 
Wait 2 hours \ •^ Assessment Survey 
/ I 
Notify 
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No 
/ \ 
/Alert up lo 2 X \ v 
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Family Support? 
1 
[Home Care Services Needed?; • 
/ \ 
Vs. 
Notify Appropriate 
Staff for Foilow-up 
and Planning 
E-Care 
Documentation 
— < 
\ / 
/ 
/ Wail 30 
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' Assessment \ 
^Compteleif? / ' 
o 
5 
A 
Assess 
Motivation 
{Survey) 
/ \ 
••'Patient Pass\ 
, / Motivation 
V Level 
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\ / 
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Stafl 
E-Care 
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/ \ 
J Efrf 1 
\ Day ' 
V 
Figure 3-3. Flow diagram for CHF interactive care pathway on day 1 part 1 
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CHF Interactive Care Pathway: Day 1 
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Figure 3-4. Flow diagram for CHF interactive care pathway on conceptual day 1 part 2 
The flow diagram of the pathway on conceptual day 2 (Figure 3-5 and Figure 3-6) shows 
an accelerated pace of teaching the management of signs and symptoms of HF, 
medication, test results, and initiation of discharge planning. The flow diagram of the 
pathway on conceptual day 3 (Figure 3-7) continues on medication teaching with new 
medical treatments, assisting patients in reviewing prior lessons on CHF signs and 
symptoms, and educating patients on the responsibility of following the treatment plan. 
The flow diagram of the pathway on conceptual day 4 (Figure 3-8 and Figure 3-9) 
finalizes the cycle by arranging the development of an individualized self-care plan for 
cardiac rehabilitation. The plan addresses healthy diet, exercise and medication adherence 
and the printing of individualized instructions, followed by reassessment of the patients' 
motivation level. 
78 
CHF Interactive Care Pathway: Day 2 
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Figure 3-5. Flow diagram for CHF interactive care pathway on conceptual day 2 part 1 
CHF Interactive Care Pathway: Day 2 
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CHF Interactive Care Plan: Day 3 
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CHF Interactive Care Plan: Day 4 
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Procedures 
The following schedule of events is summarized in Appendix A. 
Recruiting participants and informed consents. The hospital provides both 
inpatient and outpatient cardiac services. The recruiting process began after patients 
were stabilized, moved to any one of the cardiology units (2WW1, 2WW2, 2WW3, and 
2WW4), and judged to be comfortable enough to be interviewed. At this point, the 
patients should have received their diagnostic workups and qualified cardiac 
interventions. Following the outlines of a script for recruiting participants (Appendix B), 
the investigator explained the research purpose and protocol to the potential participants 
who met the inclusion criteria. Informed consent (Appendix D) was obtained from 
patients who agreed to participate in the study (see previous section on protection of 
human participants). The investigator reminded patients that information provided for 
the study was voluntary and confidential. 
Patient data collection. Demographic and clinical information were collected on 
a Medical Record Abstraction Form (Appendix E) as soon as the patient charts were 
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ready. The information was updated continuously. Some information, such as discharge 
diagnoses, was not available until after discharge. 
Disease state and medication education. During the hospital stay, nurses 
educated patients about their medications when prescribed. For cardiology, there would 
be medications from any of these classes: beta-blocker, Angiotensin Converting Enzyme 
inhibitor (ACEI) or Angiotensin Receptor Blockers (ARB), antiplatelet, diuretic, digoxin, 
lipid management, calcium blockers, nitrate, or hydralazine. Education included 
rationale for use, how to take, and adverse drug reactions. In addition, a patient educator 
coordinated the teaching efforts of the patients. The PCC group was further supported by 
interactive medication teaching via GetWellNetwork as discussed under the intervention 
section. 
Administration of survey 1 at time Ol before discharge. Approximately one 
day before the planned discharge, Survey 1 or the pre-discharge survey (Appendix G) 
was administered for the first time (01). The questionnaire was used to collect data on a 
patient's motivational factors. The investigator emphasized that the responses to the SDT 
questionnaires should reflect the healthcare encounters during the hospital stay. The 
investigator also asked the participant to estimate the percentage adherence based on 
prior experience with prescription drugs. A visual analog scale, to be discussed in the 
following subjective adherence measurement section, was provided for the patient to use. 
Administration of survey 2 at time 02. The investigator called the participant 
approximately at the end of the three-month period. The interview was conducted by 
phone, at the participant's home, or at other convenient locations as desired by the 
participant. The Post Hospitalization Questionnaire (Appendix H) was used to collect 
data on medication adherence and patients' motivational factors. The investigator 
emphasized to the participant that the responses to this questionnaire should reflect the 
healthcare encounters during the hospital stay as well as the three-month period after 
discharge. For the adherence question, the investigator collected data from two 
qualitatively different forms of adherence, namely the subjective and objective aspects. 
Statistics and Data Analyses 
Quality of data. Issues concerning the quality of study data included: 
completeness and accuracy of data, missing data, outliers, transformation of variables, 
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assumption of multivariate procedures, and multicollinearity. Each will be discussed 
below. 
To ensure the accuracy of a data file, data entries were rechecked for 
completeness and univariate descriptive statistics were applied. For continuous variables, 
ranges, means, standard deviations, and out-of-range numbers were check. 
Missing data could occur when patients died, participants became recalcitrant, 
simple errors occured in data entry, etc. A missing value analysis was performed to 
search for the pattern of missing data. There were a few options in the decision about 
how to handle missing data. If missing values were concentrated in one or two variables 
and the variables were not critical to the analysis, the variable might be dropped. If more 
than a few missing values were scattered throughout both cases and variables, and 
deletion of cases reaches the threshold of 30 per group, estimated values might be used. 
Depending on the situation, any one of the following methods might be used for 
estimation: prior knowledge, downgrade of a continuous variable to a dichotomous 
variable, and mean substitution (Tabachnick & Fidell, 2001). Finally, going back to the 
participant for missing data was always an option when the missing data was critical for 
data analysis. 
Outliers are cases with extreme values that can distort statistics, leading to both 
Type I and Type II errors. The reasons that outliers may arise include data entry errors, 
failure to specify missing value codes in computer syntax, when the case is not a member 
from the intended population, and when distribution for the variable in the population has 
a more extreme value than a normal distribution. Frequency distributions were used to 
screen for dichotomous variables with extreme splits. Those variables with 95-5 or more 
extreme splits between categories would either be deleted or recoded into fewer 
categories. Among continuous variables, univariate outliers were cases with very large 
standardized scores (>3.29, pO.OOl, 2-tailed test), z scores, that are disconnected from 
the other z scores. If cases were sampled from the target population, either variable 
transformation or score alteration would be used to reduce the impact of outliers 
(Tabachnick & Fidell, 2001). 
Transformation of variables may improve the analysis and/or reduce the impact of 
outliers. Common transformations, such as square root, logarithm, and inverse 
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transformation, along with reflection of negative skew, would be used when appropriate 
in multivariate linear regression. 
Underlying multivariate procedures and most outcomes of statistical tests is the 
assumption of normality, linearity, and homoscedasticity. Although assumptions 
regarding the distribution of predictors are not required in nonparametric procedures such 
as logistic regression analysis, normality and linearity may enhance power because a 
linear combination of predictors is used to form the exponent. Skew and kurtosis of 
dependent variables will be checked for normality. Linearity between variables related to 
any one of the hypotheses and homoscedasticity were checked with scatterplots and their 
correspondent statistics. 
High multicollinearity (r = or > 0.9) may lead not only to serious distortions in the 
estimations of regression coefficients but also to reversals in their signs (Pedhazur, 1982). 
Sometimes researchers purposely introduce collinearity when using multiple measures of 
variables in which they have greater interest or which are more important from a 
theoretical point of view (Thompson & Borrello, 1985). The three motivational 
constructs of SDT may exhibit multicollinearity because of their theoretical relationship. 
Collinearity diagnostics of SPSS were employed to screen for them. This utility produces 
a conditioning index.and variance proportions associated with each variable. The 
tolerance values (1-squared multiple correlation [SMC]) > .01 and Variance Inflation 
Value (VIF) < 10 in SPSS REGRESSION were used to screen for multicollinearity 
(Tabachnick & Fidell, 2001). 
Data analysis. 
Univariate analysis. Frequencies of data were analyzed for variables with 
nominal levels of measurement (marital status, gender, race/ethnicity, adequacy of health 
literacy, insurance, social support status, smoking status, depression, and adverse drug 
reactions). 
Bivariate analysis. 
Chi-square. Chi-square tests for association were performed to examine 
associations between variables with nominal levels of measurement (adherence status and 
group assignment, adherence status and marital status, adherence status and gender, 
adherence status and races/ethnicities, adherence status and insurance coverage, 
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adherence status and social support, adherence status and smoking status, adherence 
status and depression). Variables with significant chi-square were used to develop 
adjusted SDT models, adjusted PCC models, and adjusted SDT PCC models. 
T-test. T-test was used to compare SDT questionnaire scores (HCCQ, PCS, and 
TSRQAM) between categories of nominal variables (groups, gender, races/ethnicities, 
smoking status, depression risk, adequacy of health literacy, insurance coverage, and 
social support status). It is also used to compare the adherence indices between 
categories of nominal variables (gender, races/ethnicities, smoking status, depression 
risk, adequacy of health literacy, insurance coverage, and social support status). Variable 
pairs with significant t-test scores were used to develop unadjusted and adjusted SDT 
models, unadjusted and adjusted PCC models, and unadjusted and adjusted SDT PCC 
models. The data met the assumptions of normality, linearity, and homoscedasticity. 
Pearson correlation. Pearson correlation was be used to calculate the 
associations between variables with interval level of measurement (adherence index and 
SDT questionnaire scores [HCCQ, PCS, and TSRQ], adherence index and categories of 
patient related variables [age, illness level, prescription drug expense, and number of 
doses/day], STD questionnaire scores [HCCQ, PCS, and TSRQAM] and patient related 
variables [age, illness level, prescription drug expense, and number of doses/day]. The 
data met the assumptions of normality, linearity, and homoscedasticity. 
Equality of treatment group and comparison group. Comparison of baseline 
patient characteristics between the UC group and the PCC group were performed. The 
analyses were used to assess the degree of similarity and variance between these two 
groups. 
Multivariate analyses. Multivariate regression analyses were performed to 
develop models identifying significant predictors for the adherence measures and the 
SDT motivation factors. 
Analysis ofcovariance (ANCOVA). ANCOVA were used to test group effect on 
the three SDT constructs controlling for the pretest scores of the correspondent SDT 
constructs, as well as socioeconomic factors, socioeconomic resources, health related 
factors, and prescription drug factors as raised by Question 5. F-test of difference of 
group means of the pretest SDT variables and post-test SDT variables between the 
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treatment group and the comparison group were used to see if the means difference 
occurred by chance. Assumption of linearly related covariates, homogeneity of covariate 
regression coefficients, no covariate outliers, no high multicollinearity of the covariates, 
homogeneity of variances, multivariate normality, and independent variables being 
orthogonal to covariates were also examined in the application of ANCOVA. Levene's 
tests of homogeneity of variance were computed to test the homogeneity of variance of 
the SDT variables in each group. 
Multiple linear regression. Two multiple regression models were developed for 
the interval dependent variable, composite adherence index (cadh), to test for hypotheses 
3 and 7. Hypothesis 3 asked, "Do SDT variables predict adherence when controlling for 
socio-economic status (SES), resources, health-related factors, and prescription drug 
variables?" The model for hypothesis 3 was used to account for the variance of 
adherence index, based on the linear combinations of interval variables (HCCQ, PCS, 
TSRQ-AM, age, prescription drug expense, number of prescriptions, and number of 
doses/day), and dichotomous or dummy independent variables (gender, race/ethnicity, 
adequacy of health literacy, insurance coverage, social support, illness level, smoking 
status, depression, and side-effects). Hypothesis 7 asked the question, "How does PCC 
affect adherence after controlling for SDT factors, socio-economic status (SES), social 
economic status, resources, health-related factors, and prescription drug variables?" The 
model for hypothesis 7 was formed by adding the intervention group variable to the 
model for hypothesis 3. The multiple regression equations were developed with the form 
of y = bjXi + b2X2 + ... + bnxn + c. R2, the multiple correlation coefficient between the 
obtained and predicted Y values, was used to assess the proportion of variance in 
adherence index predicted from the best linear combination of the independent variables 
(Tabachnick & Fidell, 2001). Assumptions of correlation (i.e., linearity of relationships, 
homoscedasticity, and outliers) were examined (Garson, 2007). 
Logistic regression. Two logistic regression models were developed for adherence 
status, a dicohotomous dependent variable, to test hypotheses 3 and 7. Hypothesis 3 
asked, "Do SDT variables predict adherence status when controlling for socio-economic 
status (SES), resources, health-related factors, and prescription drug variables?" The 
model for hypothesis 3 was developed to predict adherence status (adherent or 
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nonadherent) from a set of variables that are continuous (HCCQ, PCS, TSRQ-AM, age, 
prescription drug expense, number of prescriptions, and number of doses/day), 
categorical, or dummy independent variables (gender, race/ethnicity, adequacy of health 
literacy, insurance coverage, social support, illness level, smoking status, depression, and 
side-effects). Hypothesis 7 asked, "How does PCC affect adherence after controlling for 
SDT factors, socio-economic status (SES), resources, health-related factors, and 
prescription drug variables?" The model for hypothesis 7 was formed by adding the 
intervention group variable to the model for hypothesis 3. Logistic regression models 
were developed with maximum likelihood estimation to find the odds (adjusted odds 
ratios) of being in one of the categories of adherence status (adherent or nonadherent). 
Logit coefficients (the unstandardized logistic regression coefficient b in SPSS) of the 
predictor variables were used to predict the log odds (logit) that the dependent variable 
equals one (or adherence status = adherent). The logit (log odds b) was converted into a 
formula about odds ratio of the dependent variable by using the exponential function 
(raising the natural log e to the bl power or eb). With z being the logit for adherent 
status, the logistic equation takes the form of: 
z = ln(odds(adherent)) = ln(prob(adherent)/prob(nonadherent)) = ln(prob(adherent)/[l -
prob(nonadherent)]) = bo + biXi + b2X2 + + bkXk (Garson, 2007). 
Once the logit was transformed into an odds ratio, it was expressed as a percent increase 
or decrease in odds. Logistic regression is more flexible than ordinary least square 
regression because it has no assumptions of the predictor variables in terms of normal 
distribution, linearity, and homoscedasticity. But it does assume a linear relationship 
between the logit of the independent variables and the dependent variables. Goodness-
of-fit tests such as model chi-square were used to test model appropriateness, while Wald 
statistic was used to test the significance of individual independent variables in the model 
(Tabachnick & Fidell, 2001). 
Study Limitation and Control Issues. 
Threats to internal validity. Threats to internal validity were plausible since 
randomization was not feasible for the field setting (Campbell & Stanley, 1963; Kerlinger 
& Lee, 2000). Patients were assigned consecutively to the study groups over two 
consecutive periods of recruitment. The internal sources of invalidity might include 
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selection, social desirability, history, and experimental mortality (Campbell & Stanley, 
1963; Kerlinger & Lee, 2000). 
Selection bias. Consecutive sampling is a strict version of convenience sampling 
where every available subject is selected. By studying everybody available, a good 
representation of the overall population is possible in a reasonable period of time 
(Currier, 1984). Even if potential participants knew about the study, it was unlikely that 
patients would be able to manipulate their heart attack events in order to self-select into 
the experimental group. However, people consenting to participate in the study might 
still differentially possess traits that are extraneous to the research issue. 
Social desirability. The study respondents might be tempted to appear to be more 
adherent than they actually were in studies of adherence. Socially desirable responses in 
research have typically been assumed to be a function of two factors, (1) "the demands of 
a particular situation," such as the demand to be adherent, and (2) a personality trait that 
is related to "the strength of need for approval felt by an individual" (Phillips & Clancy, 
1972). In order to control for the influence of social desirability, the self-regulation of 
medication was explained to the participants as (1) a process of making personal choices 
among many priorities in the context of one's life, (2) a bigger issue beyond simply 
adherence versus non-adherence, (3) an important factor to understand in order to design 
a more patient-centered healthcare system, and (4) an activity that is legitimate and 
acceptable to the researchers of adherence. The investigator also expressed appreciation 
for the participants' willingness to share how they regulated their medication. 
History. Though both groups were exposed to similar events in a similar 
environment over an approximately similar length of time, unforeseeable events might 
influence the outcomes since the two groups were recruited from two different time 
frames. History as rival hypotheses was plausible. 
Experimental mortality. Participants might have dropped out of the study early 
because of disease condition, not perceiving any benefit, or feelings of not being 
supported adequately. This differential drop-out might have been controlled by telling 
the participants the benefit of having a medication interview at the end of the study 
period. 
Threats to external validity. The external sources of invalidity may include the 
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interaction effects of selection biases with the independent variable and reactive effects of 
experimental arrangements (Campbell & Stanley, 1963; Kerlinger & Lee, 2000). The 
generalizability of the study is limited to that of a similar hospital in a community 
comparable to Virginia Beach, Virginia. 
Statistic control of attribute variables. Though the commonly used 
nonequivalent Control Group Design does not provide assurance that the experimental 
control group and the control group are equivalent, regression analyses were performed 
to control for the extraneous variables statistically. 
Measurement reliability. Minimization of error variance of measurement offers 
another level of control that is indirectly related to design. The adherence measure and 
the three SDT questionnaires had been used in various studies with acceptable reliability. 
Consistence in administration of the survey was aided by using a uniform script with 
specific and clear instructions to participants. 
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CHAPTER IV 
Results of Data Analyses 
The results of hypotheses testing are presented in seven sections. The first three 
sections explored the utility of a self-determination theory (SDT) adherence model in a 
CV population without the consideration of intervention: predicting adherence with SDT 
constructs; predicting adherence with socioeconomic status, resources, health-related 
factors, and prescription drug variables; predicting adherence with SDT constructs 
adjusted for socioeconomic status, resources, health-related factors, and prescription drug 
variables. The next four sections contrasted the effect of a SDT-guided intervention on a 
patient-centered care (PCC) group versus a usual care (UC) group in terms of SDT 
motivation variables and adherence with CV medications: predicting SDT constructs 
change over time; affect of PCC on SDT constructs; affect of PCC on adherence; and 
predicting adherence with PCC, controlling for SDT constructs, socioeconomic status 
(SES), resources, health-related factors, and prescription drug variables. 
For hypothesis testing, two adherence measures collected three months after 
discharge, scores from three SDT scales collected before discharge and three months 
after discharge, and patient characteristics collected before discharge were used. The 
adherence measures included an adherence index (cadh) and adherence status (adhered2). 
The SDT motivational constructs included perceived autonomous support as measured by 
the Healthcare Climate Questionnaire (HCCQ), perceived competence as measured by 
the Perceived Competence Scale (PCS), and autonomous motivation as measured by the 
Treatment Self-Regulation Questionnaire for Autonomous Motivation (TSRQ-AM). 
Patient characteristics included socioeconomic status (SES), resources, health-related 
factors, and prescription drug related variables. 
Of the 60 patients in the usual care (UC) group, ten patients were lost during the 
follow-up period and two patients died, leaving a sample size of 48 patients for analyses. 
Of the 60 patients in the patient-centered care (PCC) group, four patients were lost during 
the follow-up period and six patients died, leaving a sample size of 50 patients for 
analyses. 
Appendix K lists the evaluation of quality of data during hypothesis testing with 
various SPSS programs, and Appendix L shows the summary of all the hypotheses tested. 
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Results of Data Analyses 
Predicting adherence with individual SDT motivational constructs. It was 
hypothesized that SDT motivation variables might predict adherence. The intervention 
factor will be discussed in later sections. 
Table 4-1. 
Pearson Correlations for interval variables (n = 98) 
HCCQ PCS TSRQ HCCQ PCS TSRQ adherence .... . rxdoses 
1 1 AMI 2 2 AM 2 index ' " l e v e l a g e all 
HCCQ1 1 .328** .514** .907** .384** .590** .460** 
PCS1 1 .482** .342** .840** .414** .288** 
TSRQ j .562** .524** .847** .624** 
AMI 
HCCQ2 1 .406** .705** .586** 
PCS2 1 .559** .384** 
TSRQ 1 764** 
AM2 
Adherence 
index 
Illlevel 
Age 
Rxdosesall 
1 
.043 
-.214* 
-.070 
.095 
-.091 
.089 
.105 
1 
.135 
-.064 
.331** 
.149 
.048 
.358** 
.415** 
.256* 
1 
-.015 
-.159 
-.055 
.053 
-.137 
.070 
.117 
.543** 
.098 
HCCQ1 = baseline perceived autonomous support, PCS1 = baseline perceived competence, TSRQAM1 = 
baseline autonomous motivation, HCCQ2 = post-test perceived autonomous support, PCS2 = post-test 
perceived competence, TSRQAM2 = post-test autonomous motivation, cadh = composite adherence index 
(or adherence index), illlevel = illness level, age = age, rxdosesall = number of prescription doses per day. 
** significant at the 0.01 level (2-tailed) * significant at the 0.05 level (2-tailed). 
Healthcare Climate Questionnaire (HCCQ2) and unadjusted adherence 
measures. Hypothesis HI a: Patients with a higher HCCQ2 score, representing higher 
perceived support from the healthcare environment, would be more likely than patients 
with a lower HCCQ2 score to have a higher adherence index and would be more likely to 
be adherent. The maximum raw score for HCCQ was 42, and the maximum averaged 
score was 7.00. The average score was used in hypothesis testing. There was a 
significant correlation (r = .586) between adherence index and HCCQ2 (Table 4-1). 
Adherent patients' mean HCCQ2 scores (6.10, SD = 1.1) were significantly higher than 
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non-adherent patients' mean HCCQ2 scores (4.57, SD = 1.0) (Table 4-2). Therefore 
patients with a higher HCCQ2 score were more adherent than patients with a lower 
HCCQ2 score. 
Perceived Competence Scale (PCS2) and unadjusted adherence measures. 
Hypothesis Hlb: Patients with a higher PCS2 score (representing higher perceived 
competence) would be more likely than patients with a lower PCS2 score to have a 
higher adherence index and would be more likely to be adherent. The maximum raw 
score for PCS was 28, and the maximum averaged score was 7.00. The average score 
was used in hypothesis testing. Table 4-1 shows a significant correlation (r = .384) 
between adherence index and PCS2. Table 4-2 shows that adherent patients' mean PCS2 
scores (6.25, SD = 0.8) were significantly higher than non-adherent patients' mean PCS2 
scores (5.44, SD = 0.9). Therefore patients with a higher PCS2 score were more adherent 
than patients with a lower PCS2 score. 
Treatment Self-Regulation Questionnaire for Autonomous Motivation 
(TSRQAM2) and unadjusted adherence measures. Hypothesis Hlc: Patients with a 
higher TSRQAM2 score (representing higher autonomous motivation) would be more 
likely than patients with a lower TSRQAM2 score to have a higher adherence index and 
would be more likely to be adherent. The maximum score for TSRQAM was 35, and the 
maximum averaged score was 7.00. The average score was used in hypothesis testing. 
Table 4-1 shows a significant correlation (r =.764) between adherence index and 
TSRQAM2. Table 4-2 shows that adherent patients' mean TSRQAM2 scores (6.57, SD 
= 0.7) were significantly higher than non-adherent patients' mean TSRQAM2 scores 
(5.19, SD = 0.9). Therefore patients with a higher TSRQAM2 score were more adherent 
than patients with a lower TSRQAM2 score. 
SDT theorizes that patients who perceived autonomous support and self-
competence are likely to be more self-determining or autonomously motivated. Table 4-
1 shows significant correlations between HCCQ1 and TSRQAM 1 (.514**), PCS1 and 
TSRQAM1 (.482**), HCCQ2 and TSRQAM2 (.705**), and PCS2 and TSRQAM2 
(.559**). Regression analyses of SDT variables showed that both perceived competence 
and perceived autonomous support were significant predictors of autonomous motivation 
in pretest TSRQAM1 (HCCQ1 p = .40**, PCS1 p = .35**) and post-test TSRQAM2 
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in pretest TSRQAM1 (HCCQ1 p = .40**, PCS1 p = .35**) and post-test TSRQAM2 
(HCCQ2 p = .57**, PCS2 p = 33**). 
Predicting adherence with socioeconomic status, resources, health-related 
factors, and prescription drug variables. It was hypothesized that variables of 
socioeconomic status, resources, health, and prescription drugs would predict unadjusted 
patient composite adherence index (cadh) and unadjusted adherence status (hypotheses 
H2a to H2n). These results did not account for the intervention group effect. 
Socioeconomic status. Socioeconomic status includes age, gender, race/ethnicity 
and marital status. Adherent patients were significantly older (mean age 71.49, SD = 
10.17) than non-adherent patients (mean age 62.69, SD = 14.27) (Table 4-2). Age also 
correlated significantly with the adherence index (r = .42) (Table 4-1). The adherence 
index of patients older than 65 (89.58, SD = 14.66) were also significantly higher than 
younger patients' adherence index (75.74, SD = 22.41), with a mean difference of 13.84 
(CI= 5.37-22.30). It is plausible that in the chronic heart disease population there is a 
cumulative effect of repeat learning about cardiac medications, resulting in more 
understanding and better adherence in this older, hospitalized cardiac patient sample. It 
is also plausible that younger, non-adherent cardiac patients did not survive. There was 
no significant difference in proportion of adherent status between married patients and 
patients who were not married, between females and males, or between Caucasians and 
non-Caucasians. 
Resources. The resources category includes adequacy of health literacy, 
insurance coverage, and social support. There was no significant difference in proportion 
of adherent status between patients with adequate health literacy and patients with less-
than-adequate health literacy. Proportions of adherence status for insured patients 
(68.1%) were significantly higher than that of uninsured patients (14.3%) (Table 4-2). 
Insured patients' adherence index (86.78, SD = 17.10) was also significantly higher than 
that of the uninsured patients (56.79, SD = 20.62), with a mean difference of 29.99 (CI= 
10.88, 49.10). Proportions of adherence status for patients with social support (70.6%) 
were significantly higher than those of patients without social support (50.0%) (Table 4-
2). 
93 
Table 4-2. 
Characteristics of adherent patients versus non-adherent patients 
Characteristic 1 
(Interval) 
Perceived autonomous support 
Perceived competence 
Autonomous motivation 
Age 
Illness level 
Prescription cost/co-pay 
Number of prescription/day 
Doses of medication/day 
Characteristic 2 
(Dichotomous) 
Married 
Female gender 
Caucasian 
Adequate health literacy 
Insured 
Uninsured 
Has social support 
Has no social support 
Never smoked 
No depression risk 
No problem with ADR 
Had problem with ADR 
Adherent patients 
n = 63 
Mean (SD) 
6.10(1.1) 
6.25 (0.8) 
6.57 (0.7) 
71.49(10.17) 
5.46(1.83) 
$51.56 ($72.20) 
9.90 (4.90) 
12.48(6.47) 
Adherent patients 
n = 63 
proportion 
68.4% 
63.2% 
67.9% 
66.7% 
68.1% 
14.3% 
70.6% 
50.0% 
65.8% 
68.3% 
69.1% 
41.2% 
Non-adherent patients 
n = 35 
Mean (SD) 
4.57(1.0) 
5.44 (0.9) 
5.19(0.9) 
62.69(14.27) 
5.34 (2.06) 
$60.57 ($79.44) 
9.46(4.10) 
11.71 (6.40) 
Non-adherent patients 
(n = 35) 
proportion 
31.6% 
36.8% 
32.1% 
33.3% 
31.9% 
85.7% 
29.4% 
50.0% 
34.2% 
31.7% 
30.9% 
58.8% 
t statistic 
p (95% sig. 2-
tailed) 
6.67 (.00**) 
4.30 (.00**) 
8.23 (.00**) 
3.22 (.002**) 
2.82 (.78) 
-.556 (.58) 
4.83 (.63) 
0.56 (.58) 
X2 (Asymp. Sig. 
2-sided) 
1.02 (.314) 
0.03 (.853) 
2.66 (.103) 
0.58 (.448) 
8.21 (.004**) 
8.21 (.004**) 
3.84(0.05*) 
3.84 (0.05*) 
0.061 (.81) 
1.21 (.27) 
4.78 (.029*) 
4.78 (.029*) 
**significant at .001 level (2-sided) *significant at .01 level (2-sided) 
Health-related factors. The health-related factors category includes the variables 
illness level, smoking status, and depression risk. There was no significant difference 
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between the illness level of adherent patients and that of non-adherent patients. The 
correlation between adherence index and illness level was not significant. There were no 
significant differences in adherence index and proportion of adherent status between 
patients with a history of smoking and patients who never smoked, or between patients at 
risk of depression and patients not at risk of depression. 
Prescription drug variables and unadjusted adherence measures. The 
prescription drug related category includes the variables prescription drug expense, 
number of prescriptions, number of doses per day, and adverse drug reactions (ADR). 
Only patients who perceived adverse drug reactions to be problematic (41.2%) had a 
significantly lower proportion of adherence status than patients who perceived no 
problems with adverse drug reactions (69.1%) (Table 4-2). There were no significant 
differences in prescription co-pay, number of prescriptions per day, and number of doses 
per day between adherent patients and non-adherent patients. The correlations between 
adherence index and prescription co-pays, number of prescriptions, and number of doses 
per day were not significant. 
Predicting adherence with multiple SDT constructs. Hypothesis Him: When 
considered together in one model, the SDT variables (HCCQ, PCS, and TSRQ) will be 
significant predictors of adherence index (Cadh) and adherence status (adhered2) at post-
test. 
Correlation and partial correlation between SDT variables and adherence 
index. Table 4-3 shows the bivariate and partial correlations of each SDT variable with 
the adherence index (cadh) for the combined group (n = 98). All the correlations between 
the SDT variables and the adherence index were positive and significant (p < .01). 
Autonomous motivation and adherence index had the largest correlation of (r = .76) and 
the only significant partial correlation (.59, p < .01). 
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Table 4-3. 
Correlations and regression coefficients for adherence index (cadh) and SDT variables 
PCS2 (Perceived competence) 
HCCQ2 (Perceived autonomous 
support in healthcare) 
TSRQAM2 (Autonomous 
motivation) 
Correlations with adherence index 
Zero 
order 
.38** 
.59** 
.76** 
Partial 
-.08 
.11 
.59** 
Part (semi-
partial sr) 
-.054 
.068 
.471 
sr 
.003 
.005 
.222 
**significant at 0.01 level 
Multiple linear regression model for predicting adherence index with SDT 
variables. Models were tested with one of the SDT variables in the beginning, with 
additional variables entered until all three variables were in the model. It was found that 
the stepwise model (Model 3) with perceived competence entered first, then autonomous 
support, followed by autonomous motivation had the most consistent and significant R2 
increments, with an adjusted R of .58 (Table 4-4). The incremental effect of perceived 
competence and perceived autonomous support on autonomous motivation corroborated 
with the integral nature of the motivational constructs in SDT. Using squared semipartial 
correlation (sr2, or part correlation in SPSS, is the extent a predictor independently 
predicts the dependent variable when combined with the other predictors in a regression 
model), Table 4-3 shows a significant contribution to the prediction of adherence rate by 
TSRQAM2 (sr2 = .472 = .22), but very small contribution by HCCQ2 (sr2 = .005) and 
PCS2 (sr =.003). However, the three variables together contributed another .37 (R of 
the model 3 [.59] - sr2 of TSRQAM2 [.22]) in shared variability to adherence index. 
Table 4-4 showed that in Model 3, adherence index increased by 1.38 (95% CI= -1.28, 
4.04) when HCCQ2 increased by 1 unit, or by 1.31 (95% CI= -1.86, 4.48) when PCS2 
increased by 1 unit, or by 13.9 (95% CI= 10.05, 17.78) when TSRQ2 increased by 1 unit, 
while the other variables were being held constant. 
Logistic regression model for predicting adherence status with SDT variables. 
Adherence status was coded " 1 " for adherent status and "0" for non-adherent status. 
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Models were tested with one of the SDT variables in the beginning, with additional 
variables entered until all three variables were in the model. The models were evaluated 
with Omnibus x2 test of model coefficients and Nagelkerke's R2 (Table 4-5). Hosmer & 
Lemshow chi-square test of goodness of fit and classification table were found to be 
consistent with the Omnibus x2 test and Nagelkerke's R2 respectively. When compared to 
an intercept-only model, all models had a significant Omnibus test x2 (p < .001), 
indicating an adequate fit of data. Model 3, with perceived competence, perceived 
autonomous support, and autonomous motivation entered sequentially had consistent 
Nagelkerke's R2 increments from .22 to .57 (Table 4-5), with correct classification of 
83.7% (not shown in Table 4-5). Only the logistic regression coefficients (B) of 
autonomous motivation had a significant Wald statistic when all three SDT variables 
were entered in Model 3. Table 4-5 showed that in Model 3, the odds of being adherent 
increased by a multiplicative factor or point estimate of 1.64 (95% CI= 0.93, 2.90) as 
HCCQ2 mean score increased by 1 unit, or a factor of 1.30 (95% CI= 0.65, 2.61) as 
PCS2 mean score increased by 1 unit, or a point estimate of 3.97 (95% CI= 1.76, 8.96) as 
TSRQAM2 mean score increased by 1 unit, while the other variables were being held 
constant. 
Predicting adherence with SDT constructs controlling for socioeconomic 
status (SES), resources, health-related factors, and prescription drug variables. 
Hypothesis H3a: Patients with a higher HCCQ score, a higher PCS score, and a higher 
TSRQ-AM score at post-test will be more likely to be adherent at post-test than patients 
with a lower HCCQ score, a lower PCS score, and a lower TSRQ-AM score at post-test, 
when controlling for socioeconomic status, resources, health-related factors, and 
prescription drug variables. 
Multiple linear regression model for predicting adherence index with SDT 
constructs and controlled for other confounders. The variables age, insurance, social 
support, and adverse drug reactions were shown to predict adherence index in previous 
bivariate analyses. They were entered as another block after the three SDT variables for 
sequential multiple regression analysis. B coefficients for three of these four variables 
(age, insurance, and adverse drug reactions) were significant; adjusted R2 increased from 
.58 (Model 3) to .70 (Model 4, not shown). Other independent variables that did not 
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predict adherence (or were not statistically significant) in the previous hypotheses tests 
were also tried. Four additional factors, adequate health literacy (adeqhealit), illness 
level (illlevel), smoking status (smoked), and prescription drug doses per day taken 
(rxdosesall), though not predictive of adherence in bivariate analyses, were of interest and 
entered as another block in Model 5. B coefficients for three of these four variables 
(adequate health literacy, illness level, and number of doses taken per day) were 
significant, adjusted R2 increased from .70 (Model 4) to .73 (Model 5) (Table 4-4). Table 
4-4 showed that in Model 5, adherence index 3 months after discharge increased by 1.64 
(95% CI= -0.87, 4.16) when PCS2 increased by 1 unit, or by 1.68 (95% CI= -0.27, 3.63) 
when HCCQ2 increased by 1 unit, or by 7.97 (95% CI= 4.88, 11.06) when TSRQ2 
increased by 1 unit, or by 0.27 (95% CI= 0.10, 0.43) when age increased by 1 year, or by 
13.94 (95%o CI= 6.17, 21.71) when insurance coverage changed from no to yes, or by 
2.47 (95%) CI= -1.33, 6.27) when social support status changed from no to yes, or by 2.66 
(95%o CI= -1,06, 6.37) when smoking status changed from no to yes, or by 0.36 (95%> CI= 
0.03, 0.69) when number of daily prescription doses increased by 1 dose. Adherence 
index decreased by 5.32 (95%) CI= -9.86, -0.78) when tolerability of adverse drug 
reactions changed from no to yes, or by 4.55 (95%> CI= -9.10, -0.01) when adequacy of 
health literacy changed from no to yes, or by 1.19 (95% CI= -2.32, -0.05) when illness 
level increased by 1 unit, while the other variables were being held constant. 
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Table 4-4. 
Predicting adherence index (cadh) with multiple regression 
Independent 
Variables 
PCC intervention 
PCS2 (Perceived 
competence) 
HCCQ2 (Perceived 
autonomous support) 
TSRQAM2 
(Autonomous 
motivation) 
Age 
Insurance 
Model 3 
n = 98 
-
1.31/.07 
(-1.86,4.48) 
1.38/.10 
(-1.28,4.04) 
13.92**/.73** 
(10.05, 17.78) 
. 
-
-
B coefficient/Beta 
Model 5 
n = 95 
-
1.64/. 10 
(-0.87,4.16) 
1.68/. 14 
(-0.27, 3.63) 
7.97**/ 50** 
(4.88, 11.06) 
0.27**/.21** 
(0.10,0.43) 
13.94**/.23** 
(6.17,21.71) 
(95% CI) 
Model 6 
n = 95 
12.77**/.44 
(7.43, 18.12) 
-
-
. 
-
-
-
-
-
Model 8 
n = 95 
5.65*/.20 
(1.37,9.92) 
2.19/.28 
(-1.74,2.31) 
0.28/.02 
(-0.35, 4.74) 
7,49**/ .48** 
(4.21, 10.77) 
0.29**/.08** 
(0.12,0.45) 
-
Depressed 
Social support 
Adverse drug 
reactions 
Adequate health 
literacy 
Illness level 
Smoking status 
No. of doses/day 
Intercept 0.18 
Adjusted R2 .58 
2.47/.07 
(-1.33,6.27) 
-5.62*/-. 13* 
(-9.86, -0.78) 
-4.55*/-.13* 
(-9.10,-0.01) 
-1.19*/-.14* 
(-2.32, -0.05) 
2.66/.08 
(-1.06,6.37) 
0.36*/.14* 
(0.03, 0.69) 
-9.64 
.73 
67.57 
.44 
-3.54/-. 12 
(-7.26,0.19) 
2.18/.07 
(-1.81,6.17) 
-5.12*/-.14* 
(-9.83, -0.40) 
-1.36 
.65 
**significant at the 0.001 level *significant at 0.01 level 
Table 4-5. 
Predicting adherence status with logistic regression 
Variables Odds ratio (95% CI) 
Model 3 (n = 98) Model 5 (n = 94) Model 6 (n = 94) Model 8 (n = 94) 
PCC intervention 5.38** 7.96* (2.15,13.48) (1.00,63.28) 
PCS2 (Perceived 1.30 1.87 5.09** 
competence) (0.65,2.61) (0.76,4.62) " (1.53,16.94) 
HCCQ2 (Perceive 1.64 1.06 2.65 
autonomous support) (0.93,2.90) (0.40,2.81) " (0.98,7.17) 
TSRQAMA2 
(Autonomous 
motivation) 
Age 
Social support 
3.97** 17.48* 4.80* 
(1.76,8.96) (1.94,157.5) " (1.08,21.39) 
1.07* 1.08 
(0.99, 1.15) " (1.00, 1.17) 
10.66 
(0.83, 136.9) 
ADR 
Illness level 
No. of doses/day 
Omnibus x2 
Nagelkerke R2 
-
-
-
52.41** 
.57 
0.07* 
(0.01,0.67) 
-
-
78.16** 
.79 
-
-
-
14.40** 
.19 
0.10* 
(0.01,0.52) 
0.41* 
(0.18,0.95) 
1.31* 
(1.04, 1.63) 
81.09** 
.80 
** significant at .001 level * significant at .01 level 
B coef s were tested with Wald statistic 
Logistic regression model for predicting adherence status with SDT constructs 
and controlled for other confounders. Dichotomous variables were coded with " 1 " for 
yes for the event and "0" for no. The category variables depressed, adequate health 
literacy, social support, insurance, and adverse drug reactions were already coded as such 
to facilitate interpretation of the regression model. Age demonstrated a curvilinear 
relationship with adherence index in residual analysis. The dichotomous variable age 
over 65 was used for logistic regression analysis. With the experience gained from 
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previous multiple regression analyses, three blocks of variables were entered 
sequentially: block 1 (PCS2, HCCQ2, TSRQAM2), block 2 (social support, adverse drug 
reactions, age, insurance), and block 3 (adequate health literacy, illlevel, smoked, doses 
taken per day). Forward selection and backward selection techniques were to arrive at 
the optimized Model 5 with age, social support, and adverse drug reactions entered after 
the three SDT variables. Table 4-5 shows that Model 5 had an acceptable model fit 
(Omnibus x2 = 78.16) and accounted for 79% of the model variance. The coefficients for 
autonomous motivation, age, and adverse drug reactions were significant. The logistic 
regression model showed the odds of being adherent increased by a multiplicative factor 
or point estimate of 1.87 (95% CI= 0.76, 4.62) as PCS2 increased by 1 unit, or a factor of 
1.06 (95% CI= 0.40, 2.81) as HCCQ2 increased by 1 unit, or a factor of 17.48 (95% CI= 
1.94, 157.5) as TSRQAM2 increased by 1 unit, or a factor of 1.07 (95% CI= 0.99, 1.15) 
as age increased by 1 year, or a factor of 10.66 (95% CI= 0.83, 136.9) as social support 
changed from no to yes, but decreased by a factor of 0.07 (95% CI= 0.01, 0.67) (or 6.5% 
less likely; 0.07/[l+0.07] = 0.065) when adverse drug reactions was experienced, while 
the other variables were being held constant. 
Predicting SDT Constructs Change over Time. Contrasting the usual care 
group with the PCC intervention group, Table 4-6 shows the mean pretest score, post-test 
scores, and the mean differences between pretest and post-test scores of the SDT 
variables. 
Perceived autonomous support post-test versus perceived autonomous support 
at pretest. Hypothesis H4a: Patients will be more likely to have a higher perceived 
healthcare autonomous support score (HCCQ) at post-test than at pretest. Table 4-6 
shows that for the usual care group, there was an increase of mean HCCQ2 score over 
mean HCCQ1 score with a positive and significant difference of 0.18; for the PCC group, 
there was an increase of mean HCCQ2 score over mean HCCQ1 score with a positive 
and significant difference of 0.31. Therefore, this study supports the hypothesis for the 
usual care group and the PCC group. 
Perceived competence at post-test versus perceived competence at pretest. 
Hypothesis H4b: Patients will be more likely to have a higher perceived competence 
score (PCS) at post-test than at pretest. Table 4-6 shows that for the usual care group, 
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there was a decrease of mean PCS2 score from mean PCS1 score with a negative not 
statistically significant difference of-0.07; for the PCC group, there was an increase of 
mean PCS2 score over mean PCS1 score, with a positive and significant difference of 
0.33. Therefore, this study supports the hypothesis for the PCC group, but not for the 
usual care group. 
Table 4-6. 
Value of pretest SDT variables versus post-test SDT variables 
HCCQ 
PCS 
TSRQAM 
UC group 
Pretest 
Mean 
(SD) 
4.88 
(1.28) 
6.04 
(0.94) 
5.79 
(1.04) 
(n=48) 
Post-test 
Mean 
(SD) 
5.06 
(1.16) 
5.97 
(1.00) 
5.73 
(1.06) 
Mean 
difference 
(SD) 
0.18* 
(0.53) 
-0.07 
(0.48) 
-0.06 
(0.40) 
PCC group (n=50) 
Pretest Post-test 
Mean Mean 
(SD) (SD) 
5.72 6.03 
(1.19) (1.28) 
5.95 5.62 
(0.89) (1.05) 
6.03 6.41 
(0.82) (0.82) 
Mean 
difference 
(SD) 
0.31** 
(0.60) 
0.33** 
(0.56) 
0.38** 
(0.57) 
**significant level at p < .001 level *significance at p <..01 level 
Autonomous motivation at post-test versus autonomous motivation at pretest. 
Hypothesis H4c: Patients will be more likely to have a higher autonomous motivation 
score (Treatment Self Regulation Questionnaire TSRQAM) at post-test than at pretest. 
Table 4-6 shows that for the usual care group there was a decrease of mean TSRQAM2 
score from mean TSRQAM 1 scores, with a negative and nonsignificant difference of 
-0.06. For the PCC group, there was an increase of mean TSRQAM2 score over mean 
TSRQAM1 score, with a positive and significant difference of 0.38. Therefore, this 
study supports the hypothesis for the PCC group but not for the usual care group. 
The effect of patient-centered care on SDT constructs. It was hypothesized in 
hypothesis H5 that patients who received PCC teaching will be more likely to have a 
higher post-test score of each of the three SDT variables than patients who received UC, 
controlling first for the corresponding pretest of each of the three SDT variables, then 
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adjusting for age, gender, race/ethnicity, health literacy, insurance coverage, social 
support, illness level, smoking status, depression, prescription drug expense, number of 
prescriptions, number of doses/day, and drug adverse reaction (ADR). 
Model consideration. Multivariate analysis of covariance (MANCOVA) for 
hypothesis testing was considered because of its intuitive appeal. It was abandoned 
because of lowered power of analysis from reduced degrees of freedom for error, from 
positive or moderately negative correlation among SDT variables, ambiguity of 
interpretation, and inability to satisfy the assumption of homogeneity of covariance 
matrices with a small sample size. Analyses of covariance (ANCOVA) was considered 
instead. Pretest SDT scores were used as covariate control for the corresponding 
dependent post-test scores. After trials with various permutations of the independent 
variables, another covariate (age) and factors (insurance, social support, adverse drug 
reactions) were used as controls. ANCOVA first uses the regression function to predict 
the dependent post-test SDT variables with the pretest SDT covariates, then performs an 
ANOVA on the residuals to see if the other factors are still significantly related to the 
dependent variable after the variation due to the covariates have been removed. A 
preliminary analysis evaluating the homogeneity of regression (or slope) assumption for 
the between-group design was assessed with SPSS ANCOVA CUSTOM for each of the 
three ANCOVA models. The assumption of homogeneity of regression is that the slopes 
of the regression of the dependent variable on the covariates are the same for all cells of a 
design. A test of between-subject effects was performed to evaluate the interaction 
between the covariate and the factors in the prediction of the dependent variable. Eight 
covariate factor interaction pairs were formed by paring one of the covariates (HCCQ1, 
PCS1, TSRQAM1, or age) with one of the independent factors (group, insurance, social 
support, or adverse drug reactions) iteratively. F statistics, eta squared and significance 
were evaluated. None of the F statistics of the interaction terms were found to be 
significant. The result suggested that the potential covariate factor interactions were not 
significant, the differences on the dependent variable among groups did not vary as a 
function of the covariate, and the homogeneity of regression assumption was met. 
Assumptions of normality of sampling distributions, linearity, and homogeneity of 
variance for each of the SDT models was acceptable since Levene's test of homogeneity 
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of variance was not significant for all three SDT models. Evaluations of reliability for 
the three SDT scales were satisfactory. Cronbach's a for PCS1 = .90, PCS2 = .90, 
HCCQ1 = .94, HCCQ2 = .97, TSRQAM1 = .90, and TSRQAM2 = .92. 
ANCOVA of group effect on perceived competence. Hypothesis H5b: Patients 
who received PCC teaching will be more likely to have a higher PCS2 score (Perceived 
Competence Scale at post-test) than patients who received UC, controlling first for the 
pretest PCS1 score, then adjusting for age, insurance, social support, and adverse drug 
reactions. A one-way analysis of covariance (ANCOVA) was conducted with PCS2 as 
the dependent variable; PCS1 and age were the covariates; group, age, insurance, social 
support, and adverse drug reactions were the factors. The sums of squares was used to 
evaluate the group main effect first and then adjusted for covariates and other effects. 
Table 4-7 shows the PCS ANCOVA model with an adjusted mean PCS2 score for the 
UC group = 5.71, an adjusted mean PCS2 score for the PCC group = 5.88. The main 
effect from group (SS = 2.15) was significant. The group effect accounted for .105 of the 
variance (partial eta squared n2) of the model and suggested a weak relation between the 
group effect and perceived post-test competence. The sums of squares of the covariate 
PCS1 (SS = 49.83) was significant and accounted for .73 of variance of post-test PCS2. 
The social support/adverse drug reactions term was significant but with a very weak 
effect (partial n2 = .045). The insurance factor also had a weak significant effect (partial 
n2 = .056). The combination of these factors contributed to .1 of the model variance. The 
corrected model was significant (SS = 67.82), accounting for .79 (partial r| ) of the model 
variance, with an adjusted R2 = .75. 
ANCOVA of group effect on perceived autonomous support. Hypothesis H5a: 
Patients who received PCC teaching will be more likely to have a higher perceived 
autonomous support HCCQ2 score (Healthcare Climate Questionnaire at post-test) than 
patients who received usual care (UC), controlling first for pretest HCCQ1, then adjusted 
for age, insurance, social support, and adverse drug reactions. A one-way analysis of 
covariance (ANCOVA) was conducted with HCCQ2 as the dependent variable; HCCQ1 
and age were the covariates; group, age, insurance, social support, and adverse drug 
reactions were the factors. The sums of squares was used to evaluate the group main 
effect first, then adjust for the covariates and other factors. Table 4-7 shows the HCCQ 
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model with an adjusted mean HCCQ2 score for the UC group = 5.46, an adjusted mean 
HCCQ2 score for the PCC group = 5.37. The effect from the group source (SS = 1.17) 
was not significant, and a very weak relation was found between the group effect and 
HCCQ2 (partial rj2 = .04), controlling for pretest HCCQ1, age, insurance, social support, 
and adverse drug reactions. The effect of covariate HCCQ1 (SS = 88.34) was significant 
and accounted for .78 (partial n2 = .78) of variance of post-test HCCQ2. No statistically 
significant effect of the other covariates, factors, and interactions was found. The 
corrected model had a significant sum of squares (SS = 141.76) and accounted for .85 of 
the variance of perceived autonomous support, with an adjusted R = .82, but the group 
effect was not significant. Therefore, this study does not support the hypothesis for the 
PCC treatment. 
Table 4-7. 
ANCOVA tests of between-subjects effects (n = 98) 
SDT variables 
ANOVA 
Sum of Squares (SS) & Eta 
Intervention Group SS 
partial n2 
Pretest SDT score SS 
partial n2 
Insurance SS 
partial n2 
Ssupport*ADR SS 
partial n2 
Corrected Model SS 
partial r|2 
Corrected Model 
Adjusted R2 
UC group 
Adjusted mean score 
(95% CI) 
PCC group 
Adjusted mean score 
(95% CI) 
PCS 
2.15** 
.11 
49.83** 
.73 
1.08** 
.056 
0.873** 
.045 
67.82** 
.79 
.75 
5.71 
(5.49 : 5.92) 
5.88 
(5.62:6.15) 
HCCQ 
1.17 
.04 
88.84** 
.78 
0.434 
.017 
0.017 
.001 
141.76** 
.85 
.82 
5.46 
(5.21 : 5.71) 
5.37 
(5.07 : 5.67) 
TSRQAM 
5.03** 
.215 
35.51** 
.66 
0.602 
.032 
0.002 
.000 
77.92** 
.81 
.78 
5.89 
(5.68:6.11) 
6.09 
(5.83 : 6.35) 
PCS = Perceived Competence Scale, HCCQ = Perceived Healthcare Autonomous Support Questionnaire, 
TSRQAM = Treatment Self-Determination Questionnaire Autonomous Motivation 
**significant at .001 level F stat *significant at .01 level F stat 
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ANCOVA of group effect on autonomous motivation. Hypothesis H5c: Patients 
who received PCC teaching will be more likely to have a higher TSRQAM2 score 
(autonomous motivation at post-test) than patients who received UC, controlling for 
pretest TSRQAM1 score, age, insurance, social support, and adverse drug reactions. A 
one-way analysis of covariance (ANCOVA) was conducted with TSRQAM2 as the 
dependent variable; TSRQAM1 and age were the covariates; group, age, insurance, social 
support, and adverse drug reactions were the factors. The sums of squares was used to 
evaluate the group main effect first, and then sums of squares was used to evaluate 
covariates and adjust for all other effects. Table 4-7 shows the TSRQAM Model, an 
adjusted mean TSRQAM2 score for the UC group = 5.89, and an adjusted mean 
TSRQAM2 score for the PCC group = 6.09. The effect from the group source (SS = 
5.03) was significant, with a partial eta squared (n ) of .22 suggesting a moderate 
relationship between the group effect and TSRQAM2, controlling for pretest TSRQAM 1, 
age, insurance, social support, and adverse drug reactions. The effect of covariate 
TSRQAM 1 (SS = 35.51) was significant and accounted for .66 of variance of post-test 
HCCQ2. No statistically significant effect of the other covariates, factors, two-way (a*b) 
and three-way (a*b*c) factor-by-factor interactions was found. The effect of the corrected 
model (SS = 77.92) was significant, accounted for .81 of the variance of autonomous 
motivation, and had an adjusted R2 = .78. This study supports the hypothesis for the PCC 
treatment. 
The effect of PCC on adherence. Hypothesis H6: Patients who received 
patient-centered care (PCC) teaching will be more likely to be adherent at post-test than 
patients who received usual care (UC) teaching. An independent t-test analysis was 
conducted to evaluate whether patients in the PCC group had a higher adherence index 
than patients in the UC group. At post-test, patients in the PCC group had a higher 
adherence index (Cadh = 90.37 [SD 17.09]) than patients in the UC group (Cadh = 78.67 
[SD 19.05]), and the mean difference of 11.7 was significant (95% CI= 4.45:18.95). 
Therefore, this study supports the hypothesis. A two-way contingency table analysis was 
conducted to evaluate whether patients in the PCC group had a higher proportion of 
adherent status than patients in the UC group. The proportion of adherent patients at 
post-test was 45.8% for the UC group and 82.0% for the PCC group. Group and 
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adherence status were found to be significantly related, Pearson x2 (1, n = 98) = 13.95, p 
< .001. Effect size measured by Cramer's V was .38, p< .001. Therefore, this study 
supports the hypothesis. 
Predicting adherence with PCC, controlling for SDT constructs, socio-
economic status (SES), resources, health-related factors, and prescription drug 
variables. Hypothesis H7: Patients who received PCC teaching will be more likely to be 
adherent at post-test than patients who received UC teaching after controlling for 
perceived autonomous support (HCCQ), perceived competence (PCS), and autonomous 
motivation (autonomous motivation portion of TSRQ), as well as adjusting for age, 
marital status, gender, race/ethnicity, health literacy, insurance coverage, social support, 
illness level, smoking status, depression, prescription drug expense, number of 
prescriptions, number of doses/day, and adverse drug reactions (ADR). 
Multiple linear regression model for predicting adherence index with PCC, 
controlled for SDT constructs and other confounders. Both forward and backward 
selection techniques of sequential multiple linear regression were used to test various 
permutations of variables. Table 4-4 shows the summary of model development. When 
tested individually, the variables depression, social support, and adverse drug reactions 
did not cause a change in F statistics when entered to Model 7 (not shown). But when 
they were entered with age as a block after the SDT variables, a significant change in F 
statics (p < .001) in Model 8 was observed. Model 8 was optimized by entering the 
group variable first, then the SDT variables (PCS2, HCCQ2, and TSRQSM2), followed 
by the block of variables (age, depression, social support, and adverse drug reactions). 
The group variable, autonomous motivation, age, and adverse drug reactions contributed 
significantly to prediction of adherence index in Model 8, with an adjusted R2 of .65. 
Table 4-4 showed that in Model 8, the adherence index three months after discharge 
increased by 5.65 (95% CI= 1.37, 9.92) when group status changed from usual care to 
PCC intervention, or 2.19 (95% C= -1.74, 2.31) when PCS2 increased by 1 unit, or 0.28 
(95% CI= -0.35, 4.74) when HCCQ2 increased by 1 unit, or by 7.49 (95% CI= 4.21, 
10.77) when TSRQ2 increased by 1 unit, or by 0.29 (95% CI= 0.12, 0.45) when age 
increased by 1 year, or by 2.18 (95% CI= -1.81, 6.17) when social support status changed 
from no to yes; adherence index decreased by 3.54 (95% CI= -7.26, -0.19) when 
107 
depression risk changed from no to yes, or 5.12 (95% CI= -9.83, -0.40) when tolerability 
of adverse drug reactions changed from no to yes, while the other variables were being 
held constant. 
Logistic regression analysis model for predicting adherence status with PCC, 
controlled for SDT constructs and other confounders. Sequential logistic regression 
was employed to determine if addition of information from other variables (age, gender, 
race/ethnicity, health literacy, insurance coverage, social support, illness level, smoking 
status, depression, presciption drug expense, number of prescriptions, number of 
doses/day, and drug adverse reaction) improved prediction of adherence status beyond 
that afforded by the group variable. The Omnibus x^est of model coefficients, Hosmer 
& Lemshow chi-square test of goodness of fit, Nagelkerke's R2, and classification table 
were employed for model evaluations. Wald statistics (z-ratio) and odds ratios were 
reported for the individual logistic regression coefficients (B). To facilitate interpretation 
of the model, dichotomous variables were coded with " 1 " for the event occurring or yes, 
and "0" for no. The categorical variables depression, adequate health literacy, social 
support, insurance, and adverse drug reactions were already coded as such. Both 
backward and forward variable selection techniques were used to test permutations of 
variables individually and in groups. Initially, block 1 (group), block2 (HCCQ2, PCS2, 
TSRQAM2), block3 (age, insurance, social support, depression, adverse drug reactions), 
block4 (adequate health literacy, illlevel, smoked, doses taken per day), and block5 (male 
gender, Caucasian, married, insurance) variables were entered sequentially. When 
comparing to an intercept only model, all incremental models had a significant Omnibus 
test x (p < .001), indicating the models' estimates fit the data at an acceptable level. 
Model 8 was optimized, with the PCC intervention factor, perceived competence, 
autonomous motivation, adverse drug reactions, illness level, and number of doses taken 
per day contributing significantly to the model (Table 4-5). Model 8 had a significant 
Omnibus x2 fit test of 81.09 and accounted for 80% (Nagelkerke R2) of the model 
variance. The logistic regression analysis supports the hypothesis that patients who 
received PCC teaching will be more likely to be adherent at post-test than patients who 
received UC teaching after controlling first for perceived autonomous support, perceived 
competence, autonomous motivation, then adjusted for age, adverse drug reactions, 
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illness level, and prescription doses per day. The odds of being adherent increased by a 
multiplicative factor of 7.96 (95% CI= 1.00, 63.28) when the group factor changed from 
UC group to PCC group, or by a factor of 5.09 (95% CI= 1.53, 16.94) as PCS2 increased 
by 1 unit, or by a factor of 2.65 (95% CI= 0.98, 7.17) as HCCQ2 increased by 1 unit, or 
by a factor of 4.80 (95% CI= 1.08, 21.39) as TSRQ2 increased by 1 unit, or by a factor of 
1.08 (95% CI= 1.00, 1.17) as age increased by 1 year, or by a factor of 1.31 (95% CI= 
1.04, 1.63) as number of daily prescription doses increases by 1 dose; the odds of being 
adherent decreased by a factor of 0.10 (95% CI= 0.01, 0.52) (or 9% less likely; 
0.1/[1+0.1] = 0.09) when adverse drug reactions were experienced, or by a factor of 0.41 
(or 29% less likely; 0.41/[ 1+0.41] = 0.29) as illness level increased by 1 unit, while the 
other variables are being held constant. 
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CHAPTER V 
Conclusions 
Summary 
The purposes of this research were to examine the utility of self-determination 
theory (SDT) in understanding adherence and to test a SDT-based, patient-centered care 
(PCC) approach to enhance adherence to cardiovascular (CV) medication in high-risk 
patients. This study was conducted with two groups of hospitalized cardiac patients. 
Sixty patients were recruited for each of a standard care group and a PCC group. Patient 
adherence to prescription medications was measured three months after discharge from 
the hospital. The results of this study showed that the SDT variables, PCC intervention, 
as well as several patient factors were associated with adherence and were also predictors 
of adherence. These results can assist policymakers and healthcare providers improve the 
quality of care and outcome for patients with cardiovascular disease (CVD) by 
identifying patients at risk for non-adherence to CV medication and developing 
interventions to reduce preventable and costly hospitalization. 
Summary of SDT motivational predictors of adherence at three months. The 
study tested SDT in terms of the effects of perceived competence, perceived autonomous 
support, and autonomous motivation on adherence behavior. Patients who understood 
their disease, knew how and why to check their weight and blood pressure, knew what to 
do with their symptoms, understood the indications for their CV medications, knew how 
to take these medications, and knew what to do for adverse drug reactions tended to 
perceive themselves as competent in managing their CV medication. Patients who were 
treated as partners in disease management, particularly if they were listened to and 
encouraged to ask questions, if difficult situations were addressed, if they were 
encouraged to be autonomous without being pressured, and if decisions were made 
jointly after sharing of information and choices, tended to perceive the healthcare 
environment to be supportive of their autonomy. Patients who felt competent with 
managing their CV medications and perceived the healthcare environment to be 
autonomous supportive also tended to be autonomously motivated to adhere to their CV 
medications. Autonomously motivated patients also tended to feel responsible for their 
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own health, understand the importance of CV medications, and feel the need to learn 
about their CV medications. 
Summary of patient-centered care predictor of adherence at three months. 
The study tested the effect of PCC on adherence behavior. Patients in the PCC group 
were engaged with an interactive care pathway implemented by GetWellNetwork. The 
pathway was used as a platform to provide PCC by honoring patient choices and 
preferences, sharing information and teaching at an appropriate education level, allowing 
sufficient time for comprehension, coordinating care plans that considered both clinical 
facts and personal experiences, providing choices without the use of pressure to change, 
exploration of disagreements for opportunities to clarify areas of differences, promoting 
positive feedback, and competence. In terms of sharing information and education, the 
interactive pathway supported the teaching of disease states and their signs and 
symptoms, tests, procedures, medication usage, managing adverse drug reactions, healthy 
diet, exercise, and individualizing self-care plans for cardiac rehabilitation. Compared to 
patients in the usual-care group, patients in the PCC group were significantly more 
adherent to CV medications three months after being discharged from the hospital. 
Support of Findings and Other Findings 
SDT allows the theorization of an innate human will to make choices in 
complicated life situations such as the management of CVD with medications in the 
absence of extrinsic contingencies. The SDT framework is composed of the motivational 
constructs of perceived autonomous support, perceived competence, and autonomous 
motivation with the assumption that humans are innately oriented toward health and 
growth (Deci & Ryan, 1985). 
The psychological need for competence provides the energy for the development 
of competence and subsequently for effective behaviors. The feeling of competence with 
CV medications is a consequence of understanding experientially why and how the 
medications are used for the disease. Perceived competence contributed significantly to 
the SDT PCC logistic regression model, but not to the SDT multiple regression model, 
the SDT logistic regression model, and the SDT PCC multiple regression model. The 
weak contribution to the models might be attributed to a need for the development of 
competence over a longer period of time than three months. Perceived competence can 
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be enhanced by positive feedback after experiencing how the medications work over 
time, by feeling confident in talking about them with healthcare providers, and by 
working with physicians in adjusting the medications dosages to meet patient needs. 
Patients were likely to perceive themselves to be competent over time with their CV 
medications when they learned why and how the CV medications were used to treat CVD 
and were able to monitor and control the symptoms of CVD and the side effects of their 
CV medications. They were also more likely to be autonomously motivated and adhere 
to their CV medications under these conditions. When patients took medications without 
knowing the reason for the prescription, they were usually unclear about the diagnoses 
and progression of their disease states, unsure of the duration of the therapies, and did not 
know what signs or symptoms to watch for when they returned home. Subsequently, 
these patients were usually not very confident with their physicians, did not feel 
competent in handling their medication, and were likely to be nonadherent to their CV 
medication three months after their hospitalization. 
The other major obstacle in chronic CVD care is for the healthcare providers to 
orient their attitudes toward supporting patients' autonomy in managing a complex 
disease. When healthcare providers understood and acknowledged patients' need for 
relatedness, patients felt more coherently involved with their healthcare environment. 
Healthcare providers were also able to relate more authentically to patients' deeper need 
for autonomy. The locus of causality and direction of motivation can be shifted towards 
autonomous motivation when healthcare providers understand their role in supporting 
patients' autonomy. However, perceived autonomous support of the healthcare 
environment was not found to contribute significantly to the multiple regression models 
nor the logistic regression models. This study found that if the patients were not already 
motivated autonomously, it was typical that they were being motivated in a controlled 
manner and were not able to develop some interest and competence in their therapies 
when discharged from the hospital. It appeared that fear and anxiety during a cardiac-
related hospitalization overpowered the much more subtle autonomous supportive effort. 
If the follow-up clinic care was not autonomous supportive, the short period of hospital 
stay was not sufficient to impact on the patients' perceived autonomous support by the 
healthcare environment. After their lives became stable and the symptoms of acute 
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cardiac events subsided, these patients tended to doubt the necessity of their C V 
medications and stopped taking their medication consistently. In the study, patients who 
perceived their healthcare environment to be supportive of their autonomy were more 
likely to be autonomously motivated. 
The need for autonomous motivation or self-determination is humans' basic 
propensity to be the cause of, or to be responsible for, one's behavior. Even though many 
human behaviors are motivated by external causes, behaviors motivated intrinsically are 
preferred by the human psyche and tend to be long lasting. Motivation as a regulatory 
process for behavior is not a dichotomous construct (i.e., motivated or unmotivated), but 
is dependent on the perception of a range of locus of causality. Patients might have been 
motivated in a controlled way to adhere with medications initially by fear and anxiety 
because of uncertainty with cardiac interventions. When autonomously supported, 
patients' regulatory processes for motivation could be shifted to an identified value such 
as accepting the value of CV medications as personally important, even to integration of 
the identified value. There will be a feeling of congruence with the acquired value. 
When the behavior regulatory processes became more autonomously motivated, patients 
might develop more felt competence over time as they acquired more experiences with 
their CV medications. Perceived competence also might enhance their ability to interact 
effectively with their healthcare providers and help meet their need for self-
determination. 
The study also showed that with a complex disease state such as CVD, limited 
health literacy, the comorbidities of heart disease, and the experience of drug side effects 
did negatively impact patients' adherent behavior even when they were autonomously 
motivated. These factors also contribute to CVD-associated fear and anxiety that may 
need an extended period of time after discharge for a supportive healthcare environment 
to overcome. Older patients in this study had lower education levels and health literacy. 
However, they were more autonomously motivated and more adherent with CV 
medication than younger patients. Some of the plausible reasons may be that surviving 
older patients had more experience with chronic CVD, were more aware of the beneficial 
effect of CV medications, were more comfortable dealing with the treatment side effects, 
felt responsible for their medication management, and had been more adherent to their 
113 
CV medications than younger patients. Paradoxically, patients with a history of smoking 
were more adherent to CV medication than patients without a history of smoking. This 
might be because there was a higher percentage of older patients with smoking history 
than younger patients. In addition, older heart patients with a history of smoking had 
usually been exposed to previous smoking cessation motivational counseling. Contrary to 
most adherence studies, in this study patients who were taking more doses of CV 
medication per day were more adherent to their medication than patients who were taking 
fewer doses of medication per day. This might also be because older patients were taking 
more doses of medication than younger patients and older heart patients were more 
motivated and more adherent to CV medication than younger heart patients. The 
availability of social support was an important factor in adherent behavior. Older patients 
also had a higher level of social support than younger patients in this study. Another 
unexpected observation was that adequacy of health literacy did not predict adherence 
positively. It appeared that because of conflicting information, unclear explanations by 
healthcare providers, skepticism, or personal preferences, patients with adequate health 
literacy were not always adherent with their CV medications. The availability of 
insurance is paramount in adherence because patients were taking an average of eight CV 
medications prescriptions. Without insurance, patients were neither able to afford the 
prescriptions nor able to adhere to the medication regimen. 
Patient-centered care intervention. PCC provides the knowledge of how to 
improve the quality of healthcare and the outcomes of medical care. Human interactions 
and empowerment with information are the most important elements in the Planetree 
model of patient-centered care. In this study, SDT was used to provide an explanation 
for why PCC is able to provide more high quality healthcare. The psychological 
dynamics that take place in a PCC environment may be elucidated with the SDT 
motivational constructs. Figure 5-1 shows that the element of human interaction (i.e., 
having respect for patients' value and dignity, forming a caring partnership, providing 
emotional support, and alleviating anxiety) in PCC provides an environment that is 
congruent with the concept of an autonomous supportive environment (i.e., meeting 
patients' needs for relatedness by considering the patient's perspective, encouraging and 
answering their questions, supporting their initiatives, offering choices about treatment 
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options, and minimizing control) in SDT. SDT predicts that an autonomous supportive 
environment induces patients' perceived autonomy support. The element of 
empowerment with information such as communication and sharing information in PCC 
is similar to the methods of education advocated by SDT such as providing an 
appropriate level of information, and promoting competence with positive feedback. 
SDT predicts that this type of education enhances patients' perceived competence. 
SDT postulates that individuals have a psychological need to feel related, 
competent, and self-determining. SDT further predicts that meeting these needs will 
promote optimal motivation for the desired behavior. Such behavior is autonomously 
motivated to the extent that people experience a sense of volition, self-initiation, and 
personal endorsement of the behavior. On the other hand, in a controlled environment, 
behavior is controlled to the extent that people feel pressured to behave by external, 
interpersonal or intrapsychic forces. The practical importance of this distinction in health 
care is that only autonomous motivation is expected to yield long-term persistence in a 
behavioral change. The interactive care pathway implemented by GetWellNetwork was 
designed to individualize patient care and support the nursing staff in meeting patients' 
needs for relatedness and competence. 
Compared to patients in the usual-care group, patients in the PCC group perceived 
themselves to be more competent in self-care, perceived the healthcare environment to be 
more supportive of their autonomy, were more self-determined, and more adherent to 
their CV medications three months after discharge. In addition, older patients were more 
adherent than younger patients, and patients with social support were more adherent than 
patients without social support. 
Patient-Centered Care Adherence Model 
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Figure 5-1. Concept mapping for patient-centered care and self-determination theory 
Policy Implications 
Once patients are diagnosed with coronary heart disease, long-term management 
of these patients with the use of CV medications is important in reducing the risk of 
future CV events, morbidity and mortality. However, these therapies are neither 
consistently prescribed by physicians nor adhered to by patients (Horning, Hoehns, & 
Doucette, 2007; WHO, 2003). Figure 5-2 shows that biological, behavioral, social, and 
environmental factors and their interactions with each other that influence health 
outcomes (U.S. Department of Health and Human Services, 2000). Understanding of and 
intervening in non-physiological factors, such as promoting adherent behavior in the 
healthcare environment, are needed to improve outcomes in patients with heart disease. 
Non-adherence to CV medication is a major factor contributing to increased morbidity, 
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mortality, and cost (WHO, 2003). One solution to non-adherence is to transform the 
current healthcare system to one that is more patient-centered, safe, effective, timely, 
efficient and equitable (Institute of Medicine, 2001). A SDT-based PCC model is a 
comprehensive approach to improve the processes of care such as building better 
treatment relationships between patients and healthcare providers, improving adherence 
to CV medication. This section explores some of the potential impacts of the model in 
terms of morbidity, mortality, complications, quality of life, patient satisfaction, care 
coordination, and health cost savings. 
Behavioral. 
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Figure 5-2: Factors affecting health. Adapted and reprinted from A Strategic Plan for the 
Office of Behavioral and Social Sciences Research at the National Institutes of Health. 
(National Heart Lung and Blood Institute, 1998) 
Morbidity, mortality, complications, and quality of life. Inadequate control of 
cardiac risk factors such as hypertension and hypercholesterolemia due to non-adherence 
often leads to faster disease progression, higher morbidity and more complications 
(Sokol, McGuigan, Verbrugge, & Epstein, 2005). Patients with lower levels of 
medication adherence had significantly higher hospitalization rates than patients with 
higher levels of adherence (Sokol, McGuigan, Verbrugge, & Epstein, 2005). Patients 
who adhered to their prescription medications in the secondary prevention of 
cardiovascular diseases improved their clinical outcomes by lowering their risk of 
recurrent heart attacks, all-cause mortality, and hospital readmissions (Wei et al., 2002). 
117 
Even though more than half of the patients in this study had the more severe classes of 
heart failure, they were more adherent to their CV medication when autonomously 
motivated. Higher levels of medication adherence should help to decrease the morbidity 
and mortality normally associated with patients at risk of heart failure. 
Patient satisfaction. Though improved clinical outcomes have been assumed to 
be the reason for patient satisfaction (Sen et al., 2005), it is more likely that patients focus 
on how health care is delivered when considering satisfaction (Frampton, Gilpin, & 
Channel, 2003; Kane, Maciejewski, & Finch, 1997). Patient satisfaction surveys 
typically ask for the patient's perception about the manner in which care was delivered 
(i.e., friendliness, politeness, respecting patient's dignity, caring attitude, willingness to 
answer questions, encouragement to ask questions, and sharing of information) instead of 
about the outcome of medical care itself (Gerteis, Edgman-Levitan, Daley, and Delbanco, 
1993). It has been demonstrated that patients are more satisfied with their care in a PCC 
setting because patients felt valued and respected, had a sense of control over their lives, 
and believed they had an opportunity for meaningful participation (Frampton, Gilpin, & 
Channel, 2003; Martin et al., 1998). Since participation in care is one of the important 
factors in patient satisfaction, coordination of care should be considered in the design of 
patient satisfaction surveys when patients are more engaged with their care in the future. 
Additionally, patients satisfied with their medical services in a PCC environment may 
actually have better clinical outcome because they are more likely to adhere to their 
medication (Gu, Gai, & Hay, 2008). 
Care coordination. A SDT-guided PCC approach may enhance care 
coordination programs because of more patient participation. Engaged providers may 
help to (1) identify medical, functional, social, and emotional needs that increase 
patients' risk of adverse health events; (2) address those needs through more relevant 
education in self-care, optimization of medical treatment, and better integration of care; 
and (3) monitor patients for progress and early signs of problems. These approaches may 
be able to raise the quality of health care, improve health outcomes, and produce program 
savings by preventing costly hospitalizations (Chen, Brown, Archibald, Aliotta, & Fox, 
2000). 
Healthcare cost savings. The direct savings in health care cost due to lower 
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readmission of well-managed heart disease patients can be substantial (Stewart & 
Horowitz, 2002). In chronic illnesses, low levels of medication adherence and poor 
clinical outcomes are associated with more intensive medical treatments, longer times for 
recovery, higher hospital readmission rates, and higher mortality (Sokol, McGuigan, 
Verbrugge, & Epstein, 2005). The annual cost of hospitalization in patients with a low 
level of medication adherence almost doubled that of patients with high levels of 
adherence (Sokol, McGuigan, Verbrugge, & Epstein, 2005). Cost savings may also be 
realized indirectly by reducing avoidable operating expenses. There is a direct 
correlation between patient satisfaction in PCC environments and employee satisfaction. 
High employee turnover rates due to dissatisfaction in the work environment impacts 
negatively on operating expenses (Press Ganey Associates, 1999). Planetree PCC 
hospitals have lower employee turnover and lower vacancy rates than other comparable 
hospitals because the PCC culture supports and nurtures caregivers which increase 
satisfaction (Frampton, Gilpin, & Channel, 2003). These hospitals are more able to 
weather the healthcare workforce shortage, which is jeopardizing patient safety and 
increasing expenses for recruitment and training (Channel & Frampton, 2008). 
Additionally, a PCC environment that focuses on patients' perspectives can potentially 
reduce malpractice claims and associated operating cost increases (Frampton, Gilpin, & 
Channel, 2003). The reasons patients file lawsuits after being harmed in the hospitals are 
likely due to one of four types of communication problems: deserting the patient, 
devaluing the patient's views, delivering information poorly, and failing to understand 
the patient's perspective (Kavalier & Spiegel, 2003). There is a misconception that PCC 
requires more staff and more time and is therefore more costly. But it does not take more 
time to listen to patients, answer questions, or be kind. A randomized controlled trial did 
not find any difference in cost between operating a PCC medical-surgical unit and a 
usual-care medical-surgical unit (Martin et al., 1998). 
Policy Recommendations 
Poor adherence to medication regimens is a major obstacle to improving 
efficiency in the healthcare system, where over 70 percent of healthcare costs are spent 
on the treatment of chronic illnesses (CDC, 2004). The expected growing demand for 
healthcare services as the baby boomers age, combined with ongoing budgetary 
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constraints, will further stress the system and impact its capacity to achieve better 
outcomes. Non-adherence to medication regimens is no longer simply a problem of 
individual patients; it is relevant to major objectives of health care reform such as 
outcomes-based payment reform, widespread adoption of healthcare information 
technologies, primary care reform and care coordination reform (New England 
Healthcare Institute, 2009). A SDT-PCC approach to promote adherence that includes 
patient engagement in education, care coordination, incentives, healthcare information 
technology, and accountability will advance the cause of health care reform. 
Patient engagement in education. The key to effective PCC education is 
engaging patients in a way that is supportive of autonomy. Respect for patient 
preferences, patient involvement in decision-making, understanding of patients' overall 
needs and condition, emotional support, and continuity of care are all elements of a 
healing partnership that can be perceived as autonomy-supportive by patients. Education 
provided in an autonomy-supportive environment combined with positive feedback 
allows the resolution of potential dissonance in the situation at hand between clinical 
staff, patients, and family members. Only after misconceptions and skepticism are 
addressed will patient education be engaging and meaningful to patients. 
Care coordination. Appropriate care coordination should be a component of 
patient engagement in education because any patient concerns about or dissonance with 
their treatment plan need to be discovered. Coordinated care that is mindful of patient 
concerns and preferences is usually more effective and longer lasting. For example, if an 
education session discovers a patient's concern about forgetting to take Coumadin late in 
the evening, the prescription for Coumadin could be changed to morning dosing to 
minimize non-adherence since there is no clinical justification for dosing Coumadin in 
the evening. In addition, scheduling Coumadin dose time with other medications in the 
morning helps to simplify the prescription regimen. This kind of interaction as a part of 
care coordination will help patients to feel more competent with their therapy, perceive 
caregivers to be respectful and supportive of their autonomy, make them feel more self-
determined and capable of managing their medical care at home and make them more 
interested in further engagement with the care team. The ability to provide an 
autonomous supportive patient care environment can in time be effective in addressing 
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more challenging treatment areas such as detecting and minimizing adverse drug 
reactions. 
Incentives to promote medication adherence. Consumer health management 
programs can be developed to incorporate incentives to promote healthier patient 
behaviors and medication adherence (Claassen, Fakhoury, Ford & Priebe, 2007). 
Incentives like feedback, when used to motivate people, will not enhance autonomous 
motivation according to SDT. Specifically, financial incentives, such as paying patients 
to take their medications, will relocate the locus of control from patients' intrinsic selves 
to the financial reward system and change the direction of psychological control to 
controlled motivation (Deci & Ryan, 1985). Like behavioral modification, patients will 
report being adherent with their medication in order to receive the reward, as long as the 
reward is provided continuously. But incentives do not need to be financial. Instead, 
incentives can be developed as informational positive feedback that can be used to 
convey a sense of congratulation for self-care well done. For example, providing patients 
free access to their medical records online can be a powerful incentive. Such incentives 
can enhance patients' perceived autonomous support and autonomous motivation in self-
care and adherence. 
Healthcare information technology. System analysis of a SDT-PCC driven 
healthcare information system should refocus on the three-tiered information system 
pyramid that distinguishes the differences between the phases of management of data, 
information integration, and decision support (Whitten & Bentley, 2005). Information 
systems (IS) designed using these three tiered approach tend to be modular, easier to 
maintain, and highly flexible. A flexible system will not only serve the clinician and 
management, but will support patients who are competent and motivated to self-care. 
The data management module can be a database front end designed to collect patient 
input data such as self-monitored body weight, blood sugar, blood pressure, clotting time, 
breathing capacities and doses of medication taken. The information integration module 
can be implemented by a relational database designed to provide summary reports of 
patients' clinical data and treatment activities for both clinicians and patients. Summary 
information can be used during clinic visits for evaluation of clinical outcomes and 
planning of treatment modification. The decision support module can be a collection of 
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procedures constructed with patient alerts triggered by critical values from the data 
management phase, prompting patients or family members to take predefined critical 
actions to prevent disastrous organ decompensation. The ability to interact with useful 
health information can serve as powerful feedback in self-care that supports autonomous 
motivation and adherence to therapies. 
Accountability. State report cards and financial incentives such as pay for 
performance are used to motivate hospitals and physicians to be more accountable for 
quality of care and clinical outcomes. The traditional stick or carrot approach may have 
negative unintended consequences in the healthcare market. In terms of hospital report 
cards, hospitals serving communities with a large aging population will have worse 
morbidity and mortality scores than those of hospitals serving communities with a large 
population of younger people. In the current economically constrained environment, 
unfavorable report cards will further deprive hospitals in certain communities of the 
needed revenue streams to provide more intensive medical services for their rapidly aging 
populations. Not only should the hospitals be stratified by the types of diseases and the 
populations served (Clark, Hannan, & Raudenbush, 2010), but levels of technical 
capacity in both human and technology terms should also be adjusted in the report cards. 
Ability to provide a SDT-PCC-based card coordination system is an example of human 
technical capacity. In terms of pay for performance for clinicians, financial incentives 
may actually erode clinical staffs' autonomous motivation to provide compassionate 
quality care, resulting in lower patient satisfaction, and paradoxically, lower rather than 
higher clinician satisfaction. SDT-PCC incentives should be restructured to convey 
positive feedback such as patients' feedback on meeting the clinical goals, reports of 
patient satisfaction due to compassionate treatments, and system improvements due to 
higher levels of staff satisfaction and pride in their work. 
Future Research 
The theoretical premises of SDT have been validated by other researchers, but the 
theory has not been applied extensively to engage patients in healthcare counseling. The 
reasons for the lack of interest may be due to the difficulty of training non-psychologist 
healthcare providers in how to articulate appropriately in the subtle and difficult context 
of motivating patients. Motivation Interviewing (MI) is a set of psychotherapeutic 
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techniques developed from clinical practice to help patients be active participants in 
therapy (Miller & Rollnick, 2002). Though MI lacks theoretical grounding, the principle 
behind the techniques is compatible with SDT's concept of autonomy support 
(Vansteenkiste & Sheldon, 2006). These principles, such as expressing empathy, 
developing discrepancy, and coping with resistance have been shown to be effective in a 
number of domains such as addiction treatment, diet, exercise, hypertension, diabetes, 
and bulimia. Engaged patients can provide meaningful information on more complex 
issues that may impact patient satisfaction. These complex issues may include the role of 
autonomy in late stage of chronic illness, spirituality, need for security, and health-related 
quality of life issues that include self-need for spiritual conflict resolution. When more 
healthcare providers are able to conduct MI, a similar SDT adherence study can be 
conducted with more patients over a longer period of time for observation. 
Survey studies of adherence should include care coordination and patient 
satisfaction. GetWellNetwork was used for care coordination in this exploratory study. 
A more robust version can be implemented on a healthcare information system (HIS) that 
is designed to allow patient access. A new survey should include items related to patient 
preferences, satisfaction, quality of care coordination and concordance. Conceptually, 
concordance is a therapeutic alliance between a patient and healthcare professionals 
(Bane et al., 2007; Hughes, 2004; Chewning & Wiederholt, 2003). Concordance is a 
modified concept of adherence that is more appropriate in the context of patient 
preference and more advanced coordinated self-care. Self-care may include adjustment 
of insulin dosage based on a predefined algorithm or adjustment of diuretics in heart 
failure. It is a more flexible concept than adherence in situations where patients trained 
in self-care may act independently in adjusting their medication routine. Since 
concordance can be seen as a means for patients to achieve a satisfactory therapeutic 
result jointly with the care provider, it is a better concept than adherence in capturing 
medication usage in patient-relation centered care and shared decision-making. 
Study Limitations 
Most patients in this sample had insurance and thus were able to be more 
motivated and adherent to their medication schedules. In addition, a small sample size, 
data collected over a relatively narrow time frame, and the patient sample being recruited 
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from a single hospital all limit the generalizability of these study findings. Though a 
good representation of the overall population is possible in a reasonable period of time 
with consecutive sampling (a strict version of convenience sampling where every 
available subject is selected) (Currier, 1984), this was not a randomized controlled trial. 
Social desirability might still exist because adherence is still treated like 
compliance in the healthcare environment. While adherence often is used as a synonym 
for compliance, compliance is not value free, and non-compliance carries a negative 
connotation. Patients may feel the need to show more compliance because a non-
compliant patient implies an uncooperative patient, even a bad patient in the eye of the 
significant other or the healthcare provider. The researcher did attempt to minimize the 
effect of patients' need for approval by explaining that adherence is a normal process of 
making choices in the context of an individual's life, and there was no demand by the 
researcher for adherence in any situation. 
Contribution to Body of Knowledge 
It appears that an empirical approach to psychology in healthcare is inadequate by 
itself to explain the dynamics of patient behaviors in a complex healthcare system. 
Paradoxically, the success of behavioral modification was also the inadequacy of the 
behavioral approach. In healthcare, behavioral modification is usually effective as long 
as the behavioral coach is consistently there for the patient. When behavior coaching is 
stopped, the related behavior also dissipates in a relatively short period of time. Studies 
showed that when contact with health behavior interventionists ceased, adherence to 
medication regimens started to decline (Lee et al., 2006; Murray et al., 2007). This is a 
non-issue in acute disorders such as short-term infections. 
However, the non-sustainable effect of behavior modification in chronic diseases 
is problematic in terms of treatment outcomes and resource allocation. It appears that 
behavior modifications do not intrinsically motivate patients to behave, but something 
else innate to humans motivates patients to act. 
Though not readily observable, autonomous motivation as proposed by self-
determination theory (SDT) can be a real object that exists in time and space since it can 
affect and be affected by other objects (Schopenhauer, 1974). While the self-
determination theorists' methodology remains in the empirical tradition, there is a 
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willingness to expand into an area likened to Kant's transcendental idealism, in that the 
mind knows objects in the world by means of sensible forms (in space and time) which 
the mind produces itself. Without these innate forms, Kant argues, knowledge would not 
be possible because the mind would have no way to order or structure the data given to it 
by the senses. The implication of self-determination theory (SDT), parallel to Kant's and 
Schopenhauer's philosophy, is that the innate forms of the mind make a contribution to 
how knowledge can be known and acted upon. Though the innate forms of autonomous 
motivation do not fit in the behavioral empirical framework, empirical methodology can 
still be applied providing that the theoretical aspects of these conceptual forms are 
capable of being falsified (Popper, 2002). SDT affords an opportunity to explore a 
deeper layer of motivation dynamics of why humans behave as they do in a given 
situation. 
Though not addressed directly in this research, SDT is not meant to be orthogonal 
to behavioral intervention. Factors considered by behavioral interventionists to be 
predictive of adherence were included in the study. Conceptually, these factors can be 
categorized as socioeconomic factors and barrier factors. The barrier factors can be 
categorized broadly in two categories, general factors affecting all adherences and 
specific factors affecting medication adherence. Factors such as lack of access, cognitive 
impairment, psychopathology, psychological resistance, functional illiteracy, 
communication problems, and lack of follow-up belong to the former category. Factors 
such as insurance coverage, side effects of medications, complexity of the regimen, cost, 
inconvenience, health beliefs, and social support belong to the latter category. An 
assumption of the behavioral barrier idea is that once the barriers are minimized or 
removed, patients will be able to perform the desirable health behaviors and will do so. 
Addressing these barriers is important and necessary to initiate change, but it is not 
sufficient for maintenance of long-term engagement. The motivational approach to 
adherence via SDT means that even after the barriers are lowered, there is still a 
challenge to help patients develop sustainable engagement with their CV medication 
regimen. 
In addition, humans as autonomous beings are free inasmuch as their power of 
reason dictates a moral law for their actions, no matter how limited or nonsensical those 
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actions may seem, as long as they do not harm others. The ethics of autonomy is 
supported by John Stuart Mill's position of requiring both noninterference with and an 
active strengthening of autonomous expression, as well as Kant's moral imperative of 
respectful treatment of persons as an end rather than merely as a means (Beauchamp and 
Childress, 1994). The last observation is applicable to the idea of patient-centered care 
(PCC) where autonomously motivated patients do in fact exercise their power of reason 
for their behaviors and need to be respected for doing so. 
The study affirmed the usefulness of grounding patient adherence studies with 
theories (Munro, Lewin, Swart & Volmink, 2007; Davies, Walker & Grimshaw, 2003) 
while less than 10% of the adherence guideline implementation studies provided an 
explicit theoretical rationale for their interventions (Davies et al., 2003). 
The study showed that adherent behaviors in this CV disease patient population 
were different from the general population and that SDT could be a useful theory for 
understanding adherent behavior with CV medication. 
The adaptation of SDT in the PCC program demonstrated that SDT could be used 
to explain why and how patient-centered care might improve the healthcare environment 
with PCC proponents. 
The study showed that factors that influence adherence such as system barriers 
and competence may be perceived differently by different patients due to a different 
locus of motivation. For example, in the case of health literacy, one might infer from 
bivariate analyses that, since adequate health literacy correlated positively with perceived 
competence, and perceived competence correlated positively with adherence, adequate 
health literacy should predict more adherence. However, multivariate analyses showed 
that adequate health literacy predicted adherence negatively. The finding implied that 
these factors were not value free, because they might have different significance for 
different patients. This finding also helped to explain why these important factors were 
limited by themselves in explaining why or how patients choose to adhere to medical 
recommendations. In an information-rich society with an abundance of conflicting views 
on any given subject, patients may be skeptical of the value of information provided by 
the healthcare providers, especially when the information is not in accord with their 
understanding and belief. SDT offers an opportunity to examine how conflicting 
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information and intrapsychic dynamics may impact patients' perception of these 
important factors of adherence. 
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Appendix A 
Schedule of Events 
The study will be conducted in 2 phases, with the comparison group in the lsl phase and the 
experimental patient-centered care (PCC) group in the 2nd phase. Both groups will follow the same 
schedule as outlined in the following table with the exception that, the PCC group will be further exposed 
to motivational intervention with the 5a model (item 3), supported by interactive teaching via 
GetWellNetwork (item 4a), and monthly telephone consultation (item 7). 
1. Recruiting participants 
and informed consent 
2. Patient data collection 
3. Drug specific medication 
education. 
3a. PCC group will be 
supported by interactive 
teaching via 
GetWellNetwork 
4. General medication usage 
education and 
documentation 
5. Post-test 1: 
Administration of 
questionnaire and data 
collection at Time 01 
6. PCC group will be 
supported by a monthly 
telephone consultation 
7. Follow up phone call for 
final interview 
8. Post-test 2: 
Administration of 
questionnaire and data 
collection at time 02 
9. Compare results from the 
experimental and 
comparison group 
Pre-
recruit-
ment 
X 
Post-
recruit-
ment 
X 
X 
X 
Pre-
discharge 
interview 
X 
Post-
discharge 
monthly 
X 
Post-
discharge 
day 90 
X 
X 
Post study 
analyses 
X 
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Appendix B 
Script for Recruiting Participants 
1. Greeting: 
Good (morning, afternoon, evening), Mr/Mrs. —, my name is —. I am a . 
2. Purpose and scope: 
We are in the process of conducting a study on how our patients manage and live with cardiac 
medication. 
I am interested in ALL parents who are admitted to our hospital for cardiac care regardless of age, 
gender, ethnicity/race, financial or other social backgrounds. The analysis is focused on patient groups 
rather than on individuals. All survey responses will be kept confidential (that also includes the 
hospital, your physicians and the public). Please be aware that you do not have an obligation to 
participate in this study and have a right to stop your participation at any time before returning the 
questionnaire to the researcher. Your physicians or healthcare providers will never know how you 
respond to the questionnaires, and there are no adverse consequences to you if you decide not to 
participate. 
3. What it takes to participate: 
• Able to be contacted by phone, or visit in person x 1 at the end of 3 months. 
• Willing to share your experience with taking cardiovascular medications, about the hospital 
experience, and other personal experience that you feel comfortable sharing with the investigator, 
such as feeling about prescriptions, how prescriptions made you feel, reason why you might miss 
taking prescriptions, how staff made you feel, etc. 
• Initial interview before discharge, then phone interview or visit 3 months later. 
• If acquaintances or family member are involved in your care with medications, they will have your 
permission to share follow up information, allow me to access them by phone in your place, or 
answer the survey for you. 
4. What are the difficulties, does it cost any, etc.? 
1. Your time, no financial costs. 
2. Inconvenience. 
3. Some people may be uncomfortable in sharing personal feelings about their care or their view 
about not following medication regimen. 
Are there any benefits to participate? 
1. No financial benefits. 
2. Understand how medication affects you on an individual basis 
3. Learn to better manage medication at the end of the study period 
4. Indirect benefit to others learning from your experience 
If accepted, consent form needs to be reviewed for and signed by the patients. 
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Appendix C 
An Invitation to Participate in a Study 
Sentara Virginia Beach General Hospital, 1060 First Colonial Rd., Virginia Beach, Va. 23454. 
757-395-6750 
Dear (Mr.,/Mrs/Miss/Dr/etc)(patient's name), 
We would like to invite you to participate in a study to determine how a patient-centered care environment 
will help you as well as other cardiac patients. Patient-centered care is about respecting patients' dignity 
and preferences, sharing information, enabling patients to participate in the care of self, and collaboration 
with family members or significant others. 
The purpose of the study is to help doctors and healthcare givers understand how to best to provide PCC 
that will empower you to better manage your care after you're discharged from the hospital. 
Two major areas we will focus on are patient involvement in the treatment process and a better 
understanding of the medication being used. 
The information you provide will enable us to design a patient-centered care environment that will help us 
to better understand our patients' expectations and perceptions. 
The study is approved by a group of professionals and community members call the Institutional Review 
Board (IRB). The function of the IRB is to ensure that the participants' rights are protected. This study is a 
survey study with no risk involved. 
If you participate in the study, you will be better educated in regards to your medications and your 
condition. The researcher will interview you prior to your discharge from the hospital. This will take 
about 20 to 30 minutes. He will also contact you within three months to see if you have any concerns. A 
follow up group meeting for the second survey will be conducted for all participants. This will take about 
30 minutes. The researcher will stay for another 30 as needed for answering and explaining questions you 
may have about your condition and medication. The meeting will be in the hospital conference room. 
Sincerely yours, 
David S. Li RPh M.A. Richardean Benjamin RN, MPH, PhD Robert Williams PhD 
Doctoral Candidate Dissertation Advisor/Chair IRB Chair 
Old Dominion University Associate Dean EVMS Institutional Review 
College of Health Sciences College of Health Sciences Board 
Norfolk, Virginia Old Dominion University 721 Fairfax Avenue, 
Norfolk, Virginia Norfolk, Virginia. 
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Appendix D 
Consent Form 
Subject Consent Form 
Sentara Virginia Beach General Hospital (SVBGH) Institutional Review Board 
STUDY TITLE: Patient-centered care approach to Patient Adherence with Cardiovascular Medications: A 
Self-determination theory integration 
INVESTIGATORS: David Li (Clinical pharmacist at Sentara Virginia Beach General Hospital, Sentara 
Health System. Ph.D. candidate, Old Dominion University) 
SPONSOR: Sentara Virginia Beach General Hospital and David Li (Old Dominion University, College of 
Health Sciences, Health Services Research Ph.D. Dissertation.). 
WHAT IS THE IRB? The IRB is a group of people that includes doctors, researchers, and everyday people 
who form a board called an Institutional Review Board (IRB). Their purpose is to make sure that you are 
provided information about the research that you are going to participate in, and that you know you have 
other options and what those other options are. Please be sure that you feel comfortable with what is 
expected of you before you sign this consent form. 
WHY ARE YOU BEING ASKED TO TAKE PART? You are being asked to participate in a research 
study involving the collection of information in the form of structured interview with a questionnaire, and 
with two follow-up interviews. The purpose of the research project is to understand the relationship 
between heart medication uses in the healthcare environment and behavioral/motivational factors from your 
point view. 
WHAT ARE SOME IMPORTANT DETAILS ABOUT THIS STUDY? At this local site about 120 people 
will take part in this study. You will be interviewed while in the hospital and three months after being 
discharged from the hospital. The first interview before discharge will take about 20 to 30 minutes. The 
follow-up interview will take about 30 minutes. The investigator will stay for an extra 30 minutes as 
needed for answering and explaining questions you may have about your condition and medication. The 
interview is designed to understand the changes over time of your perception of the healthcare 
environments in supporting your gaining competence and motivation in rehabilitation and living with heart 
medications. Details of the questionnaire will be provided upon request. Participants' personal 
information will be removed and condensed in aggregated form for final analyses. We will need you to be 
in the study for three (3) months. 
WHAT ARE THE RISKS OF THE STUDY? There are no specific risks related to your participation. 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? There is no guarantee that you will 
personally benefit from taking part in this study. We hope you will have a better understanding about your 
heart condition and heart medicines, we also hope that the information learned from this study will benefit 
other people like you in the near future. The results of this research may be made available upon request. 
WHAT OTHER OPTIONS DO YOU HAVE? You may choose not to participate in this research study. 
WHAT ABOUT CONFIDENTIALITY? A risk associated with allowing your data to be saved is the 
release of personal information from your study record. Protected Health Information and your personal 
information (i.e., personal feelings, comments about the healthcare providers, etc.) will remain private and 
will not appear at the final tabulation of data, or any other reports. Protected Health Information (PHI) 
includes: name, address, telephone, fax, email, social security number, medical record number, health plan, 
account number, certificate number, license number, vehicle number, medical device serial number, web 
URLs, Internet identifiers, biometric identifiers including fingerprints and voice prints, full-faced 
photographs, any other unique identifying number, characteristic or code. 
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Questions on the survey about depression are not intended to assign a diagnosis of clinical depression but 
rather to assess your risk for depression. An accurate diagnosis of depression or other psychiatric disorders 
can only be made by a physician or qualified mental health professional after a complete evaluation, 
including a physical exam to rule out any medical illnesses or conditions. 
If you are found to be at risk of depression (answering "yes" to the first and/or second depression items) but 
have not been diagnosed or treated for depression, appropriate referral options will be discussed which may 
include but not limited to: (1) contacting hospital chaplain, community mental health services, the attending 
cardiologist, and the unit nurse. 
Your study records may be reviewed and/or copied in order to meet state and/or federal regulations. 
Reviewers may include, for example, Sentara Virginia Beach General Hospital Institutional Review Board, 
Food and Drug Administration, and other.governing agencies. 
WHAT WILL PARTICIPATION IN THE STUDY COST OR PAY? The study is not sponsor by any drug 
company or other organizations. There are no additional costs to you associated with taking part in this 
study. You will not be reimbursed for your participation. 
WHAT ARE YOUR RIGHTS AS A PARTICIPANT? Taking part in this study is your choice. If you 
decide not to take part, your choice will not affect any medical benefits to which you are entitled. You may 
choose to leave the study at any time. If you do leave the study, it will not result in any penalty or loss of 
benefits to you. 
WHO DO YOU CALL IF YOU HAVE QUESTIONS OR PROBLEMS? For questions about the study, 
contact the investigator, David S. Li, at 395-6750 or 363-2229. For questions about your rights as a 
research participant, contact a member of the Institutional Review Board through the Institutional Review 
Board Office at (757) 446-8423. 
If you believe you have suffered an injury as a result of your participation in this study, you should contact 
the principal investigator, David S. Li at (757) 395-6750 or (757) 363-2229. You may also contact Dr. 
Robert Williams, an employee of Eastern Virginia Medical School, at (757) 446-8423. 
SIGNATURE: 
You will get a copy of this signed form. You may also request information from the investigator. By 
signing your name on the line below, you agree to take part in this study and accept the risks. 
Signature of Participant/LAR Typed or Printed Name Relationship to 
Subject 
/ / 
MM/ DD/ YY 
Signature of Witness 
D Witnessed Signature Only 
D Witnessed Consent Process 
Typed or Printed Name 
/ / 
MM/ DD/ YY 
STATEMENT OF THE INVESTIGATOR OR APPROVED DESIGNEE 
I certify that I have explained to the above individual the nature and purpose of the study, potential 
benefits, and possible risks associated with participation in this study. I have answered any questions that 
have been raised and have witnessed the above signature. I have explained the above to the volunteer on the 
date stated on this consent form. 
/ / 
Signature of Investigator MM/ DD/YY 
158 
Appendix E 
Medical Record Abstraction Form 
Medical Record# 
Patient name 
Date of Birth 
Doctor name 
Age Gender 
Account # 
SS# 
Study group 
Height 
Weight 
Drug allergy 
Race/ 
Ethnicity 
(verify with 
TDS) 
Marital status 
(verify with 
TDS) 
Next of Kin/ 
relationship 
Insurance 
If yes above, 
Insurer(s) 
Cardiac 
procedures 
Chief CV 
complaints 
and 
symptoms 
1 
2 
Admit date 
= comparison group 
= intervention group 
inch cm 
kg lb 
a. 
b. 
c. 
d. 
e. 
f. 
_Si 
a. 
b. 
c. 
d. 
e. 
f. 
White 
Black/African American 
Hispanic / Latino 
Asian 
Native Hawaiian or Other 
Pacific Islander 
American Indian, Alaska 
Native 
Other 
Married 
Divorced 
Widowed 
Separated 
Never married 
A member of an unmarried 
couple 
Yes / no 
1. 
2. 
3. 
4. 
5. 
6. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
cardiac intervention, (stent, 
balloon, angiography, etc). 
coronary bypass graft (CABG) 
Heart failure without prior 
intervention or CABG 
heart failure with prior 
intervention or CABG 
heart failure with prior and 
current intervention or CABG 
Others: 
Dyspnea 
Fatique/weakness 
Edema 
Rales 
Othopnea 
fevers/chills and sweats 
chest pain 
chest discomfort 
Others: 
Relevant 
routine Lab 
value / (initial 
value) and 
date 
Relevant 
Cardiology 
lab values, 
EKG / (initial 
value) and 
date 
Med history 
(previous and 
current 
diagnoses, 
problem lists) 
1. Scr/CrCL: 
2. Na: 
3. CI: 
4. Co2/bicarbonate: 
5. K: 
6. Ca: 
7. Mag: 
8. INR: 
9. B. Glucose: normal / elevated 
lO.Liver panel: normal / elevated 
11. 
BP: EF: 
CPK-MB1: CPK-MB2: 
CK-MB2/MB1: 
Troponin I: Toponin T: 
CRP: BNP: 
NT-ANP: aldosterone: 
renin: fibrinogen: 
D-dimer homocysteine, 
plasminogen activator inhibitor T-
1: 
urinary albumin/creatine ratio: 
Sinus rhythm / atrial fibrillation: 
axis deviation: Q waves: 
T wave: 
ST up>l mm, 2 contiguous leads: 
new LBBB 
VT(>100), VFor 
AV block post PTCA: 
heart sounds: 
Medical history / Problem list / 
Admission diagnoses / 
Impressions: 
Cardiac devices: 
ICD, LVAD, pacemaker, artificial 
heart 
Discharge diagnoses: 
159 
APPENDIX E Continue 
NYHA/ 
ACC/ 
AHA class 
Comorbid 
A. Symptoms: No symptoms and 
no limitation in ordinary 
physical activity. Disease 
stages: Patients with coronary 
artery disease, hypertension, or 
diabetes mellitus who do not yet 
demonstrate impaired left 
ventricular (LV) function, 
hypertrophy, or geometric 
chamber distortion. 
B. Symptoms: Mild symptoms and 
slight limitation during ordinary 
activity. Comfortable at rest. 
Disease stages: Patients who are 
asymptomatic, meet class A 
description but demonstrate LV 
hypertrophy (LVH) and/or 
impaired LV function. 
C. Symptoms: Marked limitation in 
activity due to symptoms, even 
during less-than-ordinary 
activity. Comfortable only at 
rest. Disease stages: Patients 
with current or past symptoms of 
HF associated with underlying 
structural heart disease. This 
include the bulk of patients with 
HF. 
D. Symptoms: Severe limitations. 
Experiences symptoms even 
while at rest. Disease stages: 
Patients with truly refractory HF 
who might be eligible for 
specialized, advanced treatment 
strategies, such as mechanical 
circulatory support, procedures 
to facilitate fluid removal, 
continuous inotropic infusions, 
or cardiac transplantation or 
other innovative or experimental 
surgical procedures, or for end-
of-life care, such as hospice. 
1. fluid and electrolyte disorders 
and kidney diseases 
2. chronic obstructive pulmonary 
diseases (emphysema or chronic 
bronchitis) 
3. irregular heartbeat (cardiac 
dysrhythmia) 
4. iron deficiency and other 
anemia, 
5. solid tumor without metastasis 
and carcinomas 
Smoker 
(including 
past 
smoker) 
Alcohol 
Depression 
Current 
Medication 
list 
#ofRx: 
# 
Doses/day: 
Discharge 
date 
Dropped 
out reason 
6. hypothyroidism 
7. peripheral vascular disease 
8. renal failure 
9. Others: 
l.yes 2. No 
If smoker, status of quitting: 
1. Don't drink 2. Moderate (= or 
< 5 glasses/week) 3. Regular (>5 
glasses/week) (if not in MR, use 
survey) 
l.yes 2. no 
(if not in MR, use survey) 
Or a copy of medication 
reconciliation. 
1. Moved and decided not to 
continue 
2. Decide not to continue 
3. Deceased 
date: 
Inclusion: Patients with any of the following 
diagnoses or DRG: acute coronary syndrome, 
acute myocardial infarction, heart failure, atrial 
fibrillation, or valvular heart disease; at least 18 
years of age; be willing to provide informed 
consent; and be willing and able to be followed for 
at least 3 months. 
Exclusion: Terminal comorbidity or do-not-
resuscitate status; going to a skill cared facility 
after discharge; totally dependent on others for 
their care; from out-of-town; with psychosis, 
dementia, or mental retardation, inability to 
comprehend; cognitive impairments (sight, 
hearing) and/or other disability requiring full time 
help. 
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Medication log 
Drug Name: 
Direction: 
Please refer to drug information provided by your healthcare professionals. 
Day # of Pills in 
NEW bottle 
#of Pills left in 
OLD bottle 
Total # of 
Pills 
Reason for deviating from 
prescription 
Self initiated or 
MD instructed 
People find it difficult to always take their medicine exactly as prescribed; there are both medical reasons 
and life issue related to this fact of medication use. It will help the researcher to know the reason why you 
might have miss the medicine. Please write down the reason by the date when you've deviate from the 
original prescription, either missed a dose or took more than prescribed. This doesn't have to be medical 
reasons. A lot of time people miss taking medicine because of personal reasons. The information you've 
provided will help the healthcare providers to design more user-friendly health services. 
Example: 
Day 
3-15-06 
3-20-06 
4-15-06 
4-25-06 
4-17-06 
# Pills for 
prescription 
New Rx 30 
Refill 30 
Total # 
of Pills 
Reason for deviating from direction 
Skip a dose, felt sick 
skip a dose, slow heartbeat, MD lowered dose. 
Took a half tablet, economize 
Self initiated or 
MD instructed 
Self 
MD 
Self 
Some possible reasons are: 
Drug effects related and self controlled: 
• I want to take a drug holiday because 
• I want to take more so I can get better faster. 
• Testing to see if I feel OK if I skip a dose, or without taking it. 
• Testing if 1 am cured (if 1 feel fine without taking it, that means I am cured) 
Page: 
Doctor: 
• I was afraid that the drug may make me feel worse. 
• Don't feel good. I think the side effect of the drug did it. (please describe). 
• Don't think I need it that day 
• Don't think the medication is working 
• Don't think the medication is safe 
• Adjusting my medication by symptom 
• Adjusting my medication to see if I still need it 
Drug effect related and physician directed: 
• My doctor told me to but I don't know why 
• My doctor told me to skip it temporary, because 
• My doctor told me to skip doses because the drug 
• My doctor changed my dose to 
• My doctor told me to take a drug holiday because 
• My doctor told me that I don't need it anymore 
• My doctor changed drug 
Beyond medical reasons: 
• Try to economize; the drug or co-pay is too expensive. 
• Prevent the interruption of life events (i.e., interfere with work, church, travel, social events, etc). 
• Ran out of medication, forgot to get refill on time. 
• Ran out of refills, need authorization for refill, delay in office visit, etc. 
• My family or friend told me not to take it 
• forgot 
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Pre-discharge survey or Survey 1 
For Place Date 
1. Depression risk assessment 
a. In the past year, have you felt sad, depressed for longer than 2 weeks? 
1 2 
Yes No 
b. Have you ever been sad or depressed for over 2 years in your lifetime? 
1 2 
Yes No 
2. Health literacy assessment 
a. How often do you have someone help you read prescription bottles or hospital materials? 
0 1 2 3 4 
Never Occasionally Sometimes Often Always 
b. How confident are you filling out medical forms by yourself? 
0 1 2 3 4 
Never Occasionally Sometimes Often Always 
c. How often are you unable to understand written information about your illness or condition? 
0 1 2 3 4 
Never Occasionally Sometimes Often Always 
3. Health care environment. 
Please tell us how true the statements below are for you with the 7-point scale: 
not at al 1 true somewhat true. 
.very true 
4. Perceived competence. 
Please tell us how true the statements below are for you with the 7-point scale: 
not at all true somewhat true. very true 
a. I felt that my healthcare givers have given me 
information and choices that apply to my condition. 
b. I felt that mv healthcare givers understood how I feel 
about the situation and mv life. 
c. Mv healthcare givers made me feel that I can manage 
my heart therapy with respect to symptoms, side effects. 
d. Mv healthcare givers listened to me and help me with 
my therapy options. 
e. Mv healthcare givers encouraged me to ask questions 
about the heart disease, therapy, life style changes, and 
prevention. 
f. I felt that I was often given a chance to ask questions 
about my condition and my treatment options. 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
a. I can follow the directions on my medicine and know 
what the medicine is for. 
b. I can learn about my heart medicines. 
c. I am able to understand my condition. 
d. I can mange my heart medications, this include: 
1. I understand my symptoms 
2. I can do what I need to do for these symptoms 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
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3. I know how and why to check my weight and blood 
pressure 
4. I can maintain a healthy diet and regular activities 
related to my heart medicine 
5. Regulatory processes and perceived locus of causality. 
Please tell us how true the statements below are for you with the 7-point scale: 
1 2 3 4 5 
not at all true somewhat true 
6 7 
verv true 
A. The reason I want to participate in managing my heart medicine is: 
a. Because I will feel bad about myself if I don't. 
b. Because others will be upset with me if I don't. 
c. Because I will feel ashamed of myself if I don't do 
what my doctor said. 
d. Because I feel like I want to take responsibility for my 
own health. 
e. Because I will feel guilty if 1 don't. 
f. Because I personally believe it is the best thing for my 
health. 
g. Because it is my responsibility to learn to manage my 
heart medicine. 
h. Because my doctor tells me to. 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
B. The reason I want to follow the heart health regimen is: 
i. Because I personally believe that it is important to 
improve my health. 
j . Because I may get in trouble with others if I don't. 
k. Because I want others to see that I am really trying to 
comply with the prescription. 
1. Because I had learned to manage my medicine and 
believed it's the right thing to do. 
m. Because I would have felt guilty if I didn't comply with 
the program. 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
6. Smoking status: l=nonsmokers 
2=smoker (persistent smokers, or former smokers) 
7. Alcohol drinking habits: 
1. Don't drink 2. Moderate (= or < 5 glasses/week) 3. Regular (>5 glasses/week) 
8. Daily activity 
9. During the past month, other than your regular job, did you participate in any physical activities or 
exercises such as running, calisthenics, golf, gardening, or walking for exercise? 
1 2 
Yes no 
10. Dietar y habit 
11. Education 
1. Left high school before finish 
2. High school or G.E.D. 
3. Post high school training 
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12. Is there an yone to help you when you leave the hospital? 
1 2 
Yes No 
13. If yes to above, who 
14. Li ving arrangement a. Alone b. With spouse c. Other 
15. Do yo u have insurance for your medicine? 
1 2 
Yes No 
16. If you have insurance for your medicine, what is the name of the insurance company? 
17. If not, an y alternatives?_ 
18. Approxi mately how much did you spend on your medicine last month 
19. Where do you get your medicine: 
• Neighborhood drug store • Mail order 
D Free Clinics D Need assistance • Not sure 
20. Did you have any issues in missed filling your prescription or not getting your prescription filled on 
time? These issues may include: 
I. copay too high 2. not enough to last 3. transportation 4. late 
reauthorization 5. inconvenience 6. forgot 
7. mail delay for mail orders 
21. If missed having prescription filled, how many days out of prescription? 
Number of days: Name of prescription(s): 
22. "Ha ve to skip medications" question. "In the past month, how often did you have to skip (i.e., doctor 
recommendation for dose adjustment, side-effects, or other dosing related reasons) one or more of your 
prescribed medications?" Possible responses for the question are: 
1 2 3 
never once in the 2 to 3 times 
past month in the 
past month 
4 
once 
per week 
5 
several times 
per week 
6 
nearly 
every day 
23. The "Decided to skip medications" question. "In the past month, how often did you decide to skip 1 or 
more of your prescribed medications?" Possible responses for the question are: 
1 2 3 
never once in the 2 to 3 times 
past month in the 
past month 
4 
once 
zr week 
5 
several times 
per week 
6 
nearly 
every day 
24. The "Forgot to take medications" question. "In the past month, how often did you forget to take one or 
more of your prescribed medications?" Possible responses for the question are: 
1 2 3 
never once in the 2 to 3 times 
past month in the 
past month 
4 
once 
zr week 
5 
several times 
per week 
6 
nearly 
every day 
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25. What is t he percentage of all the medication you think you have taken during the last 1 months as 
originally prescribed? Please point to or put a cross at the point on the following scale of 0 to 100% 
showing your best guess about how much medication you have taken. We would be surprised if this 
was 100% for most people, e.g. 0% means you have taken no medication; 50% means you have taken 
half your medication; 100% means you have taken every single dose of medication. 
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 
1 1 
0 % 
didn't 
take any 
1 1 
25 
% 
sometime 
1 1 1 
50 
% 
half of 
the time 
1 1 
75 
% 
most of 
the time 
1 1 
90 100 
% % 
nearly all 
all of of 
the the 
time time 
26. Health s tatus and Health days 
1. Would you say that in general your health is 
1. excellent 2. very good 3. good 4. fair 5. poor 
2. Now thinking about your physical health, which includes physical illness and injury, for how 
many days during the past 30 days was your physical health not good? number of days. 
3. Now thinking about your mental health, which includes stress, depression, and problems with 
emotions, for how many days during the past 30 days was your mental health not good? 
number of days. 
4. During the past 30 days, for about how many days did poor physical or mental health keep you 
from doing your usual activities, such as self-care, work, or recreation? 
NUMBER OF DAYS. 
27. In the following table, please check or circle the number corresponding to each question, using the 
following 4-point scale: 
1 2 3 4 
Never Sometimes Usually Always 
a. How often do you find the education materials from the in room 
television "GetWellNetwork" is presented in a way you can understand? 
b. How often do you find the education materials from the 
"GetWellNetwork" interesting to you? 
c. How often do you find education materials from the "GetWellNetwork" 
of personal relevance or useful to you? 
d. How often do you find the education materials from the 
"GetWellNetwork" cause you to feel you can learn more? 
e. How often do you feel that the education materials from the 
"GetWellNetwork" are specifically intended to support you? 
f. How often do you find the education materials from the 
"GetWellNetwork" cause you to feel prepared for discharge from the 
hospital? 
g. How often did nurses explain things in a way you could understand? 
h. How often did doctors explain things in a way you could understand? 
i. Before giving you new medicine, how often did hospital staff tell you 
use of the medicine? 
j . Before giving you new medicine, how often did hospital staff describe 
possible side effects in a way you could understand? 
k. Sometimes patients are given conflicting information about their care by 
healthcare providers. How often did this happen to you? 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
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Appendix H 
Post hospitalization survey or Survey 2 
The interview should started by assessing a general state of health, living arrangement, and adapting to post 
hospitalization with an empathetic and nonjudgmental attitude. 
Date interviewed: 
1. Depression issue 
a. Depressed in survey 1 
1 2 
yes no 
b. If yes, is depression being treated or monitored by a physician? 
1 2 
yes no 
c. If no, is patient feeling better? 
1 2 
yes no 
The following section asks questions about your experience with the healthcare environment, your feeling 
about the medication treatments, and feeling about your ability to handle the treatment. There is no right or 
wrong answer to these questions. 
2. Health care environment. 
Please tell us how true the statements below are for you with the 7-point scale: 
1 2 3 4 
not at all true somewhat true. 
5 7 
very true 
a. I felt that ray healthcare givers have given me 
information and choices that apply to my condition. 
b. I felt that my healthcare givers understood how I feel 
about the situation and my life. 
c. Mv healthcare givers made me feel that I can manage 
my heart therapy with respect to symptoms, side effects. 
d. Mv healthcare givers listened to me and help me with 
my therapy options. 
e. Mv healthcare givers encouraged me to ask questions 
about the heart disease, therapy, life style changes, and 
prevention. 
f. I felt that I was often given a chance to ask questions 
about my condition and my treatment options. 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
3. Did you get information about what symptoms or health problems to look out for after you left the 
hospital (HCAP)? 
1 2 
Yes No 
4. Perceived competence. 
Please tell us how true the statements below are for you with the 7-point scale: 
1 2 3 4 5 6 7 
not at all true somewhat true verv rue 
a. I can follow the directions on my medicine and know 
what the medicine is for. 
1 2 3 4 5 6 7 
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b. I can learn about my heart medicines. 
d. I am able to understand my condition. 
e. I can mange my heart medications, this include: 
1.1 understand my symptoms 
2. I can do what I need to do for these symptoms 
3. I know how and why to check my weight and blood 
pressure 
4. I can maintain a healthy diet and regular activities 
related to my heart medicine 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
5 
5 
5 
6 
6 
6 
7 
7 
7 
1. Regulatory processes and perceived locus of causality. 
Please tell us how true the statements below are for you with the 7-point scale: 
1 2 3 4 5 6 7 
not at all true somewhat true very true 
A. The reason I want to participate in managing my heart medicine is: 
a. Because I will feel bad about myself if I don't. 
b. Because others will be upset with me if I don't. 
c. Because I will feel ashamed of myself if I don't do 
what my doctor said. 
d. Because I feel like I want to take responsibility for my 
own health. 
e. Because I will feel guilty if I don't. 
f. Because I personally believe it is the best thing for my 
health. 
g. Because it is my responsibility to learn to manage my 
heart medicine. 
h. Because my doctor tells me to. 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
B. The reason I want to follow the heart health regimen is: 
i. Because I personally believe that it is important to 
improve my health. 
j . Because I may get in trouble with others if I don't. 
k. Because I want others to see that I am really trying to 
comply with the prescription. 
1. Because I had learned to manage my medicine and 
believed it's the right thing to do. 
m. Because I would have felt guilty if I didn't comply with 
the program. 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
6. Smoking status: l=nonsmokers 
2=smoker (persistent smokers, or former smokers) 
7. Alcohol drinking habits: 
1, Don't drink 2. Moderate (= or < 5 glasses/week) 3. Regular (>5 glasses/week) 
8. Daily activity 
9. During the past month, other than your regular job, did you participate in any physical activities or 
exercises such as running, calisthenics, golf, gardening, or walking for exercise? 
1 2 
Yes no 
10. Dietar y habit 
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11. Is there an yone to help you when you leave the hospital? 
1 2 
Yes No 
12. If yes to above, who 
13. Approxi mately how much did you spend on your medicine last month 
14. Did you have any issues in missed filling your prescription or not getting your prescription filled on 
time? These issues may include: 
1. copay too high 2. not enough to last 3. transportation 
4. late reauthorization 5. inconvenience 6. Forgot 7. mail delay for mail orders 
15. If missed having prescription filled, how many days out of prescription? 
Number of days: Name of prescription(s): 
16. "Ha ve to skip medications" question. "In the past month, how often did you have to skip (i.e., doctor 
recommendation for dose adjustment, side-effects, or other dosing related reasons) one or more of your 
prescribed medications?" Possible responses for the question are: 
17 
18 
1 2 
never once in the 
past month 
3 
2 to 3 times 
in the 
past month 
4 5 
once several times 
per week per week 
6 
nearly 
every day 
The "Dec ided to skip medications" question: "In the past month, how often did you decide to skip 1 or 
more of your prescribed medications?" Possible responses for the question are: 
1 2 
never once in the 
past month 
3 
2 to 3 times 
in the 
past month 
4 5 
once several times 
per week per week 
6 
nearly 
every day 
The "Forgot to take medications" question. "In the past month, how often did you forget to take one or 
more of your prescribed medications?" Possible responses for the question are: 
1 2 
never once in the 
past month 
3 
2 to 3 times 
in the 
past month 
4 5 
once several times 
per week per week 
6 
nearly 
every day 
19. What is t he percentage of all the medication you think you have taken during the last 1 months as 
originally prescribed? Please point to or put a cross at the point on the following scale of 0 to 100% 
showing your best guess about how much medication you have taken. We would be surprised if this 
was 100% for most people, e.g. 0% means you have taken no medication; 50% means you have taken 
half your medication; 100% means you have taken every single dose of medication. 
+ + + + + + + + + + + + + 4- + + + + + + + + + + + + + + + + + + + 4- + 
1 1 
0 
% 
didn't 
take any 
1 1 
25 
% 
sometime 
1 1 1 
50 
% 
half of 
the time 
1 1 
75 
% 
most of 
the time 
1 1 
90 100 
% % 
nearly all 
all of of 
the the 
time time 
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20. Nu mber of prescription medications 
21. Nu mber of doses of medication taken in a day 
22. Perform pill cou nts for each prescription and record on the medication log. Adherence rate of each 
medication = # pills taken divided by #pills prescribed for the period xlOO 
_ . . # pills # pills Adh Main 
Rx taken % Reason for change 
14. Antithrombotic 1 Aspirin 
15. Antithrombotic 2 Plavix 
16. Antithrombotic 3 Warfarin 
17. ACEI/ARB e.g. Altace, Zestril, 
Avapro. 
18. Angina management with Nitrate 
e.g. Imdur 
19. Beta-blocker e.g. Toprol 
20. Alpha/Beta-blocker e.g. Coreg 
21. Cholesterol mgm 1: LDL e.g. 
Zocor, Lipitor, Crestor 
22. Cholesterol mgm 2: HDL e.g. 
Niaspan 
23. Cholesterol managment 3: 
Triglycerides, etc. e.g. Zetia 
24. Cigarette cessation with Bupropion 
(Zyban) 
25. Ca channel blocker e.g. Norvasc 
26. Digitalis e.g. Digoxin 
27. Diuretic e.g. Lasix 
28. Antialdosterone eg. 
Spironolactone, eplerenone 
29. Dysrhythmias management 1: e.g. 
Cordarone, Betapace 
30. Diabetic medication management 
1 : e.g. Glyburide 
31. Diabetic medication management 
2: e.g. Metformin 
32. Electrolyte and fluid management: 
e.g. KCL 
33. - 30. Miscellaneous add on 
31. Mean adherence rate ( m_adh%)d 
X (Adh% of item 1 :n) / n 
32. Cadh (co mposite adherence index) 
[VAS dose% + m adh%]/2 
33. Ad herence status: adherent or non-adherent 
0 1 
No (Cadh =or<80%) Yes (Cadh >80%) 
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23. Health s tatus and Health days 
1. Would you say that in general your health is 
1. excellent 2. very good 3. good 4. fair 5. poor 
2. Now thinking about your physical health, which includes physical illness and injury, for how 
many days during the past 30 days was your physical health not good? number of days. 
3. Now thinking about your mental health, which includes stress, depression, and problems with 
emotions, for how many days during the past 30 days was your mental health not good? 
number of days. 
4. During the past 30 days, for about how many days did poor physical or mental health keep you 
from doing your usual activities, such as self-care, work, or recreation? 
NUMBER OF DAYS. 
24. A ny post discharge issues? 
a. Mood change f. Othopnea(# of pillow) 
b. Dyspnea g. fevers/chills and sweats 
c. Fatique/weakness h. chest pain 
d. Edema i. chest discomfort 
e. Weight gain 
25. If read mitted during study period, readmission day: 
Describe incident: 
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Data Dictionary 2: Data variable names, labels and responses used in statistic database 
I. Adherence measures 
Variable 
name 
adh_subj4.1 
adh_subj4.2 
adhasa 
adh_plavix 
adhwarf 
adhace 
adh-nitrate 
adhbetabloc 
adh-coreg 
adhantilipid 
adhzyban 
adhcalbloc 
adhdig 
adh_diuretic 
adhantialdo 
adhantiarrhy 
adhdiabetic 
adh electro 
Variable label 
self reported % medications taken as 
prescribed at pretest 
self reported % medications taken as 
prescribed at post-test 
Adhere to Antithrombotic 1 Aspirin at time 
02 
Adhere to Antithrombotic 2 Plavix at time 
02 
Adhere to Antithrombotic 3 Warfarin at 
time 02 
Adhere to ACEI/ARB e.g. Altace, Zestril, 
Avapro, at time 02 
Adhere to Angina management with Nitrate 
e.g. Imdur, at time 02 
Adhere to Beta-blocker e.g. Toprol, at time 
02 
Adhere to Alpha/Beta-blocker e.g. Coreg, at 
time 02 
Adhere to antiCholesterol management e.g. 
Zocor, Lipitor, Crestor, Niaspan, Zetia at 
time 02 
Adhere to Cigarette cessation with 
Bupropion (Zyban), at time 02 
Adhere to Ca channel blocker e.g. Norvasc, 
at time 02 
Adhere to Digitalis e.g. Digoxin, at time 02 
Adhere to Diuretic e.g. Lasix, at time 02 
Adhere to Antialdosterone eg. 
Spironolactone, Eplerenone, at time 02 
Adhere to Dysrhythmias management 1: 
e.g. Cordarone, Betapace, at time 02 
Adhere to Diabetic medication management 
1 : e.g. Glyburide, Metformin at time 02 
Adhere to Electrolyte and fluid 
management: e.g. KCL, at time 02 
adhrxtotal Objective adherence measure at time 02 
cadh 
adh status 
Composite adherence index (Cadh) at time 
02 
Adherence status at time 02 
Level of Variable label value 
Measure /Response 
, „ . Visual Analog Scale 
I n t e r v a l
 0% to 100% 
Interval same as above 
# pills taken divided 
Interval by #pills prescribed 
for the period x 100 
T , , Same as above. 
Interval 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Interval Same as above. 
Sum of percentage of 
Interval all prescriptions/ # of 
prescriptions 
(VASdose % + Total 
Interval Adherence %) divided 
by 2 
adherent: Cadh >80%; 
Nominal non-adherent: < or 
=80% 
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//. Perceived autonomy support (Healthcare Climate Questionnaire HCCQ) 
Variable 
name 
Hccq.a.l 
Hccq.b.l 
Hccq.c.l 
Hccq.d. 1 
Hccq.e.l 
Hccq.f. 1 
Hccq.a.2 
Hccq.b.2 
Hccq.c.2 
Hccq.d.2 
Hccq.e.2 
Hccq.f.2 
Variable label 
HCCQ at Ol question la: 
I felt that my healthcare givers have given me 
information and choices that apply to my 
condition. 
HCCQ at Ol question lb: 
I felt that my healthcare givers understood how I 
feel about the situation and my life, 
HCCQ at Ol question lc: 
My healthcare givers made me feel that I can 
manage my heart therapy with respect to 
symptoms, side effects. 
HCCQ at Ol question Id: 
My healthcare givers listened to me and help me 
with my therapy options. 
HCCQ at Ol question le: 
My healthcare givers encouraged me to ask 
questions about the heart disease, therapy, life 
style changes, and prevention. 
and other issues. 
HCCQ at Ol question If: 
I felt that I was often given a chance to ask 
questions about my condition and my treatment 
options. 
HCCQ at 02 question la: 
I felt that my healthcare givers have given me 
information and choices that apply to my 
condition. 
HCCQ at 02 question lb: 
I felt that my healthcare givers understood how I 
feel about the situation and mv life. 
HCCQ at 02 question lc: 
My healthcare givers made me feel that I can 
manage my heart therapy with respect to 
symptoms, side effects. 
HCCQ at 02 question Id: 
My healthcare givers listened to me and help me 
with my therapy options. 
HCCQ at 02 question le: 
My healthcare givers encouraged me to ask 
questions about the heart disease, therapy, life 
style changes, and prevention. 
and other issues. 
HCCQ at 02 question If: 
I felt that I was often given a chance to ask 
questions about my condition and my treatment 
options. 
Level of 
Measure 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Variable label value 
/Response 
7 point Likert scale 
from 1 to 7: l=not at 
all true, 4=somewhat 
true, 7=very true 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
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///. Perceived Competence as measured by Perceive Competence Scale (PCS) 
Variable 
name 
Pcs.a. 1 
Pcs.b.l 
Pcs.c.l 
Pcs.d.l 
Pcs.a.2 
Pcs.b.2 
Pcs.c.2 
Pcs.d.2 
Variable label 
PCSatOl questional 
I can follow the directions on my medicine and know what 
the medicine is for. 
PCSatOl question b: 
I know what kind of side effects to expect from my medicine 
and feel that I know how to deal with them when they 
happen. 
PCSatOl question c: 
I am able to understand my heart condition, understand the 
symptoms, and know what to do with them. 
PCSatOl question d: 
I am able to mange my regimen in terms of: 
• I know how and why to check my weight and blood 
pressure 
• I can maintain a healthy diet and regular activities 
related to my heart medicine 
PCS at 02 question a: 
I can follow the directions on my medicine and know what 
the medicine is for. 
PCS at 02 question b: 
I know what kind of side effects to expect from my medicine 
and feel that I know how to deal with them when they 
happen. 
PCSatOl question c: 
I am able to understand my heart condition, understand the 
symptoms, and know what to do with them. 
PCS at 02 question d: 
I am able to mange my regimen in terms of: 
• I know how and why to check my weight and blood 
pressure 
• I can maintain a healthy diet and regular activities 
related to my heart medicine 
Level of Variable label 
Measure value /Response 
Ordinal Same as above. 
Ordinal Same as above. 
Ordinal Same as above. 
Ordinal Same as above. 
Ordinal 
Ordinal 
Ordinal 
Same as above. 
Same as above. 
Same as above. 
Ordinal Same as above. 
IV. Autonomous motivation as measured by questions d, f, g, i and I of the Treatment 
Self Regulation Questionnaire (TSRQ) 
Variable 
name 
Tsrq.d.l 
Tsrq.f.l 
Tsrq.g.l 
Tsrq.i.l 
Tsrq.1.1 
Tsrq.d.2 
Variable label 
TSRQ at 01 question d: Because I feel like I want to take 
responsibility for my own health. 
TSRQ at 01 question f: Because I personally believe it is the 
best thing for my health. 
TSRQ at Ol question g: Because it is my responsibility to 
learn to manage my heart medicine. 
TSRQ at 01 question i: Because I personally believe that it 
is important to improve my health. 
TSRQ at 01 question 1: Because I had learned to manage my 
medicine and believed it's the right thing to do. 
TSRQ at 02 question d: Because I feel like I want to take 
responsibility for my own health. 
Level of 
Measure 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Variable label 
value /Response 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
Same as above. 
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Tsrq.f.2 
Tsrq.g.2 
Tsrq.i.2 
Tsrq.1.2 
TSRQ at 02 question f: Because I personally believe it is the 
best thing for my health. 
TSRQ at 02 question g: Because it is my responsibility to 
learn to manage my heart medicine. 
TSRQ at 02 question i: Because I personally believe that it 
is important to improve my health. 
TSRQ at 02 question 1: Because I had learned to manage my 
medicine and believed it's the right thing to do. 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
V. Controlled motivation (questions a, b, c, e, h,j, k and m of the Treatment Self-regulation 
questionnaire (TSRQ)) - Though not part of the PCC Adherence model, this portion of 
TSRQ is a critical part of the contextual background of the Self-determination theory. 
Variable 
name 
Tsrq.a.l 
Tsrq.b.l 
Tsrq.c.l 
Tsrq.e. 1 
Tsrq.h.l 
Tsrq.j.l 
Tsrq.k.l 
Tsrq.m.l 
Tsrq.a.2 
Tsrq.b.2 
Tsrq.e.2 
Tsrq.e.2 
Tsrq.h.2 
Tsrq.j.2 
Tsrq.k.2 
Tsrq.m.2 
Variable label 
TSRQ at 01 question 3a: Because I will feel bad about 
myself if I don't. 
TSRQ at Ol question 3b: Because others will be upset 
with me if I don't. 
TSRQ at Ol question 3c: Because I will feel ashamed of 
myself if I don't do what my doctor said. 
TSRQ at Ol question 3e: I will feel guilty if I don't do 
what my doctor said. 
TSRQ at 01 question 3h: I will just do it because my 
doctor said to. 
TSRQ at Ol question 3j: 1 may get in trouble with others 
if I don't follow all the prescriptions. 
TSRQ at Ol question 3k: I want others to see that I am 
really trying to take the medication as prescribed. 
TSRQ at Ol question 3m: I feel guilty if I don't comply 
with taking all the prescriptions. 
TSRQ at 02 question 3a: Because I will feel bad about 
myself if I don't. 
TSRQ at 02 question 3b: Because others will be upset 
with me if I don't. 
TSRQ at 02 question 3c: Because I will feel ashamed of 
myself if I don't do what my doctor said. 
TSRQ at 02 question 3e: I will feel guilty if I don't do 
what my doctor said. 
TSRQ at 02 question 3h: I will just do it because my 
doctor said to. 
TSRQ at 02 question 3j: I may get in trouble with others 
if I don't follow all the prescriptions. 
TSRQ at 02 question 3k: I want others to see that I am 
really trying to take the medication as prescribed. 
TSRQ at 02 question 3m: I feel guilty if I don't comply 
with taking all the prescriptions. 
Level of 
Measure 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Variable label 
value 
/Response 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
Same as 
above. 
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VI. Group assignment 
Variable name Variable label 
PCC intervention 
Group Study group 
Level of 
Measure 
Dichotomous 
Variable label value 
/Response 
0=usual group 
l=experimental group 
VII. Other independent variables and potential confounding variables 
Variable name 
age 
gender 
race (for Race/ 
ethnicity) 
NYHA 
fluid 
Copd 
dysrhy 
anemia 
tcancer 
hypothy 
pad 
renal 
comorbid 
illlevel 
smoke 1, 
smoke2 
depress 1.1, 
depress 1.2 
depress2.1, 
depress 2.2 
depress3.1, 
depress 3.2 
depressed 1, 
depressed2 
Illiteracy 1 
hliteracy2 
hliteracy3 
Illiteracy 
Variable label 
Age 
Gender 
Multiple race categories 
NYHA category 
Comorbidity 1 fluid & 
electrolyte 
Comorbidity 2 COPD 
Comorbidity 3 dysrhythmia 
Comorbidity 4 anemia 
Comorbidity 5 tumor and cancer 
Comorbidity 6 hypothyroidism 
Comorbidity 7 peripheral 
vascular disease 
Comorbidity 8 renal failure 
Total comorbidity 
Illness level 
Smoking status at 01 and 02 
Depressed x2 weeks last year at 
01 , 02 
Depressed x2 years in life at 0 1 , 
02 
Takes any antidepressant at 0 1 , 
02 
Depression risk at 0 1 , 02 
How often do you have someone 
help you read hospital materials 
or prescription bottles? 
How confident are you filling 
out medical forms by yourself 
How often do you have 
problems learning about your 
medical condition because of 
difficulty understanding written 
information? 
Final assessment 
Level of 
Measure 
Ratio 
Nominal 
Nominal 
Ordinal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Ordinal 
Ordinal 
Ordinal 
Nominal 
Nominal 
Nominal 
Variable label value /Response 
age in year 
l=male, 2=female 
1= White 2=Black or African 
American 3= Hispanic or Latino 
4=Asian 5=Native Hawaiian or Other 
Pacific Islander 6=American Indian, 
Alaska Native 7=0ther or Multiracial 
1=A, 2=B, 3=C, 4=D 
l=yes 2=no 
l=yes 2=no 
l=yes 2=no 
l=yes 2=no 
l=yes 2=no 
l=yes 2=no 
l=yes 2=no 
l=yes2=no 
0-8 
NYHA+ each additional 
comorbidity; range=l to 12 
l=nonsmokers, 2=former smokers, 
3=quitters, 4=persistent smokers 
l=yes2=no 
1 =yes 2=no 
l=yes 2=no 
Nominal 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
l=yes 2=no, or yes to any of above 3 
questions 
0=Never, 1 Occasionally, 
2=Sometimes, 3=0ften, 4= Always 
Same as above. 
Same as above. 
1 inadequate, 2=marginal, 
3=adequate 
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VII. Other independent variables and potential confounding variables continued 
insured 1 
insured2 
rxcostl 
Rxcost2 
ddoses 1 
ddoses2 
ssupportl 
ssupport2 
Prescription insurance available 
Ol 
Prescription insurance available 
02 
Prescription expenses including 
co-payment or coinsurance at 01 
Prescription expenses including 
co-payment or coinsurance at 02 
# of medication doses/day at Ol 
# of medication doses/day at 02 
Social support available at Ol 
Social support available at 02 
Nominal 
Nominal 
Ratio 
Ratio 
Ratio 
Ratio 
Nominal 
Nominal 
l=yes 2=no 
l=yes 2=no 
Total $dollar per month 
Total Sdollar per month 
Number of doses per day 
Number of doses per day 
l=yes, 2=no 
1 =yes, 2=no 
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IRB Approval 
EASTERN VIRGINIA MEDICAL SCHOOL 
OFFICE OF RESEARCH SUBJECTS PROTECTIONS 
I N S T I T U T I O N A L R E V I E W B O A R D 
May 7, 2009 
David Li, Pharm.D. 
Sentara Virginia Beach General Hospital 
1060 First Colonial Road 
Virginia Beach, Virginia 23454 
RE: IRB#05-12-FB-1014 
Principal Investigator: David Li, Pharm.D. 
This form provides additional information to the Continuing Review Report that accompanies this letter. The continuing review form is the 
official document that confirms IRB review and type of approval and includes the IRB#, study title, IRB stamp that includes approval and 
expiration dates, and an appropriate chair, vice-chair or IRB member signature. 
E3 As you are aware, Sentara Virginia Beach General Hospital recently requested that the Eastern Virginia Medical School 
Institutional Review Board provide IRB review for, studies'at their institutjbfV, An agreement was signed on June 2, 2008 for 
EVMS to be an IRB of record for SVBGH studies. One of the ways we are accomplishing this is to review studies of SVBGH 
investigators as they are due for Continuing Review 
£3 Completed Continuing Review Form 
ESI Consent Form: Subject Consent Form. Version and Date: November 18, 2006 
Please remember that a signed written consent form Is not a substitute for discussion but should be an educational process including a full 
explanation of the study while allowing time for questions prior to signing. The subject's signature is considered verification of the investigator's 
explanation of the research prior to, not after, initiation of the research. Also} all changes, including the use of additional subjects, require IRB 
approval before initiation. 
K You have satisfied the Human Subjects Protection Training requirements. 
E3 You have completed an Investigator Assurance 
[X] The Continuing Review was reviewed and approved by Karen Mitchell, RN, BSN, CCRC, Chair of the 1st Thursday IRB 
Institutional Review Board, Eastern Virginia Medical School on April 24, 2009.' 
E3 Your protocol expiration date is April 23,2010. Continuing review reports are due 60 days prior to protocol expiration. 
[53 Please remember that prompt reporting to the IRB of proposed changes in a research activity (e.g., changes to the protocol, 
consent form(s), advertisements, or other study-related material) is required. In addition, the changes must be reviewed and 
approved by an EVMS IRB before the changes can be initiated excepf when necessary to eliminate apparent immediate hazards 
to the subject. 
Remember that a copy of all correspondence relating to any site visit or regulatory visit must be submitted to the IRB office within 
five (5) days of receipt by the EVMS site. Refer to the 2007 EVMS IRB SOPs Section 22.0 for more information. 
NEW INFORMATION RELATED TO EXPEDITED REVIEW OF ON-GOING STUDIES: 
On July 11, 2002, the Office for Human Research Protections issued "Guidance on Continuing Review." Under expedited 
Category 8, an expedited review procedure may be used for the continuing review of research previously approved by the 
convened IRB where no subjects have been enrolled and no additional risks have been identified. Further, OHRP clarified that 
for multi-center studies, an expedited review procedure may be used as long as the criteria are satisfied for that site. The 
criterion that "no additional risks have been identified" is interpreted to mean that neither the investigator nor the IRB at EVMS 
has identified any additional risks from any site or other relevant source, 
P.O. B O X 1 9 8 0 N O R F O L K , V A 2 3 5 0 1 - 1 9 8 0 
T E L E P H O N E : (757) 4 4 6 - 8 4 2 3 FAX: (757) 6 2 4 - 2 2 7 5 
I R B - I N F O @ E V M S . E D U 
IRB#05-12-FB-1014 
May 7, 2009 
Page 2 
Eastern Virginia Medical School (EVMS) has a Federalwide Assurance (FWA 00003956) from OHRP. The Institutional Review Boards 
(IRB 00000460 and IRB 00001345) are registered with OHRP and are in compliance with 45 CFR 46. 21 CFR 50, and 21 CFR 56. 
Please reference the IRB number, principal investigator and study title in any correspondence regarding this protocol. 
Thank you for your continued cooperation with the Institutional Review Board. 
Sincerely, 
•i H^ 
Betsy C. Conner, CIP 
IRB Manager 
Appendix K 
Data quality evaluation 
179 
Issues Method of evaluation Outcome and 
resolution 
General inspection of 
the interval variables 
SPSS FREQUENCIES and FREQUENCY PLOT were 
used to examine the means, standard deviations, 
skewness, kurtosis, normality, and missing values. 
Satisfactory 
The assumption of 
linearity, normal 
distribution and 
homogeneity of 
variance between 
interval variables 
SPSS PARTIALPLOT and SCATTERPLOT were used 
to examine for symmetrical linear relationship and 
residuals between interval variables (i.e., residuals were 
plotted against various independent variables with the 
estimated outcome of adherence index). PPLOT was 
also used to investigate whether the data are from a 
specified distribution. 
Satisfactory 
Adequacy of 
expected frequencies 
for goodness-of-fit 
SPSS CROSSTABS /TABLES were used to examine 
the dichotomous outcome variable adherence status with 
other independent categorical variables. The Chi square 
goodness-of-fit requirement for multivariate analysis 
was met: either all the cells of the 2-way tables contain 
expected cell counts >5, or not more than 20% of the 
cells contains expected cell counts <5. 
None of the 
expected cell counts 
of the 2-way tables 
was less than 5. 
Satisfactory 
Missing data Examination of frequency analysis None detected. 
Multicollinearity in 
regression analyses 
Examination for any tolerance values (1-squared 
multiple correlation [SMC]) > .01 and Variance 
Inflation Value (VIF) < 10. 
None detected. 
Outliers, out of range 
values 
SPSS CASEWISE OUTLIERS was used during 
regression analyses to detect for outlying cases with 
standard residuals > 3.0 for multiple linear regression 
analyses, and for cases with standard residuals >2.58 for 
logistic regression analyses. 
Deleted during 
model testing 
Assumptions for 
ANCOVA 
Normality of distributions, linearity, homogeneity of 
variance were examined with Levehe's test Satisfactory 
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H# HYPOTHESIS Support 
H1 SDT will predict Adherence. 
Patients with a higher HCCQ score (higher perceived autonomous support) will be v t 1 
H1 a more likely than patients with a lower HCCQ score to (1) have a higher Cadh, (2)
 Y _ 
be adherent. 
Patients with a higher PCS score (higher perceived competence) will be more likely Yes to 1 
than patients with a lower PCS score to (1) have a higher Cadh, (2) be adherent. Yes to 2 Hlb 
H2 
H2g 
Yes to 1 Patients with a higher autonomous motivation score on TSRQ (higher autonomous Hlc motivation) will be more likely than patients with a lower autonomous motivation v t ? 
score on TSRQ to (1) have a higher Cadh, (2) be adherent. 
When considered together in one model, all of the SDT motivation variables
 Y . 
Him (HCCQ score, PCS score, autonomous motivation score on TSRQ) at post-test will
 Y ~ 
be significant predictors of (1) Cadh, (2) adherence status at post-test. 
Socio-economic status, resources, health related factors and prescription drug 
variables will predict adherence. 
Older patients (age = or > 65) will be less likely to be adherent (1 Cadh, 2 
adherence status) than younger patients at post-test. Alternative hypothesis is Older No to 1 
H2a patients (age = or > 65) will be more likely to be adherent (1. Cadh, 2 adherence 
status) than younger patients at post-test. (If the direction of H2a is reversed, the No to 2 
result would support for 1 and 2.) 
Married patients will be more likely to be adherent (1 Cadh, 2 adherence status) 
than patients who are not married at post-test, (married was recoded from assigning 
H2b lfor marital code=l, and 0 for marital codes = 2, 3,4, 5, 6. marital code: 
l=married, 2=divorced, 3=widowed, 4=seperated, 5=never married, 6=a member of 
unmarried couple). 
H „ Female patients will be more likely to be adherent to (1 Cadh, 2 adherence status) No to 1 
than male patients at post-test. No to 2 
„_ . Caucasian patients will be more likely to be adherent (1 Cadh, 2 adherence status) No to 1 
than non-Caucasian patients at post-test. No to 2 
No to 1 
No to 2 
No to 1 Patients with an adequate level of health literacy will be more likely to be adherent H2e (1 Cadh, 2 adherence status) than patients with a less adequate level of health N t 9 
literacy at post-test. 
Patients with insurance coverage for prescription drugs will be more likely to be v t i 
H2f adherent (1 Cadh, 2 adherence status) than patients without insurance coverage at
 v _ 
post-test. 
Patients with social support will be more likely to be adherent (1 Cadh, 2 adherence No to 1 
status) than patients without social support at post-test. Yes to 2 
No to 1 Patients with a higher illness level (illness-comorbidity index) will be more likely to H2h be adherent (1. Cadh 2 adherence status) than patients with a lower illness level at
 N ~ 
post-test. 
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H# HYPOTHESIS Support 
H2i 
H2j 
H2k 
H21 
H2m 
H2n 
Patients who smoked will be less likely to be adherent (1 Cadh, 2 adherence status) 
than patients who don't smoke at post-test. 
Patients at risk of depression will be less likely to be adherent (1 Cadh, 2 adherence 
status) than patients who are not at risk of depression at post-test. 
Patients who spend more for prescription drugs will be less likely to be adherent (1 
Cadh, 2 adherence status) than patients who spend less for prescription drugs at 
post-test. 
Patients who take fewer prescriptions will be more likely to be adherent (1 Cadh, 2 
adherence status) than patients who take more doses of prescriptions at post-test. 
Patients who take fewer doses of medication per day will be more likely to be 
adherent (1. Cadh, 2. adherence status) than patients who take more doses of 
medication at post-test. 
Patients who perceive drug side-effects to be tolerable will be more likely to be 
adherent (1. Cadh, 2. Adherence status) than patients who perceive drug side-effects 
to be intolerable at post-test. 
No to 1 
No to 2 
No to 1 
No to 2 
No to 1 
No to 2 
No to 1 
No to 2 
No to 1 
No to 2 
No to 1 
Yes to 2 
H3 SDT will predict adherence when controlling for SES, resources, health-related factors, and prescription drug variables. 
Patients with a higher HCCQ score, a higher PCS score, and/or a 
higher TSRQ-AM score at post-test will be more likely to be 
adherent (1 Cadh, 2. Adherence status) at post-test than patients 
with a lower HCCQ score, a lower PCS score and/or a lower 
H3a TSRQ-AM score at post-test, when controlling for age, gender, 
race/ethnicity, adequate health literacy, insurance coverage, social 
support, illness level, smoking status, depression, prescription 
drug expense, number of prescriptions, number of doses/day, and 
side-effects. 
Yes to 1 when adjusted for 
age, insurance, ssupport, 
ADR, adeqhealit, illlevel, 
smoked, and rxdosesall. 
Yes to 2 when adjusted for 
age, social support, and 
ADR. 
H4 
H4a 
H4b 
H4c 
Levels of SDT factors will increase over time. 
Patients will be more likely to have a higher HCCQ score (perceived Yes to 1 
autonomous support) at post-test than at pretest (1 while group, 2 UC group, 3 Yes to 2 
PCC group). Yes to 3 
Patients will be more likely to have a higher PCS score (perceived 
competence) at post-test than at pretest (1 while group, 2 UC group, 3 PCC 
group). 
Patients will be more likely to have a higher autonomous motivation score on 
TSRQ (higher autonomous motivation) at post-test than at pretest (1 while 
group, 2 UC group, 3 PCC group). 
Yes to 1 
No to 2 
(reversed) 
Yes to 3 
Yes to 1 
No to 2 
(reversed) 
Yes to 3 
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H# HYPOTHESIS Support 
H5 PCC will predict a higher level of SDT constructs. 
H5a 
Patients who received PCC teaching will be more likely to have a 
higher HCCQ score (perceived autonomous support) at post-test 
than patients who received UC, controlling for HCCQ score at 
pretest, SES, resources, health and prescription drug related factors. 
No (tendency, Sig. of 
0.052 for group effect) 
when adjusted for 
HCCQ1, age, insurance, 
social support and ADR. 
H5b 
Patients who received PCC teaching will be more likely to have a 
higher PCS score (perceived competence) at post-test than patients 
who received UC, controlling for PCS score at pretest, SES, 
resources, health and prescription drug related factors. 
Yes when adjusted for 
PCS1, age, insurance, 
social support ADR, 
ssupport*ADR 
interaction. 
Patients who received PCC teaching will be more likely to be have 
a higher autonomous motivation score on TSRQ-AM (more 
H5c autonomously motivated) at post-test than patients who received 
UC teaching, controlling for TSRQ-AM score at pretest, SES, 
resources, health and prescription drug related factors. 
Yes when adjusted for 
TSRQAMl,age, 
insurance, social support 
and ADR. 
H6 PCC will predict adherence 
H6a 
H7 
Patients who received PCC teaching will be more likely to be 
adherent (1 Cadh, 2 adherence status) at post-test than patients who 
received UC teaching. 
PCC will predict adherence controlling for SDT and other patient 
factors 
Yes to 1 
Yes to 2 
H7a 
Patients who received PCC teaching will be more likely to be 
adherent (1 Cadh, 2 adherence status) at post-test than patients who 
received UC teaching after controlling for perceived autonomous 
support (HCCQ), perceived competence (PCS), and autonomous 
motivation (autonomous motivation portion of TSRQ), SES, 
resources, health and prescription drug related factors. 
Yes to lwhen adjusted 
for group, 3 SDT 
variables, age, depression 
risk, social support and 
ADR. 
Yes to 2 when adjusted 
for group, 3 SDT 
variables, age, ADR, 
illness level and doses 
taken per day. 
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FOOTNOTE 3-1. 
GetWellNetwork in patient-centered care 
GetWellNetwork (GWN): GetWellNetwork is a technology company specialized 
in providing an interactive patient platform by utilizing the in-room television monitors to 
support patient-centered care. A patient centered environment is created around a 
patient's ability to control the flow of entertainment and information content to the 
television in the patient's room via a bedside control; this can be either a keyboard or a 
television remote control device. The system is interactive in that it utilizes a push-and-
pull system to control the information flow. Information can be "pushed" into the 
environment, while patient feedback can be "pulled" out of the environment. A 
multidisciplinary team including hospital staffs and company representatives is organized 
to develop and implement the system. 
The goals of GetWellNetwork: The Goals of employing GetWellNetwork in the 
patient-centered care environment are: (1) Empowering patients to control their lives 
during a hospital stay. Patients and families can gain access to an array of education, 
entertainment, services and Internet resources via the PatienfLife:)System. (2) Support 
healthcare providers for their primary mission of providing top-quality care to their 
patients. Healthcare providers are supported for direct patient care with relevant 
technology that can save time on automatable tasks and routine documentation. (3) Assist 
administrators to achieve their goals through real-time resources that inform service 
delivery decisions, ease the administration of regulatory compliance and improve 
financial performance. 
The system: The PatientLife:)System of GetWellNetwork navigates patients 
through their hospital stay, providing access to all the people and resources they need to 
have a quality care experience - transforming the care process into a patient centered 
environment. It is comprised of three distinct, yet integrated software suites that together 
focus on enhancing the patient's life while in the hospital. Underneath the 
PatientLife:)System is the PatientPathway:)Architecture. The architecture dynamically 
launches features within the system to automate clinical and non-clinical processes— 
including patient education, pain assessment, services, admission and discharge 
instructions. By deploying Patient Pathways, hospitals can deliver a coordinated, 
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cohesive and efficient experience for the patient. The system includes three sub-
modules: PatientResource:)Suite, PatientCommunication:)Suite, and PatientCare:)Suite. 
PatientResource:)Suite: The sub-system PatientResource:)Suite enables patients 
to continue with their daily life while in the hospital. The Suite includes Internet Access, 
Healing Resources, Movies, Community Information, GWN Telelvision, Hospital 
Information, Journal, Music & Games. 
PatientCommunication:)Suite'. PatientCommunication:)Suite enables all members 
of a care team, including the patient, to communicate to each other during the patient's 
hospital stay - enhancing service efforts. The suite includes the following functionality: 
Survey, Instant Response, Staff Recognition, Event Manager, Email, Instant Messaging, 
Alert, Comment, Patient Admission Pathway, Patient Satisfaction Pathway. 
PatientCare:)Suite: PatientCare:)Suite enables nurses and physicians to inform 
and care for the specific needs of individual patients during their hospital stay while 
providing administrators with documentation tools to aid regulatory compliance efforts. 
The suite includes the following functionality: Patient Safety, Education, Dietary, Pain 
Management, Pain Management Pathway, Patient Profile, Patient Education Pathway, 
and Patient Safety Pathway. 
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